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SUMMARY.
The prostate is a male secondary sex organ 
dependent on a supply of androgens from the blood 
for its growth, maintena.nee and function. Within 
the gland, testosterone is reduced to 5d- 
dihydrotestosterone (DHT) by the enzyme testosterone 
5oc-reductase, and it is the DHT which appears to be 
the active hormone within this organ. Benign 
prostatic hyperplasia is a common condition in 
elderly men, and a raised tissue concentration of 
DHT has been implicated as a possible cause.
In this thesis, several compounds which decrease 
DHT production, by inhibition of the testosterone 
-reductase, were investigated for their possible 
usefulness in the treatment of benign prostatic 
hyperplasia.
The polysaccharide, heparin, showed competitive 
kinetics with respect to both substrate and 
cofactor of the prostatic enzyme. The inhibition 
was not reversed by zinc ions. Several other 
natural and synthetic monosaccharides and 
polysaccharides were tested with the enzyme system, 
but no pattern, of either monosaccharide unit, degree 
of sulphation, molecular weight or glycoside linkage, 
could be discerned as the prime cause of the 
observed inhibition. Administration of heparin to
( x x i )
rats caused no significant effect on the testosterone 
5ot-'reductase activity of the gland. An uronic acid 
containing substance was extracted from human 
prostatic tissue which was able to inhibit the 
testosterone 5o(-reductase.
Metabolites of spironolactone, the aldosterone 
antagonist, were also tested with the testosterone
5 -reductase. Canrenoate showed no significant 
effect, and aldadiene proved to be a poor inhibitor.
The kinetics of this inhibition could not be 
resolved even with a more homogeneous microsome 
preparation. The implications of the observations 
are discussed.
An isotope, effect was shown to occur during both 
chemical and biological oxidation of
testosterone. Fo isotope effect was observed in the 
5oC-reduction of this compound.
Progesterone and other hydroxylated progestins 
were incubated with testosterone 5oC-reductase. The 
inhibition observed with each compound depended on 
the number and position of hydroxyl groups present. 
Progesterone exerts competitive inhibition. The 
addition of progesterone to an in vitro superfusion 
system showed that the progesterone was capable of 
inhibiting the conversion of testosterone to DHT 
but only at much higher concentrations than expected 
from homogenate incubations. The lack of potency
(xxii)
of progesterone could not be accounted for by lack 
of entry of this steroid into the tissue.
Progesterone was shown to be extensively metabolised 
by prostatic tissue to Çc^-reduced metabolites. The 
implications of these observations are discussed in 
terms of the value of testosterone 5o(-reductase 
inhibitors in the control of benign prostatic 
hyperplasia.
CHAPTER I.
CHAPTER I.
GENERAL INTRODUCTION.
1 « Structure and Eunc'tion of the Prostate Gland.
The prostate gland is an integral part of the 
male reproductive tract, being an accessory sex organ 
whose normal function is to manufacture and secrete 
many of the components of semen. In man the prostate 
gland is also the site of two common pathological 
conditions and as such has attracted considerable 
clinical attention for many years. Benign prostatic 
hyperplasia (BPH) is a condition which often causes 
urinary retention, whilst prostatic carcinoma is 
second only to lung cancer as the most common 
malignancy found in males. The discovery that the 
prostate gland is an androgen dependent organ has 
prompted widespread research in an attempt to 
understand the aetiology of these two conditions and 
it is the purpose of this introduction to summarise 
the present state of knowledge.
A. Structure.
In man the prostate gland is situated at the neck 
of the bladder surrounding the urethra (fig. 1-1).
It weighs only a few grams at birth and consists of a
1 a
Fig.I - 1
Aliatomical Location of the Human Prostate.
Peritoneum
Urinary Bladder
•Ureter
—  Spine 
Seminal vesicle 
Ejaculatory duct
-Prostate
“Rectum
Pubis
•Ductus deferens
Epididymus
Urethra Testis
2duct system embedded in a stroma of muscle and 
connective tissue. At puberty the gland undergoes 
an androgen induced growth, the increase in size 
being due to the modification of ducts and 
development of the end buds of the follicles, A 
reduction in the volume of the stroma in relation to 
the epithelium results. ' These changes in the fine 
structure occur in six to twelve months, after which 
growth continues slowly until,by about twenty years 
of age,the gland has reached fifteen to twenty grams 
(Warwick & Williams, 1973). During the third 
decade of life the foldings of the epithelium become 
more complex, although the size of the prostate 
remains stable until fifty - sixty years of age, 
when it may either progressively atrophy or undergo 
a second growth spurt (Siiteri & Wilson, 1970).
The prostate has five lobes which can be traced 
from the openings of the ducts into the urethra 
(Pig.l - 2a), The posterior lobe lies behind the 
urethra and the ejaculatory ducts; the median lobe 
lies between the ejaculatory ducts; the anterior 
lobe (which may be absent or atrophic) lies in front 
of the urethra; and two lateral lobes which lie on 
either side of the urethra (Price, 1963). However, 
on superficial examination the whole structure appears 
uniform and no functional or histological differences 
are seen between the divisions which are based purely
2a
PiK.I " 2 .
(a) Anatomical divisions of the prostate.
(Kerr et al., (1960)
Transverse Section Sa^ital Section
-Urethra
Ejaculatory
ducts
A - Right lateral lobe 
B - Anterior lobe 
0 “ Left lateral lobe
D — Posterior lobe 
E - Median lobe
(b) Histological divisions of the prostate.
(Franks,1954)
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External 
or prostatic 
glands 
proper
Submucosal
glands
Urethral crest 
Urethral sinus
on foetal anatomy (Mann, 1964).
The prostate may more easily be divided into 
inner and outer zones (fig. l-2b). The inner zone 
consists of mucosal and submucosal glands which have 
short duct systems, and is more susceptible to the 
estrogen induced metaplasia which is often seen in 
new born infants as a result of circulating maternal 
estrogens. It is in this inner region that benign 
prostatic hyperplasia most often arises in elderly 
men (Blandy,, 1976). The outer region or prostate 
gland proper has a longer and more branched duct 
system and is the usual site of origin of prostatic 
carcinoma (Franks, 1954; Scott, 1963). A true 
capsule separates the outer zone from the loose 
pelvic fascia and is adherent to the underlying 
gland.
Examination of the fine structure of the human 
prostate gland show's it to have a tubulo-alveolar 
structure, with a secretory epithelium lining the 
alveoli. The epithelial cells have a basement 
membrane resting on a stroma of connective tissue 
containing smooth muscle which surrounds the ducts. 
There is a rich blood supply, and nerve endings are 
found in both the smooth muscle and epithelium. At 
ejaculation the smooth muscle fibres contract under 
stimulation from the sympathetic nervous system and 
the alveoli are partially emptied of their secretions.
A typical section of normal human prostate is shown 
in fig. I“3a. Benign prostatic hyperplasia results 
in an increase in stromal/epithelial ratio of the 
tissue as is shown in fig. l-3b and in prostatic 
carcinoma there is a loss of structural 
differentiation (fig. I-3c) (Price, 1963).
Apart from man the two animals most commonly 
used in studies of the prostate are the dog and the 
rat. The dog, like man, has a single compact 
prostate which completely surrounds the urethra at 
the neck of the bladder. The dog is the only other 
animal commonly reported to have naturally occurring 
hyperplasia and for this reason has been intensively 
studied (King & Mainwaring, 1974). However, the 
hyperplasia arises in the outer region of the canine 
gland and has a cystic rather than nodular type of 
development (Price, 1963) and involves the acini 
rather than stroma (Blandy, 1976). This significant 
difference means that caution must be exercised in 
the extrapolation of experimental data obtained in dogs 
to the situation in man. It is only in the ageing 
rhesus monkey that anything is seen which can be 
compared to benign nodular hyperplasia in man 
(Blandy, 1976).
In the rat the prostate is composed of paired 
ventral lobes at the neck of the bladder, and paired 
dorsal and paired lateral lobes which surround the
4a
Fig.I - 3
Histology of Normal, Benign Hyperplastic and 
Carcinomatous Human Prostate.
(a) Hormal Prostate.
The gland has a tubulo-alveolar structure, 
with the secretory columnar epithelial cells 
lining the alveoli! the epithelial cells 
have a basement membrane resting on a 
stroma of connective tissue containing smooth 
muscle cells which surround the alvâoli.
(b) Benign Hyperplastic Prostate.
There is an increase in the stromal/epithelial 
ratio, although there is still structural 
differentiation.
(c) Carcinomatous Prostate.
There is loss of structural differentiation, 
although both epithelial and stromal elements 
are present.
Magnification: x 300.
4b
Fig.I - 3
at
urethra (Price, 1963). It is the rat ventral 
prostate which is used in most experimental work as 
it is easily dissected free of other tissues and 
responds rapidly to hormone manipulations. The 
histology of the rat ventral prostate differs from 
that of man and dog, being a less compact tissue and 
having a higher epithelial to stromal cell ratio.
Thus whilst this gland is useful in many ways for 
the study of androgen action it should not be seen 
as a model for human prostate,
B. Function.
The ejaculated semen is a suspension of 
spermatozoa in a fluid medium. This fluid is made 
up of the secretions of the male accessory organs of 
reproduction and the mixture is known as the seminal 
plasma.
The composition of the seminal plasma and the 
relative contribution of the different accessory sex 
glands to it varies from one species to another, and 
is discussed extensively by Mann (1964). The semen 
volume and sperm density is also subject to wide, 
species differences. In man 2-6ml is the average 
volume range for ejaculates and sperm density averages
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10 cells/ml, so that only 1 of the ejaculate is 
sperm and the rest is seminal plasma (Mann, 1964).
Human seminal plasma is made up of secretions 
from the prostate, epididymi, vas deferentia.
ampullae, seminal vesicles, bulbo-urethral and 
urethral glands. Between 13 and 35% of seminal 
plasma is due to the prostatic secretion (Lundquist, 
1949) which is a colourless fluid, usually slightly 
acid, pH6.5 (Huggins, 1947), has high proteolytic 
enzyme activity and is noted for an almost complete 
absence of reducing sugars. The prostatic secretion 
is the main source of the citric acid and acid 
phosphatase of the human semen, and analysis of these 
two components provides a convenient chemical 
indicator test for the functional state of the gland. 
Citric acid formation in the prostate appears to be 
androgen dependent (Humphrey & Mann, 1948, 1949), 
disappearing after castration but reappearing after 
testosterone administration. The exact function of 
citric acid is not certain. It does not appear to 
influence markedly the aerobic or anaerobic 
metabolism of spermatozoa (Humphrey & Mann, 1949), 
but may have a beneficial effect on sperm motility 
(Lardy & Phillips, 1945), function as a calcium- 
binding substance (Huggins, 1945) or have a role in 
maintaining the osmotic equilibrium in semen 
(Mann, 1954).
Acid phosphatase production, like that of citric 
acid, is androgen dependent. Levels of the enzyme 
are low in childhood but increase rapidly at puberty 
(Gutman & Gutman, 1938,b). Under physiological
conditions acid phosphatase does not pass into the 
blood stream, although handling of the prostate 
during clinical procedures may cause a transient 
rise in blood level of the enzyme (Marberger et al., 
1957). Malignant growth of the prostate and 
métastasés of prostatic cancer in the bones also 
result in an increased blood level, and the 
determination of this prostatic acid phosphatase 
activity in the blood has proved to be a useful tool 
in the diagnosis and treatment of prostatic carcinoma 
(Gutman & Gutman, 1938,a; Huggins et al., 1941; 
Watkinson et al., 1944).
Other notable constituents of the human prostatic 
secretion are the nitrogenous bases, spermine and 
spermidine. The physiological role of these 
substances is not yet clear but there are observations 
which suggest that spermine has a stabilising 
influence on whole cells, mitochondria, ribosomes, 
certain bacteriophages and certain enzymes, including 
prostatic acid phosphatase (Mann, 1964).
The prostate and prostatic secretion have 
extremely high levels of zinc. The mean zinc 
content of human prostate is 69.2mgZn/1OOg dry tissue 
(Mawson & Fisher, 1952), which is considerably 
higher than that found in other tissues such as 
liver, muscle, brain, testis or blood. Only a small 
percentage ( 10%) of this zinc can be accounted for
by metalloproteins such as carbonic anhydrase or 
acid phosphatase, the remainder being either free 
ionic zinc or zinc non-covalently bound to proteins 
or small molecules. The zinc content of the 
prostate like so many of the components of the gland 
is controlled by the circulating androgens and 
indicates the general androgen dependence of the 
gland as a whole.
2. The Prostate as an Androgen Dependent Organ.
In the male, the testes not only produce
spermatozoa, but also have an endocrine role in the 
production of the steroid hormone testosterone.
Within the testis steroid production is localised to 
the Leydig (interstitial) cells which lie between the 
seminiferous tubules and adjacent to blood capillaries 
and the lymphatic system. Like the ovaries in the
female, the testes are under the control of the
pituitary gonadotrophins, luteinising hormone (LH) 
and follicle stimulating hormone (PSH), which are in 
turn, controlled by a releasing hormone from the 
hypothalamus. The role of LH is to control growth 
and to stimulate testosterone secretion by the Leydig 
cells. The testosterone, in conjunction with FSH, 
promotes spermatogenesis and the growth of the 
seminiferous tubules (Turner & Bagnara, 1971).
Apart from its role in spermatogenesis
9testosterone, and its principal metabolite 
5o(“dihydrotestosterone (DHT), have important 
anabolic and androgenic effects on muscle and hair 
growth, maintain the prostate, seminal vesicles and 
other accessory organs and play an important role in 
mating behaviour of the male.
The dependence of secondary sex organs on the 
testis was shown in the classical study of Hunter 
(1786) when he observed the post castration 
involution of the prostate and seminal vesicles. 
Later Pezard (1911) showed that extracts from the 
testis contained some biologically active substance 
which was capable of preventing the atrophy of the 
accessory sex glands caused by castration. This 
active substance was eventually isolated (David 
et al,,1955) and shown to be testosterone. The 
androgen dependent nature of the prostate gland in 
particular led Huggins (Huggins & Hodges, 1941) to 
employ castration and estrogen therapy in the 
treatment of carcinoma of the prostate.
According to classical endocrinology the 
testosterone secreted by the Leydig cells passes 
into the adjacent blood capillaries and thence into 
the general circulation via the spermatic vein.
For many years it was assumed that this was the only 
route for the transport of androgens to the prostate 
gland,but more recently Pierrepoint and co—workers
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(1973, 1975) have shown that in the rat and dog 
there may he passage of testosterone along the vas 
deferens to the prostate, and that the deferential 
vein may also act as a local transport system for 
androgens. Support for this latter route was given 
by Lewis & Moffat (1975) who described a mechanism 
for blood flow from the deferential vein into the 
prostatic venous plexus when conditions of raised 
central venous pressure prevailed*
In blood, testosterone is transported mainly 
bound to proteins. In man this binding is 
principally to one specific (3-globulin, sex steroid 
binding globulin (SBG), which has a high affinity 
but low capacity not only for testosterone but also 
for estradiol and other sex steroids (Murphy, 1968). 
Only in certain clinical syndromes, where there is an 
abnormally high level of steroid secretion, is there 
significant binding of androgen to high capacity but 
low affinity proteins such as cortisol binding 
globulin (GBG) or albumin (King & Mainwaring, 1974).
Hot all higher animals have high affinity binding 
proteins related to SBG. For example in the rat 
and dog the high affinity binding of testosterone is 
to CBG (Murphy, 1968).
The effect of androgen binding within the plasma 
is to reduce the amount of hormone available to 
target tissues, including the prostate gland, and
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it has been suggested that only the relatively small 
fraction of unbound steroid is readily available to 
the tissue, and hence biologically active (Vermeulen 
& Verdonck, 1972). Data obtained from organ culture 
(Lasnitzki & Franklin, 1974; Mercier-Bodard et al., 
1976), and in vitro superfusion (Giorgi & Koses, 1975) 
would seem to support this, as in both cases, addition 
of plasma to the medium decreased the uptake of 
radioactive testosterone and DHT by prostate tissue.
The availability of testosterone to the prostate 
gland is thus determined not only by the total plasma 
concentration of the steroid but also by the 
concentration and extent of binding to SBG.
It- would appear that the entry of testosterone 
into the cell is achieved by passive diffusion, as 
the amount of steroid found in the cytoplasm has been 
shown to be proportional to the amount injected into 
castrated rats (Rennie & Bruchovsky, 1975). However 
in vitro work with superfused human prostate tissue 
slices has demonstrated that not all steroids enter 
the tissue at the same rate (Grant & Giorgi, 1972) 
and it is possible that some element of selectivity 
towards testosterone may be involved. Within the 
cell the transport of androgens is controlled by 
specific binding proteins or receptors, which will 
be discussed more fully in a later section.
It is now generally accepted that for the
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maintenance of normal prostatic function testosterone 
is only a prehormone which requires reduction within 
the gland to the active hormone 5o(-“dihydrotestosterone 
(DHT). Evidence for this comes from many workers 
and from several different approaches. (For reviews 
see Wilson, 1972; King & Mainwaring, 1974.)
In 1961 Pearlman & Pearlman first showed that 
the prostate and other male accessory sex glands were 
capable of reducing the double bond in the A ring of 
testosterone. Such a metabolic step is not unique, 
for testosterone reduction also occurs in the liver 
(Tomkins, 1957), but a fundamental difference exists 
between the metabolism in this gland and in the 
accessory sex organs,in that the liver produces both 
5ot and 5^ reduced androgens whilst the sex organs 
produce almost exclusively .reduced steroids
(King &. Mainwaring, 1974). This difference may be
explained in terms of the relative functions of the 
organs for whilst in the liver steroid reduction is 
a, method of diminishing the biological potency of a 
variety of hormones, in the sex organs the reduction 
of testosterone is the key metabolic step in the 
normal control of those glands.
That DHT is a more potent androgen than 
testosterone in the prostate can be demonstrated by 
the relative ability of these steroids to maintain 
epithelial cell heights and secretory activity
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(Lasnitzki, 1970; Rebel et al.,1971). Furthermore,
administration of DHT to immature castrated rats
produces a greater proliferative effect on the
ventral prostate than does testosterone (Lesser &
Bruchovsky, 1975; Schmidt et al.,1972) and after
prolonged castration of male rats there is a very
slow regeneration of the prostate during the first
week of testosterone administration compared to the
immediate response to DHT administration. Lesser &
Bruchovsky (1973) suggest that the delay observed
with testosterone replacement may represent the time
necessary for the induction of the 5%-reductase
enzyme which facilitates the conversion of
testosterone to DHT.
%
When H-testosterone is injected into castrated
rats there is rapid and selective uptake of the
steroid into the prostate. The radioactivity can
?
be detected in the prostatic nuclei as ^H-DHT boimd
to an acid nuclear protein as early as 15min* after
administration (Anderson & Liao, 1968; Bruchovsky &
Wilson, 1968,b; Hansson et al., 1 971 ). There is
selective retention of the DHT in the prostate for
?
at least six hours although H-testosterone disappears 
from the blood long before this time (Fang et al., 1969).
Whilst there is much evidence to show that DHT 
is the most potent androgen in the prostate and 
certain other androgen dependent tissues of man
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this is probably not a universal finding for all 
androgen dependent or responsive tissues. For 
example in rabbit and rat embryos DHT formation is 
rapid only in the urogenital sinus (Wilson &
Lasnitzki, 1971), and may be an inherent property 
of the tissue rather than a result of androgen action. 
In contrast the mullerian and wolfian ducts acquire 
the ability to form DHT only after the initial stages 
of differentiation implying that the acquisition of 
testosterone reductase activity in these 
particular tissues may be the result of testosterone 
itself (Wilson & Lasnitzki, 1971).
The human embryo exhibits a similar pattern of 
events (Siiteri & Wilson, 1974), DHT formation in the 
urogenital tract being greatest at the onset of male 
differentiation, whereas in the wolfian ducts DHT 
formation is not demonstrated until late in male 
differentiation. This suggests that testosterone 
itself may have a role to play in this important 
stage of development, a suggestion which is supported 
by Gupta & Bloch (1976), who showed a testosterone 
binding protein which increases in concentration with 
progressive wolfian duct differentiation. From 
measurements of testosterone and DHT in plasma and 
various tissues Robel et al., (1973) propose that in 
the adult animal testosterone is the active hormone 
in muscle, kidney, hypothalamus and pituitary, whereas
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it is a prehormone, requiring reduction to DHT, 
in the prostate, seminal vesicles and other 
accessory glands.
This complex situation concerning the relative 
physiological roles of testosterone and DHT in 
androgen action at target tissues has in part been 
clarified by Hhi^rato-McGinley et al, , (1974), who 
have located a group of male pseudohermaphrodites in 
a village in the Dominican Republic. These affected 
males (46XT) are born with ambiguity of the external 
genitalia and are mostly raised as females. At 
puberty there is marked virilisation and the subjects 
assume their true male phenotype. A geneological 
table indicates that the syndrome exhibits autosomal 
recessive inheritance. Biochemical evaluation 
reveals a decreased plasma DHT concentration 
secondary to a decrease in testosterone 5^-red‘actase 
activity. By studying the clinical details linked 
to this deficiency it has been possible to distinguish 
between organs which are sensitive to testosterone 
and others which are sensitive to DHT. Testicular- 
testosterone acts directly on wolfian ducts to cause 
differentiation to vas deferens, epididymi and 
seminal vesicles, but in the urogenital sinus and 
urogenital tubercle testosterone functions as a 
prehormone where its conversion to DHT results in 
the differentiation of the external genitalia and
16
prostate. Again at puberty both testosterone and 
DHT are necessary for the androgen induced changes.
In particular increase in muscle mass, growth of 
phallus and scrotum and deepening of the voice appear 
to be mediated by testosterone and occur in the 
affected males. Prostate growth, facial hair, 
temporal regression of the hairline and acne do not 
occur and appear to be mediated by DHT. Sexual 
orientation after puberty is male even although the 
subjects have been raised as females, thus male sex 
drive appears to be testosterone rather than DHT 
related.
3- Testosterone 5%-Heduction within the Prostate Gland.
Bruchovsky (1971) compared the fate of seven 
natural androgens administered to castrated, 
functionally hepatectomised rats and found that for 
all these steroids the major metabolite in the 
prostatic nuclei was DHT,and he suggested that all 
natural androgens possessing a significant degree of 
potency are metabolised in varying amounts to DHT.
The initial 5‘^ -reduction of testosterone thus plays 
a central role in the mechanism of androgen action 
and since this fact has been recognised considerable 
research has been directed towards a study of the 
various steroid metabolising enzymes in the prostate 
and other androgen dependent tissues,and especially
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to the enzyme which facilitates the conversion of 
testosterone into DHT, the NADPH:A^^-^-ketosteroid- 
3%-oxidoreductase (B.C.1.3.1.4.) or as it is more 
conveniently called, testosterone 5#-rednctase.
This work has been reviewed by King & Mainwaring,
(1974) and Wilson & Gloyna, (1970). A scheme for 
this key reaction is shown in fig. 1-4.
Testosterone 5ot-reductase is located 
predominantly in the nuclear and microsomal fractions 
of the cell (Nozu & TCtmaoki, 1973), the nuclear 
enzyme being located on the outer nuclear membrane 
(Moore & Wilson, 1972). This is in contrast to 
testosterone 3*-reductase in liver which is located 
in the cytoplasmic fraction (Hajj, 1 972)»
Testosterone 5oC-reductase has an absolu be 
specificity for NADPH as its cofactor (Chamberlain 
et al,, 1966) and for both the microsomal and nuclear 
enzymes of rat ventral prostate the stereospecific 
transfer of the proton is from the 4-pro-8-proton of 
NADPH (Hozu & Tamaoki, 1974).
The kinetic properties of the nuclear and 
cytoplasmic (microsomal) 5#^reductases of the rat 
prostate have been studied in great detail and on 
the grounds of pH optima and Km values for 
testosterone it was suggested that the two forms are 
identical (prederiksen & Wilson, 1971). This is not 
surprising since the outer nuclear membrane in which
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the 5o(.-reductase is located is merely an extension
of the endoplasmic reticulum which results in the
microsomal fraction.
It is not yet known whether the location of the
5oC-reductase on the outer nuclear membrane serves anj’
physiological function. Nozu & Tamaoki (1973)
observed that cytosol caused the inhibition of 
%
E-testosterone reduction in microsomal incubations 
but not in nuclear incubations. This appears to be 
the only major difference between the two enzymes 
and they suggest that in vivo the nuclear membrane 
may be the more important site of DHT production.
Moore & Wilson (1974) have partially purified 
the rat prostatic 5(K-reduotase using digitonin and 
potassium chloride. They report a 90 fold 
purification of the NADPH stabilised enzyme which 
sediments at 13.5 - 15s and has a molecular weight 
of 250,000 - 350,000. The pH optima of 6,9 and 
Km of 0,7x10"^M(nuclear) and 0,8x10™^M(microsomal.) 
are similar to those foimd in intact nuclei and 
mlcrosomes. Digestion of the nuclear membrane by 
phospholipase A was the method used by Shimazaki 
et al,, (1973) to obtain a 20 fold purification of 
the enzyme. The pH optima here was reported to be 
around 7.2 and again there is a requirement for 
NADPH as the obligatory hydrogen donor.
The liver also contains a high testosterone
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5oc-reductase activity. However, the intracellular 
distribution is different in the liver with only 
about \ fo of the activity being associated with the 
nuclei, the vast bulk being recovered from the 
cytoplasmic membranes (Roy, 1971). It also appears 
that hepatic 5X-reductase is not a single species, 
and at least five 5&-reductases have been detected, 
each having different substrate specificities, and 
regulated to different extents by protein and steroid 
hormones (McGuire & Tomkins, 1960; McG-uire et al.,1960).
From a comparison of kinetic parameters it would 
appear that the liver and prostatic nuclear 
testosterone 5&-reductases are not only functionally 
but probably structurally different, and regulatory 
control of the enzymes also appears distinctly 
different (Gustafsson & Pousette, 1974) since the 
prostate enzyme, unlike that of the liver, cannot 
reduce steroids with oxygen substitutions at  ^ (e.g. 
cortisol and corticosterone) (McGuire & Tomkins,1960), 
but can reduce 17«--hydroxy-4-pregnene-3,20-dione and 
20#-hydroxy-4-pregnene-3nne at a greater rate than 
the liver enzyme (Frederiksen & Wilson, 1971).
The liver enzyme is also stimulated by administration 
of medroxyprogesterone, (Gordon et al., 1971) whereas 
the prostate enzyme is not affected (Frederiksen & 
Wilson, 1971).
Recently Moore &. Wilson (1976) have reported that
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in fibroblasts from genital skin there are two 
distinct 5'^-reductase enzymes. The major activity 
is located in the microsomal fraction and has a 
narrow pH optimum around pH 5.5. The second 
activity which is not limited to genital skin and 
found largely in the 100,000g supernatant has 
maximum activity over the range pH T~9. The 
physiological significance of this observation is 
not certain.
The testosterone o^^ —reductase of rat prostate 
is itself androgen dependent since castration causes 
a decreased concentration of the enzyme which can be 
reversed by androgen replacement therapy (Gustafsson 
& Pousette, 1974; Moore & Wilson, 1973).
A study of DHT formation in the prostates of 
several species before and after puberty reveals a 
fall in enzyme activity in the cat and bull, and an 
increase in the dog, whilst in man and rat the levels 
remain high (Gloyna & Wilson, 1969). These authors 
suggest that the high levels of DHT after maturation 
in the prostate glands of man and dog may have 
implications in the development of benign hyperplasia, 
although DHT levels are also high in the rat prostate 
which is not normally subject to this condition. In 
the same study a wide range of rat tissues were 
assayed for 5&-reductase activity and were:-
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prostate> epididymus > seminal vesicle > 
penis > scrotum > kidney > skin > liver > others.
A similar study by Verhoeven et al., (1974) 
showed the order of activity to be;-
lung > prostate > kidney > submaxillary gland > 
midbrain.
It is probable that androgens exert their effects 
by different mechanisms in androgen dependent tissues, 
such as prostate, and in androgen responsive tissue 
such as liver (Tomkins, 1957) and kidney (Verhoeven 
& De Moore, 1971) and this may account for the 
different constraints imposed on the 5ot~reductases 
from the various tissues studied.
Moreover, the in vitro demonstration of the 
testosterone 5oC-reductase activity within a specific 
tissue does not necessarily imply that the enzyme 
has a key role to play in the intact cell since 
discrepancies between in vitro and in vivo DHT 
formation have been observed in liver and kidney 
(King &L Mainwaring, 1974).
An important feature of the testosterone 
5oC-reductase enzyme is that the reaction it catalyses 
appears to be irreversible both in vitro (McGuire 
et al., I960; Roy, 1971) and in vivo (Robel et al., 
1971). The reaction is usually assumed to be a 
direct transfer of hydrogen from NADPH to 
testosterone. However Roy (1971) has suggested that
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this in fact may not he the case, especially since
most enzymes involved in the reduction or formation
of a carbon-carbon double bond require a flavin, e.g*
acyl CoA dehydrogenases, succinic dehydrogenase,
and the 5p”Steroid dehydrogenase from
P^testosteroni (Davidson & Talalay, 1966). Also,
most reactions involving NADPH directly are freely
reversible. There is however no evidence for the
involvement of a flavin, since atebrin is not an
inhibitor of the reaction (McGuire et al., I960;
Roy, 1971). It has also been suggested by Roy (1971)
that 5&-reductase activity may not be due to a single 
may
enzyme but^bè a function of the cytochrome P^^^ 
system and although he showed that carbon monoxide 
does not inhibit the testosterone 5<X-reductase of 
rat prostate microsomes, the involvement of some 
cytochrome cannot be totally excluded.
The distribution of testosterone 5#-reductase 
activity between the different cellular components of 
the prostate has been investigated, but agreement on 
the matter has not yet been reached. Becher and 
co-workers (1972) reported that in human benign 
prostatic tissue the amount of testosterone 
5ct-reductase activity depended on the proportion of 
epithelial elements in the tissue, but Jenkins & 
McCaffery (1974) reported no such correlation. Two 
groups of workers have separated stromal and
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epithelial elements of hinnan. pro static tissue and 
whilst Harper et al., (1974) report higher activity 
in the epithelial fraction, Cowan et al., (1977) 
found enrichment of testosterone 5oC-neductase 
activity in the stromal fraction.
4# Farther Androgen Metabolism withkthe Prostate>
Although testosterone 5(A-reductase may he 
regarded as being of central importance in androgen 
action in the prostate, it is not the only steroid 
metabolising enzyme present, and DET is far from 
being the only androgen isolated from the tissue. 
Numerous reports have been made of the capacity of 
prostatic tissue to metabolise steroids (King & 
Kainwaring, 1974) and a detailed description is 
beyond the scope of this section. However, an 
attempt will be made to summarise the concensus view 
of androgen metabolism in the human gland, and 
differences between species will be illustrated.
Quantitatively the 3#-androstanediol8 are major 
constituents of human prostatic tissue and although 
3%^androstane-3#»17^ -diol is the most abundant of 
these, the isomeric diol 5&-androstane-3p,17p-diol is 
also formed in small quantities (Bruchovsky & Wilson, 
1968(b)) indicating clearly that both 3oc~hydroxysteroid 
dehydrogenase and 3p“hydroxysteroid dehydrogenase are 
present in the tissue.
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Whilst ïaurog and co-workers (1975) could detect 
no 50^ —androstane-3p> 17p-diol formation from DHf in 
the rat prostate, Levy and associates (1974) on the 
other hand did show reduction of DHT to this 
androstanediol in the cytosol fraction, but activity 
of the 3(^ “hydroxysteroid dehydrogenase was much lower 
than that of the 3o(-hydroxysteroid dehydrogenase and 
would indicate that the pattern of 5^‘“androstanedio3.s 
is very similar to that of the human gland. In the 
canine prostate there is a notable difference, where 
in addition to the two specified 5#-androstanediols, 
both 9#^androstane-3#,17^-diol and 5#^androstane—3^, 
17o^-diol have also been isolated as products of 
testosterone metabolism (Griffiths^^1970; Harper et al., 
1971). The possession of a 17oC-hydroxyl, group suggests 
that DHT is not involved as an Intermediary in the 
formation of these steroids. It has been claimed that 
very low levels of the 17#-hydroxy-5#-androstanediols 
can also be found in cultures of rat prostatic tissue 
(Griffiths, 1970), but superfusion of human 
hyperplastic tissue with labelled precursor failed to 
demonstrate significant levels and at best the 
1 7o<-hydroxy-5oC“'androBtanediols are minor metabolites 
of testosterone in the human gland (Beastall, 1975),
The conversion of DHT into 5c<-andro8t@ne-5(f-"17^- 
diol is a reversible reaction in vivo since the 
administered diol is rapidly taken up by the prostate
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and converted readily to DHT. In a similar 
experiment the ^P-isomer remained almost unchanged 
(Horst et al.» 1975). These findings confirm the 
earlier in vitro observations of Lasnitzki (1970).
More recently Malathi & Gurpide (I977,a)have shown 
significant interconversion of DHT and 5tX-androstane~ 
3w,17p-diol in superfused human prostate, with the 
equilibrium favouring DHT formation. However, a 
partially purified preparation of 3%-hydroxysteroid 
dehydrogenase from rat prostate favoured the reduction 
of DHT (Inano et al., 1977).
The intracellular location of and 3^- 
hydroxysteroid dehydrogenases has not been finalised 
for whilst Bruchovsky & Wilson (1968b) report that 
both the enzymes of rat prostate are located in the 
soluble fraction, Levy and associates (1974) produce 
evidence that the 3oC-hydroxysteroid dehydrogenase of 
the same tissue is found in all subcellular fractions 
but is concentrated in the microsomes. In the canine 
prostate both 3^- and 3p“-hydroxysteroid dehydrogenase 
have been found in microsomal and soluble fractions 
(Jacobi & Wilson, 1976). The cofactor requirements 
of the two enzymes are also a little uncertain foi* 
whilst both NADH and NADPH are effective cofactors for 
both reactions in canine prostate (Jacobi & Wilson,
1976), the former is preferred for the 3P““hydroxysteroid 
dehydrogenase of rat prostate (Levy et al., 1974) and
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the latter preferred for the 3oC“hydroxysteroid 
dehydrogenase of the same tissue (Inano et al .,1977).
The physiological function of the 5&-androstane- 
diols can at present only he speculative. By 
analogy to the liver it may he tempting to suppose 
that reduction of the ketone group on carbon atom 3 
Is merely an effective way of inactivating BET prior 
to excretion, but the accumulation of these diols 
in the tissue contraindicates such a supposition, as 
does the reversible properties of the 3<i™hydroxysteroid 
dehydrogenase itself.
Whilst possessing some androgenic activity, 
boC-androstane -3#^1^3-diol is much less potent than 
either testosterone or BET in maintaining the structure 
and function of the prostate, In castrated rats
the androgenicity may be explained by its conversion 
to BET (Schmidt et al., 1973). Baulieu et al., (1968) 
have suggested that whilst BET and 5%-androstane-3#, 
17^-diol stimulate cell division and perhaps 
hyperplasia, 3#-androstane-3^,17p"diol maintains 
epithelial cell height and stimulates secretory 
activity. Such a conclusion must, however, be 
treated with caution since the data on which it was 
based was obtained by the addition of non- 
physiological amounts of steroid to tissue culture 
preparations. The role of the hydroxysteroid 
dehydrogenases in the aetiology of human benign
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prostatic hyperplasia is thus uncertain although 
Geller et al., (1976) suggest that the accumulation 
of DHT in BPH may in part be related to a relative 
reduction in the activity of the 3#-hydroxysteroid 
dehydrogenase.
In canine prostate it seems more likely that a 
role may exist for 5%-androstane-3#,17%-diol since 
Evans and Pierrepoint (1975) have demonstrated a 
specific cytosol receptor for this diol which does 
not bind either testosterone or DHT, and the same 
steroid was the only one of the four isomeric 
5#-androstanediol8 which maintained the epithelial 
height and secretory activity of explants of tissue 
cultured for up to 5 days (Sinowatz & Pierrepoint,
1977).
Although DHT and the androstanediols are the 
major products of testosterone metabolism in the 
prostate, in vitro incubations of radioactive 
testosterone have produced a multiplicity of products. 
For example Chamberlain et al., (1966) identified ten 
metabolites during long term incubations of human 
prostatic homogenates. The incubation conditions 
of high substrate concentration and long incubation 
times (2h) permitted the full metabolic potential of 
the tissue to be expressed, and thus it was shown to 
contain 3(2» and 17f>-hydroxysteroid dehydrogenases, 
and 5 ^ - and 5p-reductase8 and some unidentified
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hydroxylases.
In vivo perfusion studies of human hyperplastic 
tissue have confirmed the existence of the three 
hydroxysteroid dehydrogenases but not the 5^-reductase 
(Morfin et al., 1970). In vitro perfusion of 
hyperplastic human prostatic tissue also failed to 
confirm ^^-reduction and Beastall (1975) suggests 
the pattern of metabolism shown in fig. 1-5 as the 
most appropriate for the human gland. From this 
scheme all the 5#-reduced steroids containing at 
least one hydroxyl group appear to be retained in the 
tissue more avidly than testosterone whilst the two 
diketones are apparently liberated from the tissue 
more readily than testosterone.
To this point the discussion of the steroid 
metabolising capacity of the prostate gland has been 
centred around its ability to convert testosterone as 
substrate. The human prostate gland contains a very 
active dehydroepiandrosterone sulphate sulphatase and 
as such is capable of hydrolysing some of the large 
number of conjugated steroids transported in plasma 
(Farnsworth, 1973). However the ability of the tissue 
to metabolise steroids unsaturated between carbon 
atoms 5 and 6 is very limited (Beastall, personal 
communication) although small amounts of 
dehydroepiandrosterone have been reported to be 
converted into DHT (Harper et al., 1974). Human
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prostate Is imable to convert steroids such as
pregnenolone and progesterone into the 0^g androgens 
(Struthers, 1975) and although the G^^ steroids may 
well have a key role in the control of androgen 
metabolism this results from their ability to inhibit 
the enzymes of androgen metabolism rather than from 
conversion into the androgens themselves.
5. Factors Controlling Androgen Metabolism within
the Prostate Gland.
Testosterone metabolism within the prostate is 
of central importance for the maintenance of structure 
and function of the gland. Control of this androgen 
metabolism is essential in maintaining the proper 
concentration of each metabolite and integrating the 
function of the gland with that of the whole animal. 
Several compounds, both synthetic and natural, have 
been shown to influence this metabolism, and a brief 
discussion of these is appropriate at this point.
It was stated earlier that the prostate has a 
high zinc content, and that the concentration and 
metabolism of this metal is under androgenic control 
(Mann, 1964). At least three specific zinc binding 
proteins from the prostate have been reported (Habib 
& Stitch, 1975; Reed & Stitch, 1975), and one of 
these has been purified and amino acid analysis shows 
it to have a high molar proportion of histidine, which
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probably accounts for its zinc binding capacity
(Heathcote & Washington, 1973). Although the zinc
content of the gland is under androgen control, the
zinc itself appears to influence testosterone
metabolism. In human hyperplastic prostate there
is an inverse relationship between the total zinc
content and testosterone 5ot-reductase activity
(Habib et al., 1975). Other divalent cations such
as H , Cu , Cd and Mg have also been shown to
affect the activity of this enzyme in both the human
(Wallace, 1975) and rat prostate (Frederiksen &
Wilson, 1971). These cations exhibit competitive
kinetics with respect to the HADPH cofactor, and the
explanation for this may be due to the inactivation
of an -SH group at or near the cofactor binding site
as reasoned by similar results being obtained with
specific thiol group blocking agents (Wallace, 1975),
Circulating hormones may also influence prostatic
androgen metabolism. The responsiveness of rat
accessory sex organs to androgens is diminished by
hypophysectomy and augmented by several pituitary
hormones, particularly prolactin (Baker et al., 1977).
These workers suggest that their results of increased 
%
H-DHT uptake into the nuclei may be due to an 
alteration in the androgen receptor mechanism. 
NegrO“Vilar et al., (1977) also obtained evidence 
for a role of prolactin in the growth of rat prostate
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and seminal vesicles by the use of anterior 
pituitary grafts. However, at physiological 
concentrations the conversion of testosterone to 
DHT in cultured rat ventral prostate cells was not 
affected by prolactin (Johansson, 1976).
It has been suggested that the adrenal glands 
also may influence prostatic growth (Fingerhut &
Veenema, 1967; Tisell, 1970; Tullner, 1963),
Tullner (1963) showed that ACTH affected the ventral 
prostate of immature castrated rats, but not if they 
were also adrenalectomised•
Estrogen therapy has been widely used in the 
treatment of prostatic cancer to suppress growth. 
Pharmacological doses of the steroid results in a 
lowering of testosterone secretion from the testis 
through suppression of pituitary gonadotrophins. 
However, there is also evidence of a direct influence 
of estrogens on the androgen metabolism within the 
prostate. Changes in metabolic clearance rate and 
transport have been reported (Bird, et al., 1971) 
and it is suggested that the beneficial effects of 
estrogen therapy in patients with prostatic carcinoma 
may be related to this increase in testosterone 
metabolism. Estrogens, both natural (estradiol) 
and synthetic (stilboestrol and ethinylestradiol) 
also inhibit the testosterone 5oC-~red\ictase in vitro, 
but at pharmacological concentrations (Bonne &
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Raynaud, 1973; Jenkins & McCaffe.ry, 1974; 
lee et al., 1974).
Progestins as a group also have distinct 
antiandrogenic properties, and,like estrogens^part 
of this activity almost certainly includes suppression 
of pituitary LH (Chisholm, 1970). Cyproterone 
acetate acts by selectively blocking the binding of 
DHT to the androgen receptor in the rat prostate but 
has no effect on the testosterone 9%-reductase 
activity (Fang & Liao, 1969; Orestano et al., 1975). 
Progesterone itself may bind to the androgen receptor 
but in vitro has been shown to be a potent inhibitor 
of the testosterone 5tX-reductase (Jenkins & McCaffery, 
1974; Tan et al., 1974). The effect of these and 
other progestins will be discussed more fully in 
Chapter VI.
Some aldosterone antagonists have progestin 
like structures and in this context have aroused 
interest as possible antiandrogens. Basinger &
Gittes (1974) reported a 40^ atrophy of the prostate 
and seminal vesicles of mature rats injected with 
spironolactone for ten days. Apart from a direct 
antiandrogenic effect on the prostate by binding to 
the androgen receptor (Bonne & Raynaud, 1974;
Corvol et al,, 1975), spironolactone also decreases 
the activity of testicular 17^-hydroxylase (Menard 
et al,, 1974) resulting in Increased plasma
pprogesterone and 1To^-hydroxyprogesterone (Stripp 
et al,, 1975). These compounds also will be 
discussed more fully in the appropriate chapter 
(chapter IV).
Heparin is a naturally occurring polyanionic 
mucopolysaccharide, and is a drug in common use in 
anticoagulation therapy. It has been reported to 
inhibit the steroid 5^—reductases in several organs, 
including the testis (Kizanowski & Troop, 1968), 
adrenals (Lakatos et al., 1970), liver (Steinberger 
&  Fisher, 1971) and more relevant to the 
considerations here, in rat prostate (Blaquier & 
Calandra, 1975)» Most of these observations have 
been made in vitro but in vivo small effects on 
liver b&^reductase have been reported (Carter et al,,
1 968) and heparin was also observed by these authors 
to have an antiinflamatory effect in intact, but not 
in adrenalectomised rats. Like progesterone and 
spironolactone, heparin will be discussed more fully 
in the appropriate following chapter (Chapter III).
6. The Mode of Action of Androgens.
Steroid hormones have been known for many years 
to exert dramatic effects on their target cells, but 
it is only in recent years that their mode of action 
has been elucidated.
Early work by G-orski & Morgan (1 967) and
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Jensen et al., (1968) followed the progress of 
17^-estadiol within its target organ, the rat uterus, 
and showed that it hound to two distinct types of 
protein. The proteins which bound the steroid 
with low capacity but high affinity were called 
specific receptors, and were responsible for the 
transportation of the bound steroid from the 
cytoplasm to the nucleus. The other proteins, with 
high capacity and low affinity were called storage 
receptors (Wurtman & Jensen, 1968) and were probably 
plasma binding globu].ins. Considerable interest 
was stimulated by these findings and it was not long 
before a general picture for the action of all steroid 
hormones emerged. (See King & Mainwaring, 1974? 
O'Malley & Schrader, 1 976, for general reviews.)
The steroid must first pass through the plasma 
membrane before binding to the specific receptor in 
the cytoplasm. A transformation of the hormone 
receptor complex takes place followed by transfer 
to the nucleus, where the steroid can interact with 
the chromatin, ultimately causing the synthesis of 
new proteins. In the case of 17p>~ostradiol the 
plasma steroid is bound directly to the cytoplasmic 
receptor. On the other hand steroids such as 
testosterone in the prostate, require modification 
by cytoplasmic enzymes before binding to the 
specific receptor takes place. A scheme for the
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mode of action of testosterone within the prostate 
is shown in fig. 1-6.
It is apparent from the above brief account 
that the mechanism of action, of the steroid hormone 
is fundamentally different from that of the protein 
hormones whose receptors are contained in the plasma 
membrane, and it is therefore perhaps not surprising 
that cyclic il'-IP cannot mimic the androgen effect 
(Graven et al., 1974; Lesser & Bruchovsky, 1973; 
Sanborn et al., 1975).
Vdien the prostatic cytoplasmic receptor was 
isolated two to five minutes after the administration 
of [pH]"testosterone to rats, binding was found 
predominantly to a protein with a sedimentation 
coefficient of 8S, whereas at longer times of 
labelling a 3,58 receptor was predominant (Mainwaring 
&  Beterkin, 1971), indicating that some transformation 
takes place after the binding. This conversion from 
8S to 3.58 form of receptor has been shown to be 
temperature dependent, and to precede the transfer 
of the DHT-receptor complex into the nucleus.
The specificity of the prostatic androgen 
receptor has been studied and the apparent binding 
constants for a number of androgens, antiandrogens 
and estrogens showed that all the common prostatic 
metabolites of testosterone had a measurable affinity 
for the rat cytoplasmic receptor and demonstrated
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that the presence of a 3™keto or 17(2>“hydroxy function 
on the steroid nucleus Is a strong determinant of the 
binding efficiency (Shain & Boesel, 1975). Skinner 
et al.» (1975) showed that DHT binding was inhibited 
by several steroid analogues, the most effective had 
generally planar geometry and were known to possess 
potent androgenic activity.
The receptors in various organs other than the 
prostate have also been studied. Krieg & Voigt 
(1976) showed that whilst the androgen receptor has 
the same physiochsmical properties in the prostate, 
levator ani and skeletal muscles, the dissociation 
constants for testosterone, DHT and 19~nortestosterone 
were different in the different tissues. Conversely 
a comparison of the binding properties of the 
androgen receptor for testosterone and DHT in the rat 
testis, epididymis and prostate (Wilson & French,
1976) suggested that in these three tissues the 
receptors are Identical. These differing results 
may perhaps be explained by the fact that in the 
first study a mixture of androgen dependent and 
androgen responsive tissues were studied whereas in 
the second study only androgen dependent tissues were 
investigated.
The presence of the androgen receptor in 
androgen responsive cells is of prime importance, 
and it might be expected that at least a small
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receptor concentration would be present at all 
times, regardless of the androgen status of the 
animal. Whilst this may be partially true there is 
evidence that external factors also exert an 
influence on the receptor level* Ageing in the rat 
has a marked effect on the prostatic androgen 
receptor concentration, A decrease in receptor 
content is seen to occur abruptly at about 300 days 
of age, falling to about 57^ of the level found in 
the younger animals. The histology of the prostates 
from the older group revealed an increase in the 
number of alveoli containing low epithelial cells, 
and a decrease in secretion, indicating a regression 
in the gland as a whole (Shain et al., 1975).
Castration has also been shown to have an effect 
with an initial fall in the rat androgen receptor 
concentration to virtually undetectable levels being 
seen after four days (Sullivan & Strott, 1973) or 
seven days (Bruchovsky & Craven, 1975) post surgery.
The difference in the rate of decrease is probably 
due to the different experimental methods employed, 
Sullivan & Strott (1973) reported that whilst the 
receptor level in the prostate as a whole remained 
low after the fourth day, the levels per cell 
returned to near normal by the eighth day, and were 
maintained for six weeks at least. This can only 
occur if there is a net synthesis of protein, or
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a loss of DÏÏA without loss of receptor, the latter 
being unlikely. As these observations were also 
made with animals which had been either 
adrenalectomised or hypophysectomised at the time of 
castration it would indicate that the observed 
restoration of receptor is independent of androgens, 
Bruchovsky & Craven (1975) indicate by tissue mixing 
experiments that day 7 prostates contain factors, 
presumably proteolytic enzymes from disrupted 
lysosymes, which can eradicate the binding of DHT 
to the receptor and may in part explain the 
initial fall in receptor level.
To date, the majority of information about the 
androgen receptor has been obtained from the rat 
prostate. This tissue is easily obtainable, and 
homogenises well, and the hormone status of the 
animal can. be changed by castration, adrenalectomy, 
hypophysectomy or drug administration. The human 
prostate on the other hand is more difficult to 
obtain, especially normal tissue, and because of 
the large proportion of stromal and connective 
tissue the human gland is much more difficult 
to work with. Good liaison with surgeons and 
improved techniques have resulted in the use of 
benign hyperplastic and carcinomatous human tissue 
by several groups of workers, and one hopes that this 
will lead to a rapid increase in our knowledge about
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androgen receptors in the human gland,
T, Benign Prostatic Hyperplasia and Prostatic
Carcinoma.
A. Benign prostatic hyperplasia.
It has been estimated that up to 80^ of men 
over 70 years of age have enlarged prostates 
resulting from benign prostatic hyperplasia (BPH) 
(Pranks, 1954). This is a nodular hyperplasia which 
arises in the inner region of the prostate near the 
urethra, and is distinct from prostatic carcinoma 
which arises in the outer region (Scott, 1963). The 
majority of hyperplasias seen are stromal in origin, 
but there are also a substantial number of cases of 
adenomatous (epithelial) hyperplasias. The factors 
responsible for the initiation of BPH have not been 
fully elucidated. After middle age the production 
of androgen falls and the relative ratio of estrogens 
increases and it may be that prostatic enlargement 
results from this change. However, if the 
enlargement were due simply to reduction in androgen 
secretion, then it would be expected that hyperplasia 
would follow castration, but this never occurs.
Thus it appears that some element of testicular 
secretion may be required (Hewsam & Thomson, 1974).
There is evidence that 5cC-dihydi*otestosterone 
may be implicated, as the concentration of this steroid
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in hyperplastic tissue (0.60 g/100 tissue) was found 
to be higher than in normal tissue (0.13 g/IOOg tissue) 
and that in prostates with early hyperplasia the DHT 
content in the periurethral (inner) area where 
hyperplasia usually commences, was two and three times 
greater than in the outer region of the gland (Siiteri 
& Wilson, 1970). However whether this increased DHT 
content is a cause or an effect of the benign 
hyperplasia remains to be decided by further 
experimentation,
The development of a hyperplastic prostate in 
itself poses no great danger to the patient as this 
is a benign condition. However, enlargement of the 
gland may interfere with the proper functioning of 
the bladder thus causing discomfort and greatly 
increasing the risk of urinary tract infection and 
kidney disorders.
Growth of the median lobe into the bladder can 
cause an increase in residual urine behind the 
projection, or may cause obstruction of the bladder 
opening into the urethra. Growth of the lateral 
lobes in the area surroimding the urethra gradually 
compresses the outer region of the prostate into what 
is known as the false capsule and continued growth 
will cause pressure on the urethra making urination 
more difficult. These symptoms may be temporarily 
removed by catheterisation, but in the long term the
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only satisfactory method of treatment is the surgical 
removal of either the whole or the offending part of 
the prostate.
Prostatectomy for benign enlargement consists 
of removal of the enlarged inner glands and leaves 
intact the compressed outer group of glands (false 
capsule) and the true capsule. A plane of cleavage 
allows easy digital enucleation by several approaches. 
After removal, the raw prostatic cavity becomes lined 
with epithelium in seven to ten days (Newsam &
Thomson, 1974).
Hormonal therapy ha,s also been, advocated as it 
has been repeatedly shown that growth of the prostate 
depends on its hormone environment. This would be 
especially attractive as many patients with benign 
prostatic hyperplasia fall into the poor surgical 
risk class.
Pituitary hormones exert a direct effect on the 
prostate, as was shown by Grayhack (1963) using 
hypophysectomised and castrated rats. The 
hypophysectomy causing greater prostatic regression 
than castration, Lawrence & Landau (1965) showed that 
prostatic uptake of H-testosterone was much less in 
hypophysectomised animals, and Farnsworth (1970) 
suggested that prolactin may also be involved since 
slices of BPH tissue take up more H-testosterone 
when prolactin is present in the culture medium,
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than do controls.
In the past, treatments using estrogens or 
androgens (Heckel,1944) or combinations of both, 
have been tried but conflicting results were obtained. 
Synthetic estrogens, such as ethinyl estradiol have 
proved valuable in halting or reversing the growth 
of prostatic carcinoma, but have little effect on 
benign hyperplasia (Briggs & Briggs, 1973) and 
unpleasant side effects including breast enlargement 
are known to occur.
Progestins as a group have a similar effect to 
estrogens. Their mode of action almost certainly 
includes the suppression of pituitary hormones 
(Chisholm, 1970) and thus testicular testosterone, 
as well as any direct effect. Results of drug 
trials give conflicting results as to the usefulness 
of many of the compounds, but some encouraging 
results have been observed. Further discussion of 
progesterone treatment will be found in Chapter VI.
B. Prostatic Carcinoma.
Prostatic carcinoma is the second most common 
cancer of the male, and causes approximately 7^  ^- 
of all deaths due to tumours in men over fifty 
years of age in the United-Kingdom (Franks, 1974), ■
The cause of prostatic cancer, like that of most 
other cancers remains obscure, but the incidence 
appears to be subject to some racial and
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geographical differences (Franks, 1974).
The outer region of the gland is the most
common site of origin of the carcinoma (Scott, 1965)
and many of these growths are androgen dependent.
The androgen dependent nature of the disease led to 
the widespread use of estrogens for the clinical 
control of the disease (Huggins & Hodges, 1941). 
Pharmacological quantities of estrogens lower 
testicular secretion of testosterone, probably 
through suppression of pituitary gonadotrophin 
release. Although estrogen therapy causes shrinkage 
of the primary lesion in the prostate it is not a
cure, but only delays the fatal consequences of the
disease.
The prostatic tumour commonly invades local 
tissues such as the bladder, seminal vesicles and 
less commonly the rectum; and transport by both 
blood and lymphatics may cause involvement of more 
distant lymph nodes. ' Bone métastasés are also an 
important feature of prostatic carcinoma, the head 
of the femur, the pelvis, the lumber spine and the 
ribs being the most common sites involved (Hewsam 
& Thomson, 1974).
Diagnosis of the condition may be aided by 
rectal examination and biopsy. High acid 
phosphatase levels are also an indication of the 
condition, although actual levels do not have a
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prognostic value. Bone scanning also has a useful 
place in detecting métastasés (Bhuttelworth & Blandy, 
1976).
Treatment of the disease depends to a great 
extent on the advancement of the tumour and to the 
condition of the patient. Radical prostatectomy 
for a localised growth may he successful, and 
estrogen therapy or removal of the testis may give 
rapid and prolonged relief of symptoms.
Radiotherapy has also become more popular in recent 
years. Varying success rates have been reported 
for each of these treatments, and with continuing 
research one hopes that the prognosis for these 
patients will improve dramatically in future years.
8. Outline of Research.
The initial aims of this project were to 
investigate the effects of heparin and related 
mucopolysaccharides on the prostatio testosterone 
5o(.--reductase enzyme in vitro and in vivo with a view 
to assessing these compounds as potential non-steroidal 
antiandrogens. Measurement of prostatic tissue 
content of heparinoids wa.s also planned.
The work was expanded to investigate the effects 
of the aldosterone antagonists, aldadiene and 
canrenoate, on the ^x-reductase enzyme, since these 
compounds had previously been shown to have
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antiandrogenic side effects.
Many antiandrogenic compounds have a steroid 
nucleus based on that of progesterone and hence have 
progestational actions. Experiments were designed 
to determine the effect of progesterone itself on the 
5oC-reductase enzyme both on homogenised tissue 
preparations and using in vitro superfusion tecniques 
on tissue slices.
At the conclusion of this project it was hoped 
that a greater understanding would be gained of the 
control of testosterone reduction within the human 
prostate, which in turn might contribute to the 
elucidation of the aetiology of benign prostatic 
hyperplasia.
CHAPTER II.
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CHAPTER II.
MATERIALS AND METHODS.
1. MATERIALS.
A. Radiochemicals.
Radiochemicals were obtained from the
Radiochemical Centre, Amersham, as follows:-
[1,2-^h] -Aldadiene 53 Ci/mmole
(Grift from Searle )
[4 —^^C ] -Androstenedione <• 60mCi/mmole
[1 ] “5 c^ "“Dihydrotestosterone .. 47 Ci/mmols
[4-"^ ^ 0 ]-5 “Dihydrotestosterone 50mCl/iTJmole
[1 ,2,6,7-^h] -Cortisol , # 85 Ci/mmole
[^^S ] -Heparin .. 36.7mCl/g on 9/9/1974
( t-i“ = 87*1 days )
[1 ,2,6,7“*^ H ] “Progesterone 80 Ci/mmole
[1,2-^h]-Testosterone ' ,, 49 Ci/mmole
[4- ^ ]  -Testosterone .* 59mCi/mmole
[l7^-^H] -Testosterone •# 5*5 Ci/mmole
The piirity of all radiochemicals was tested by 
chromatography and purification was carried out where 
necessary, before use.
B# Chemicals.
General chemicals were obtained from BDH Chemicals
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Ltd., Poole, England, or from Sigma, London, and were 
of the highest quality available. In addition, the 
following specific chemicals were used:-
Chondroitin Sulphate (Sigma) Grade III 
from whale and shark cartilage,
D-Glucose—6-Phosphate (Sigma) 
monosodium salt.
D-Glucose-6-sulphate (Sigma) 
potassium salt.
D—Glucuronic Acid (Sigma) Grade II 
sodium salt.
D-Glucuronolactone (BDH)
Heparin (Sigma) Grade X 158 1-A units/mg, 
from porcine intestinal mucosa.
N—Acetyl Glucosamine (Sigma)
HAD (Boehringer Mannheim GmbH) Grade I 
Free Acid.
HADP (Sigma)
monosodium salt.
HADPH (Sigma)
tetra sodium salt.
Protamine Sulphate (Sigma) Grade X
from Salmon - essentially histone free,
Poly-L-Glutamic Acid (Sigma) Type 1
sodium salt. Degree of polymerisation - 90.
Rol - 8507 (Hoffmann - Roche, gift)
H-formyl-chitosan polysulphuric acid,
Ro2 - 5055 (Hoffmann - Roche, gift)
mepesulphate.
Ro2 - 7509 (Hoffmann - Roche, gift)
• sulphated cyclohepta amylase.
Ro2 - 7529 (Hoffmann - Roche, gift)
sulphated cyclohexa amylase.
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C* Steroids.
Non-radioactive steroids were obtained from
Steraloids Ltd., Croydon. These were of the purest 
commercially
quality^available and were tested by recrystalisation 
followed by observation of the melting point of the 
crystals obtained.
Aldadiene and Potassium Canrenoate were gifts 
from Searle.
D. Solvents.
Ethanol and methanol, A.R. grade, were obtained 
from Burroughs Ltd. All other solvents were 
purchased from BDH ChemicaJ-S Ltd., and were used 
without further purification.
All aqueous solutions were prepared from glass 
distilled water.
E. Scintillation Materials.
Toluene and Triton X-100 were obtained from 
BDH Chemicals Ltd., Poole, England.
2,5-Diphenyloxazole (P.P.O.) activatoi* and 
1^4Di[2-(5~phenyl-oxasolyl)3 -benzene (P.O.P.O.P.) 
were obtained from Koch-Light Laboratories Ltd.,
England.
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P. Miscellaneous,
Alumina
Aluminoxide 60, PP 254+366 (Type E) 
Merck, Darmstadt.
Silica Gel
Kieselgel HP 254+366 nach. Stahl (Type 60) 
Merck, Darmstadt.
Chromatography paper
Whatman No.l, 5cm wide rolls.
Nybolt, Nylon Bolting Cloth
25T, 45/jpores, obtained from
John Shaniar & Co., Manchester
The scintillation vials used throughout the 
study, unless otherwise stated, were of the plastic 
disposable type and were in general, obtained from 
Intertechnique Ltd., Middlesex.
Several commercially available enzymes were used 
in this studyr Glucose-6-phosphate dehydrogenase
(360 units/mg protein) and 6-phosphogluconate 
dehydrogenase (20 units/mg protein) were obtained 
from Sigma; Pronase (45,000 PUk Units/mg) and 
Trypsin (reagent grade) were obtained from BDH 
Chemicals Ltd., Poole, England.
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2 . METHODS.
A. Chromatographic Methods.
Paper chromatography was used for the purification 
of steroid substrates before use and for the separation 
of metabolic products after experimentation.
The fraction to be chromatographed was evaporated 
under nitrogen, dissolved in a few drops of acetone 
and transferred to a 5cEa x 50cm strip of Whatman No.1 
chromatography paper before being placed in a 
chromatography tank to equilibriate for at least two 
hours. The tank walls were lined with heavy 
chromatography paper saturated with the mobile phase, 
and another strip of chromatography paper was 
suspended into a trough of stationary phase. After 
equilibriation, the paper was developed for 2h by 
descending chromatography, taken from the tank and 
dried in air.
For all the paper chromatography in this study 
a Bush B-3 solvent system was employed (Bush, 1952). 
This has a stationary phase of Methanol/Water:4/1 
and a mobile phase of Benzene/Bet.Ether (Bpt.80-100^0): 
2/1. Both phases were equilibriated with each other 
before use.
The strips were scanned with a Packard 
Radioautogram, scanner to locate the steroids. The
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appropriate regions were cut into 1cm squares and 
eluted overnight with 5-10ml of methanol/HgO:29/1.
The eluate was decanted and the paper rinsed with 
a further 5ml of the solvent. The pooled methanol 
extracts were evaporated under a stream of nitrogen,
(ii) Thin Layer Chromatography (TLG).
Glass thin layer plates (20cm x 20cm) were 
coated with a slurry of either Alumina PF 254+366 
or Silica Gel HF using a Shandon plate
spreader adjusted to give layers 0..3mm thick. The 
powdered adsorbents were mixed with distilled water 
in the ratio Alumina 50g/water 55ml or Silica 25g/ 
water 55ml, to give sufficient slurry for 5 plates.
The coated plates were activated by drying at 115^0 
for l-^ hrs. and stored in airtight cabinets over silica 
crystals prior to use.
Samples to be chromatographed were dissolved in 
a few drops of an appropriate solvent and applied to 
the plates in 2cm streaks with a Pasteur pipette.
A maximum of five lanes per plate were employed to
ensure there was no overlapping of samples when the
plates were developed. The plates were placed in a 
glass tank with a saturated atmosphere and containing 
1-2cm of solvent and developed by ascending 
chromatography until the solvent front was within 
4-5cm of the top of the plates. The plates were
removed from the tank and allowed to dry in the air
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before the spots were visualised under UY light. 
Steroids containing conjugated double bond systems 
were visualised under a 254nm lamp whilst other 
substances were visualised under a 350nm wavelength 
light.
Where appropriate, steroids were removed from 
the plate by scraping the adsorbent into an inverted 
Pasteur pipette plugged with cotton wool and attached 
to a water suction pump. The steroids were then 
eluted either into a scintillation vial or a test 
tube with 2x2ml diethyl ether.
The solvent systems used for separating the 
various steroids are listed in Table II - 1 along 
with their Rf values.
(iii) Gas Liquid Chromâtograchy (GLC).
A Pye 104, type 1 chromatograph fitted with an 
autosolid injection device was used for monitoring 
the recovery of certain steroids.
For the quantitation of 5<X-androstanediols and 
their diacetates, a 7ft. x -J-inch column filled with 
SE30 on Gas chrom (A was used at 240^0, whilst for 
progesterone, 5X-pregnane-5,20-dione, and 3§-hydroxy- 
5c/-pregnane-20-one the column was 6ft, x 'J-inch 
filled with SE30 on Gas chromd and maintained at 
210°0. In both cases the carrier gas was Nitrogen
used at a flow rate of 60ml/min,
A standard flame ionisation detector was employed,
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Table II - 1
Solvent systems used for the separation of steroids 
and the Rf.values obtained.
1 .
Solvent
System
CyTohexane/
Ethylacetate
3/1
Type of 
TLC 
Plate
Steroid
Alumina 5û^-pregnane- 
3“0l ,—20—one
progesterone
testosterone
acetate
50s.-pregnane ~
5,20-dione
DHT acetate
5oC-androstane-5c<»
17(^-diol
diacetate
Rf
0.22
0.29
0.33
0.41
0.45 
0.64
2.
3.
Chloroform/
Acetone
7/1
Silica 
Gel
testosterone
DHT
androstene-5 rl7
dione
5o<-androstane~ 
5,17-dione
Chloroform/
methanol
99/1
SAL ica 
Gel
5<X-pregnane- 
312>—ol—20—one
5o<-pregnane- 
3 "^0l—20—one
Progesterone
5(X-pregnane-
3,20-dione
0.31
0.42
0.54
0.62
0.25
0.31
0.54
0.57
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the flame being supported by a mixture of hydrogen 
from a generator,and air. Peak areas were measured 
by an Autolab 6300 digital integrator, and steroid 
recovery determined by reference to the peak areas 
of relevant standards.
B. Measurement of Radioactivity.
{i) Paper and thin layer chromatogram scanners,
(a) Paper Scanner,
Location of radioactivity on paper strips after 
chromatography was facilitated by a Packard Radio- 
chromatogram Scanner, The high voltage was set at 
1200, V, the gas flow rate at 200ml/min, and a time 
constant of 1—3 was used throughout. A scanning 
speed of 2cm/min was used for routine purposes, or 
1 cm/min when overnight scanning was necessary. The 
sensitivity setting depended on the concentration of 
steroid on the paper strip.
(b) Thin Layer Chromatogram Scanner,
A Thin Layer Chromatogram Scanner (Panax Equipment 
Ltd., Surrey)-was used for the location of radio­
activity on thin layer plates after chromatography.
The B.H.T. wa.s set at 1 052 volts, the disc-bias 
at 1OOmV and the time constant at 0.1 seconds. The 
gas flow rate was adjusted to 60ml/min. Scanning
conditions were constant throughout the data presented 
and the range (c.p.s.) adjusted to give peaks of
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suitable height for measurement,
(ii) Liquid Scintillation Counting.
A Tri-Carb liquid scintillation spectrophotometer 
(Model 5380 Packard Instrument Co.) was used 
throughout all experiments for the counting of 
radioactive samples. Unless otherwise stated, 
plastic vials were used for counting. Two types of 
scintillation fluid were used. Samples which had 
previously been dried were counted after the addition 
of "non-aqueous" scintillator (6ml). The 
scintillation fluid had a toluene base and contained 
2,5 diphenyloxazole (P.P.O.) activator (4g/l) and 
1,4Di[2-(5”Phenyl“Oxazolyl)3-benzene (P.O.P.O.P) 
spectrum shifter (0.2g/l), This scintillator was 
chosen because the compounds used with it were 
completely soluble in toluene, the efficiency was 
high, and minimal quenching occurred. Samples which 
were water soluble .or had a high water content were 
counted in "aqueous" scintillator, which was made 
by the addition of Triton-X100 emuJ.sifier in a 
proportion of 2 parts *non-aqueous• scintillator to 
1 part Triton-X100. Aqueous samples were counted 
in this fluid by adding 6ml scintillator to 0.5ml 
sample, or 10ml scintillator to 1 ml sample followed 
by thorough mixing. The efficiency of these 
scintillation fluids are shown in Table II-2.
Double isotope counting was performed in two
Table II - 2
Counting efficiencies,in each channel»of 
scintillation fluids.
54a
Scintillation
Fluid Isotope
Efficiency io
Red Green Blue
Non-aqueous % 27-30 — 35-40
7-8 50-56 24-28
Aqueous 5a 20-25 - 23-28
1 2—1 4 30-33 38-42
Non-aqueous scintillator was used with dried, 
toluene soluble compounds.
Aqueous scintillatior was used with water 
soluble compounds in a ratio of either 6ml 
scintillator to O.521I sample, or 10ml scintillator 
to 1m]. sample.
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channels (red and green) of the scintillation 
spectrophotometer. The width of the green channel 
was adjusted to count carbon-14 alone, whilst in the 
red channel both tritium and carbon-14 were counted.
The exact degree of spillover of carbon-14 into the 
red channel was determined under experimental counting 
conditions by the inclusion of a carbon-14 standard 
in each set of samples. The spillover value was 
subtracted from the total counts in the red channel 
to give the true value for tritium. In cases where 
tritium alone was to be counted the blue channel was 
used as the window setting allowed the total tritium 
spectrum to be counted thus maximising the efficiency.
The channel selection controls were set as 
follows :-
Channel Window Setting Amplification
Red A -- B A50 - B1 95 50^
Green 0 -- D 0210 - D1000
Blue E -- F E50 - FI 000 50fo
Counts were accumulated in each channel to give 
an S.E.M. of less than one per cent, which in most 
samples required counting for 1Omin.
C. Processing of Scintillation Counter Output.
The requirement of correction for procedural 
losses, and the involved but repetitive nature of 
many of the calculations meant that the use of a
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programmable calculator was important in reducing
the time required for processing data obtained from
the scintillation counter.
Output from the scintillation counter was
simultaneously typed in numerical form and on punch
tape, and calculations performed on a Wang 600 series
programmable calculator with a high-speed Optical
Paper Tape Editor. Programmes were written and
stored on magnetic tape for standard calculations 
B 14-such as H/ G ratios, correction of procedural 
losses, calculation of specific enzyme activity and 
of superfusion parameters.
D. Purification of Steroids.
(i) Non-Radioactive steroids.
The steroids used were of the purest quality 
commercially
available^jand the purity was tested before use by 
recrystalisation followed by observation of the 
melting point of the crystals obtained.
(ii) Radioactive steroids.
Radioactive steroids to be used as substrates 
were required to be of the highest possible purity. 
Purity was tested by recrystalisation from hexane/ 
acetone after the addition of approximately 1Omg of 
pure unlabelled steroid and pure samples of the 
appropriate [^H]-steroid for P^c]-samples or
^c]-steroid for [^EL]-samples . The samples were
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deemed pure if the isotope ratio of the original 
solution, the crystals and the mother liquor were 
within of each other. If the steroids were 
outwith this limait appropriate chromatography was 
performed followed by another test recrystalisation 
until the required purity was attained,
E. Chemical Methods,
(i) Acétylation of Steroids. Bush (1961,a)
Steroids to be aeetylated were evaporated to
dryness under air before the addition of 10(^1 of 
dry pyridine and 10(^1 acetic anhydride. The samples 
were incubated for either 1 hr at 60^0 or 1 Shr at room 
temperature. The acétylation reaction was stopped 
by adding 2ml water, the steroids extracted with 8ml 
chloroform, the aqueous phase removed and the solvent 
evaporated to dryness.
In later experiments it was found that the 
addition of 2ml of ethanol assisted the evaporation 
of the pyridine and acetic anhydride mixture and thus 
permitted the omission of the extraction step.
(ii) Chromic Acid Oxidation of Steroids. Bush (1961,b) 
Steroids requiring oxidation were first
evaporated to dryness. Glacial acetic acid (1 ml) 
and chromium trioxide (0.5ml, 2% in water) were added 
and the solution incubated at room temperature for 
30min. It was important that this time was not
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exceeded since destruction of the steroid nucleus 
could take place. The steroids were extracted 
following the addition of 2ml water and 8ml ethyl 
acetate. The aqueous phase was removed and the 
ethyl acetate layer washed repeatedly with 2ml 
fractions of distilled water, potassium carbonate 
(2ml of 2fo in water) and finally distilled water. 
Evaporation to dryness was carried out under a 
stream of nitrogen.
F ♦ Preparation of Buffers.
In all cases glass distilled water was used in 
the preparation of the following buffers :-
(i) Tris buffers.
(a) Tris/HCl.
This basic buffer contained 50mM Tris and 
30mM Nicotinamide and v/as brought to pH 7.4 before 
making to its fj.nal volume.
(b) Tris/HCl + Sucrose.
For the preparation of crude tissue homogenates 
Tris/HCl buffer was supplemented with 0.25M Sucrose 
to produce an isotonic solution,
( c ) TKM.
The preparation of a microsome fraction requires 
the presence of divalent cations to prevent clumping. 
Thus, for work involving ciicrosomes Tris/HCl was 
supplemented with 25mM KCl and 5mM MgCl^*
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(d) TKM + Sucrose
TKM + 0.25M Sucrose 
Storage of Tris Buffers.
Owing to the unpredictable arrival of human 
prostate tissue for experimentation,it was found 
prudent to have stocks of prepared buffers at hand. 
Tris/HCl and TKM buffers were made at X10 concentration, 
stored in suitable aliquots and kept frozen at -20^0. 
These were made up to the correct concentration, 
supplemented with sucrose as required and kept at 4^C 
for only limited periods of time.
(ii) Krebs-Ringer Bicarbonate buffer.
(Cohen, 1957)
This buffer was prepared freshly before use from 
six stock solutions which were stored at 4^C and 
replaced at intervals of less than six months. Prior 
to use the buffer was bubbled with a gas mixture of 
95% Og and 5% 00^ for 30min. and the pH adjusted to 
7.4 by adding 0.1M NaOH dropwise.
Solution Vol. used 
(ml)
Concentration 
of stock 
(g/100ml)
Final
Concentration
(mï'4)
NaCl 10 6.780 116.00
KGl 10 0.347 4.65
NaHCO^ 10 2.050 24.40
Glucose 10 1 .000 0.055
EHgPO^ 1 1 .573 1 .16
KgS0^.7H^0 1 2.860 1 .16
CaCl^.ôH^O 1 5.300 2.42
H20 57
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(ill) Phosphate buffers•
(a) Standard phosphate buffer.
Solutions of 50mM KH^PO^ and 5QniI4 K^îïPO^ were 
mixed in the appropriate ratio to give a pH of 7.0, 
the resultant buffer was supplemented with EDTA , 
0.05% p)-mercaptoethanol and 20% glycerol, and stored 
at 4^0.
(b) Pyrophosphate buffer.
Solutions of 20ml't Na^P^Or^ .1 OH^O and 20ml4 
Na^H PgO^ were mixed to give a solution of pH 8.9.
The buffer was stored at 4^0 awaiting use.
G. Preparation of Prostate Tissue.
Human or rat ventral prostate was dissected free 
of fat and membranes, chopped into small (5imn) cubes, 
washed in saline (0.9% NaCl) and either homogenised 
immediately or frozen in liquid nitrogen and stored 
at -70°G until use. The latter method results in 
little if any loss of testosterone 5c<-reductase 
activity during freezing, a loss of 50% activity 
during the first few days of storage at -70'^ 0 
followed by a much more gradual decline to GOyh of 
the original activity at day 50, after which the 
activity remains constant for at least another 
month (Wallace, 1975). Freezing and storing the 
tissue in this way helps to overcome some of the 
problems of an irregular supply of human tissue
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although it does mean that in preparing enzyme 
solutions the age of this tissue must be taken 
into account,
H. Assay of Testosterone 5oL-Reductase. E.C. 1.3.1*4#
(i) Enzyme Preparation,
0>7O different enzyme preparations were used 
in the assay of testosterone 5o(-reductase :
(a) Homogenate enzyme (b) Microsomal enzyme
(a) Homogenate enzyme.
For preliminary experiments a crude homogenate 
preparation was found to be adequate. This was 
prepared by suspending finely chopped tissue in ice 
cold Tris/HCl+Sucrose buffer in a ratio of 1 g rat 
prostate/20ml or 1 g fresh human prostate/1 00ml, and 
homogenised by two ten second bursts of an 
Ultra-turax homogeniser, with one minute for cooling 
between bursts. The homogenate was then filtered 
through fine mesh gauze (Nybolt No.25T, 4^Pores) 
to remove any large clumps of cells and fibrous 
material. Throughout the process the tissue and 
solutions were kept on ice. On microscopic 
examination the filtrate was seen to contain 
cellular fragments, nuclei, whole cells and some 
small clumps of cells (probably epithelial sheets).
(b) Microsomal enzyme.
For kinetic experiments a more purified enzyme
62
preparation was employed. Testosterone 5o(-reductase 
is a membrane bound enzyme, located in the outer 
nuclear membrane and in the endoplasmic reticulum.
A microsome fraction, consisting largely of 
endoplasmic reticulum fragments, was found to give 
a suitably enriched enzyme preparation.
Fresh tissue was suspended in TKM + Sucrose 
buffer in a ratio of 1g tissue/1 Oral buffer and 
homogenised and filtered as above. The suspension 
was then centrifuged at 15,000g for 1Omin. to 
precipitate whole cells, nuclei and mitochondria.
The low spin supernatant was then recentrifuged for 
a further 60min. at 105,000g which caused most of the 
membrane fragments to sediment. The supernatant was 
decanted and the pellet resuspended in TKf‘I+Sucrose 
buffer. The most suitable volume for resuspension 
was found to be 5n ml where n is the number of grams 
of tissue homogenised.
The suspensions were made as homogeneous as 
possible with 5 strokes of a Thomas homogeniser.
Again all solutions were kept on ice and refrigerated 
centrifuges were employed.
(ii) Incubation.
The basic incubation medium contained 0,25mî4 NADPH 
and 4.3nM [l , 2“^H]-testosterone (S.A. 1 2.5Ci/mmole ) in 
Tris/HCl or TKM buffer (depending on the enzyme 
preparation used). A].l solutions were kept on ice
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and the reaction started by adding enzyme
solution, and plunging the tubes into a shaking 
water bath at 37^0. Unless otherwise stated, final 
incubation volumes were 1.6ml«
The reaction was stopped by the addition of 
2ml ethanoljfollowed by rapid mixing. For monitoring 
recoveries, carrier testerone (lOOjug), DHT ( 10Oyjg) 
and 5ü-androstane-3Kf17p-diol (100/ig) were added 
together with 2000cpm each of [4“”^ ^ c]—testosterone 
and [4-^  -DHT. Lipids were extracted with 
chLoroform (8di1)s, evaporated to dryness under air, 
and acetjrlated. Separation of the aeetylated steroids 
was carried out on alumina TLO plates using solvent 
systen 1. Three spots %vere visualised, coresponding 
to testosterone acetate,, DHT acetate and ^^c-androstane- 
3#p17p-diol diacetate. These vfere scraped from the 
platesÿ eluted in diethyl ether, evaporated to dryness 
and radioassayed in a liquid scintillation spectro­
photometer using a non-aqueous scintillator» Half 
of the 5c/v*“androstane-3o(., 1 7p“diol diacetate was 
retained for monitoring recovery by gas liquid 
chromatography.
The metabolism to 5#^androstane-3#^17^-diol was 
always checked in control incubations, but fractions 
were only fully worked up for the rest of any 
particular experiment if the incorporation of 
radioactivity was more than 5% of the total product.
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(ill) Calculation and expression of results.
Correction for procedural losses was necessary
for each individual incubation. This was done for
testosterone and DHT by the addition of a, constant
amount of ^c]-steroid after the incubation, and
counting the separated steroid acetates in the liquid
scintillation spectrophotometer with window settings
such that the two isotopes could be distinguished.
1 4Standard C was also counted to allow correction for 
spillover between channels. The equation used for 
the calculation was corrected cpm in sample;
X cpm Gch Stdrcpm Rch A _ cpm Rch Std [_cpm Gch A cpm Gch Std
where Rch = channel measuring.
Gch - " "  ^C
A = sample
Std = C standard
Background radiation was subtracted from each 
value used in the calculation.
The 5o^-androstane-3o(, 1 7(3-diol diacetate recoveries 
were measured by gas liquid chromatography.
After correction for recoveries the corrected 
cpm of the products were summed and the results 
expressed in terms of constant time and protein 
concentration i.e. pmoles substrate reduced/h/mg 
protein. This allowed comparison of activity 
between different enzyme preparations.
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I, Assay of 1 7 fi-Hydroxysteroid Dehydrogenase.
(e.g. 1.1.1.51. )
(i) Enzyme preparation.
Lyophylised powder of Pseudomonas Testosteroni 
(0,25g) was mixed with 3.5ml of standard phosphate 
buffer, placed in an ice bath, and sonicated at 
20 kHz for 15 mins. using an MSE sonicator. The 
resulting preparation was centrifuged at 20,000g for 
6Omin. at 4°G. The supernatant was mixed with 
glycerol to a final concentration of 50% and stored 
at -20^0. This preparation is stable for several 
weeks and was diluted in pyrophosphate buffer 
immediately before use » Aliquots (0»5ml) of a 
1/4,000 dilution were found to be most suitable.
(ii) Incubation.
The incubation (final volume 2ml) was carried
out in pyrophosphate buffer containing 50ng
testosterone, 0.5mM NAD and 0.5ml enzyme solution.
The testosterone contained either [i7o^”H]-
testosterone or [l ,2%]-testosterone ard [4-^c]-
3 14testosterone in a H / C ratio of approximately 
10/1, and non-radioactive testosterone to make up 
the required concentration.
The assay tubes were preincubated at 37^0 and 
the reaction started by adding the enzyme solution. 
The reaction was stopped after the appropriate time 
by the addition of 5ml ethyl acetate followed by 
15sec. vortexing. The aqueous phase was removed and
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after the addition of carrier steroid the remaining 
liquid was evaporated to dryness under air. The 
steroids were separated on silica TLC plates in 
solvent system-2. Bands corresponding to 
testosterone and 5^-androstane-3,17-dione were eluted 
with diethyl ether, evaporated to dryness and 
radioassayed in a liquid scintillation spectro­
photometer using non-aqueous scintillator.
J. guperfusion Techniques.
(i) Tissue preparation.
Fresh prostatic tissue was cut into 2x1x1 cm 
blocks and sliced by hand with a Stadie-Riggs 
microtome. The mean thickness of the slices was 
calculated to be 0.54mm, by measurement of area and 
weight of slices taken at random. The slices were 
transferred from the microtome to ice-cold petrie 
dishes lined with saline moistened filter paper.
Blocks of tissue to be sliced were chosen at random, 
but slices were transferred to the petrie dishes in 
a non-random fashion so that each superfusion 
channel could contain tissue of as similar composition 
as possible.
The tissue slices were weighed and divided into
0.5g ” 1 g aliquots depending on the type of experiment 
being performed. In each separate experiment all 
the chambers contained equal amounts of tissue.
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Tissue aliquots were washed three times in 2-3ml 
saline to remove small debris and excess prostatic 
secretion, prior to transfer to the superfusion 
chamber.
(ii) guperfusion apparatus.
The apparatus employed is shown in Fig.II-1 .
An all glass system was used, the various pieces 
having ground glass joints which are held together 
by sprung metal clips. The tissue chamber is 
formed by the space between two sintered glass 
filters. In experiments where tissue had to be 
removed during the perfusion an open chamber was 
used. The chambers were submerged in a water bath 
at 37^0, and connected via a 100ml glass syringe to 
a pump (Multisyringe Attachment, P135, O.P. Palmer 
Ltd., London) which vras set to deliver the medium 
through the chamber at a constant rate of 25ml/h.
(iii) guperfusion - general details.
The perfusion medium was Krebs-Ringer bicarbonate 
buffer, prepared freshly before use. Purified radio­
active and non-radioactive steroids were made up in 
ethanol and added to the buffer such that the final 
concentration of alcohol was less than 1%.
In order to prevent further metabolism of 
steroid by any enzymes which may have been released 
from the tissue slices, perfusates were collected in 
tubes standing in crushed ice.
Fl2.II 1 .
The Superfusion Apparatus.
*   nm  M ' »>n— — ^ u — — 1'I » * I II# "I iiw  i ■ h i— b« — —
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pump-^È:
A 7 c m
b
B
J
12 cm
C
\ /
A
S/
2 0 c m
An all glass superfusion apparatus is 
employedo The three sections A, B and C are 
held together with spring clips. Tissue 
slices are placed between the glass sinters.
D
ass sinter
V
A
25cm
Section D replaces Sections B and 0 when 
tissue is to be removed during the 
superfusion.
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Medium from the syringes was also kept for 
analysis.
The tissue was removed from the apparatus 
either at intervals during, or at the end of the 
perfusion, rinsed in ice-cold Krehs-Ringer 
bicarbonate buffer (2 x 3ml) and for metabolic 
experiments suspended in acetone.
All samples were kept at -20^0 until processed.
(iv) Analysis of fractions following superfusion 
with T/1
The perfusates and medium were thawed at room 
temperature and shaken well to disperse any 
precipitated salts, before a measured aliquot (5ml) 
was removed and extracted with ethyl acetate (10ml) 
which contained ["* -testosterone and [^^c]-DHT 
to allow for the correction of procedural losses.
Tissue slices were removed from the acetone, 
minced, suspended in glass distilled water and 
homogenised with a fine bladed Ultra-turax 
homogeniser. The homogenate and acetone were 
combined and extracted together as described for 
the perfusates.
The aqueous phase of all the samples was 
removed, the organic phase washed twice with 
distilled water (5ml) and evaporated under at 
less than 60°C. The residue was dissolved in 
250^1 acetone and spotted onto a paper chromatogram,
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which was developed and eluted as described 
previously. Cold carrier steroids were added at 
this stage (lOOjug testosterone and 250^g DHT) to 
assist visualisation during subsequent stages.
The DHT fraction was divided into two parts 
and all tubes evaporated to dryness under air, before 
acétylation of the testosterone and one DÏÏT fraction, 
and oxidation of the second DHÏ fraction. The 
acétylation products were chromatographed on Alumina 
TLG plates in solvent system 1, the testosterone 
acetate, or DHT acetate bands visualised, eluted 
and counted in non-aqueous scintillator until the 
SEM was 0.5/^ * The oxidation products were 
chromatographed on Silica TLG plates in solvent 
system 2»
The spots corresponding to 5o(“androstane-3,1 7™ 
dione were visualised, eluted and counted as for the 
acetylated fractions. A flow diagram for the method 
is given in Fig.II - 2.
K • Miscellaneous Methods,
(1) Colourimetric estimation of heparin.
The assay employed was based on that of the 
Bitter and Muir (1962) modification of the method of 
Dische (1947) and measures the reaction of carbaaole 
with uronic acid residues.
Reagents.
(a) Sulphuric acid reagent was made from 0.025M
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Figure XI - 2
Flow Diagram for Superfusion Work Up.
Tissue
Medium Homogenise Perfusate
Medium, Tissue, Perfusate 
containing [17«-^h ]-T, [i7«-%]-DHT, [i,2-^h]-DHT
Add and '^qI-DHT
Extract
Purify paper chromatography
Testosterone fraction DHT fraction
Acetylate 
4. Purify TIC 
[17« -^ h]-T
V '^ c]-T
0
Acetylate 
Purify TLG
4" 4-
Oxidise
Purify TIG
V 4'
h]-dht [1,2 -^h]-dht
hJ-dht c]-DHT
B
T = testosterone DHT — 5#-dihydrotestosterone
^0] is used to monitor recoveries.
[17^“^ h] dht is determined by the difference between 
B and C .
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disodium tetraborate.1 OH^O dissolved in sulphuric 
acid of specific gravity 1.84*
(b) Carbazole reagent consisted of 0»125^ 
carbazole in absolute ethanol or methanol and was 
stable for 12 weeks in the dark at 4^0,
(c) Standards of glucuronolactone and heparin 
in the range 4-1OC^g/ml were prepared by dilution in 
distilled water saturated with benzoic acid.
Wherever possible unknown samples were also made up 
in benzoic acid saturated water.
Method.
Sulphuric acid reagent (3ml) was placed in 
stoppered test tubes, and cooled to 4^0. Sample or 
standard (0.5ml) was carefully layered on top of the 
acid, the tubes stoppered and shaken gently with 
constant cooling, to mix the two phases. At no time 
did the temperature of the mixture exceed room 
temperature. The tubes were heated for lOmin, in a 
vigorously boiling water bath, and cooled again to 
room temperature. The carbazole reagent (0,1 ml) 
was layered on. top, the tubes shaken and heated in the 
boiling water bath for a further 15min. After cooling 
again to room temperature the optical density was read 
at 530nm in a Unicam 81600 spectrophotometer. The 
optical density of a sulphuric acid blank was 
consistently below 0.025*
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(il) Protein determination.
Protein concentrations over the range 50-500yjg 
were measured by the method of lowry et al., (1951).
Standard solutions were prepared as in distilled 
water as follows:-
A - 2% Ha^GO^
B - 25^0 Na K tartarate
0 - 1% GuS0^.5E^0
D - This was prepared daily from 100ml A +
1ml B + 1ml G.
E - Folin & Glocalteu's Phenol Reagent,
diluted 1/1 to make it IN with respect 
to acid.
Standard protein solutions and all samples were 
precipitated by standing for at least 30min. after 
the adding of 10?^  trichloroacetic acid (TCA) (1ml). 
The tubes were centrifuged at 1700g for 5min. and 
inverted to allow the TCA supernatant to drain out. 
The protein precipitate was dissolved in IF FaOH 
(0.5ml) and after 10min. solution D (5ml) was added. 
After a further lOmin. solution E was added and 
mixed immediately. The optical density at 625nm 
was read in a Unicam SP600 spectrophotometer after 
the colour had been allowed to develop for 20min,
CHAPTER III.
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CHAPTER III
HEPARIN AND RELATED COMPOUNDS 
IN THE CONTROL OF 
PROSTATIC TESTOSTERONE 5%-REDUCTASE
1. INTRODUCTION.
Heparin, a naturally occurring polyanionic 
mucopolysaccharide commonly used as an anticoagulant, 
has recently been reported to inhibit steroid 
5ot-reductase enzymes in testis (Kizanowski & Troop, 
1968), adrenal (Lakatos et al., 1970), liver 
(Steinberger & Fisher, 1971) and rat prostate 
(Blaquier & Calandra, 1973). It seemed reasonable, 
therefore, to examine j.ts role in the control of 
prostatic testosterone 5d.-reductase especially since 
heparin is often found associated with connective 
tissue, v/hich is a major component of the human 
prostate gland (Schubert & Hammerman, 1968).
Many studies have been made of the chemical 
structure of heparin, with investigations of the 
glycosidic linkage, the nature of the uronic acid 
component, the sulphur content, the presence of 
additional groups and the extent of branching.
These studies have been reviewed by Ehrlich &
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Stivala (1973). Both 1->4 and 1~>6 linkages are 
present with the 1->4 form predominating. The major 
uronic acid component is B--glucuronic acid, although 
L-iduronic acid has also been reported. As a 
result of degradation studies with Flavobacteriim 
heparinium it was concluded that the heparin molecule 
is composed largely of repeating sequences of 
( 1 4 ) -linked 4-0™(c<-L-idopyranosyluronic acid 2- 
sulphate ) -2- ( deoxy~2-sulf amino--o<-D~glucopyranosyl-6- 
sulphate)biose residues (Berlin et al., 1971), 
although Helting & Lindahl (1971) proposed a structure 
of repeating tetrasaccharide units each of which 
contained both glucuronic and iduronic residues 
(fig. Ill - la). More recently Silva & Dietrich 
(1975) using a similar enzyme degradation technique 
have suggested that trisulphated and disulphated 
disaccharides with the structure shown in fig. Ill — 1b 
are linked alternately in a proportion of 3:1.
Heparin is polydispersed and molecular weights from 
6,000 to 20,000 have been reported. It is usually 
considered to be a linear molecule although this has 
not been conclusively proven. Horner (1971) has 
isolated heparin with a molecular weight of 1*1 s 10^ 
from rat skin and he suggested that this 
raacromolecular heparin is a multichain form which 
must be depoLymerised to become biologically active.
Heparin is distributed widely throughout the body
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Pie.Ill - 1
gueeested Forms for the Basic Structure of Heparin 
(a) Helting & Lindahl (1971)
CH^S03 coo ÇW2O SO3 
O.
n
(h) Silva & Dietrich (1975)
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trisulphated disaccharide
ÇH2OSO3
disulphated disaccharide
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and has been isolated from the skin of many animals. 
Although its concentration in blood is small it has 
been found in significant quantities in kidney and 
liver (Ehrlich & Stivala, 1973), whilst commercial 
heparin is prepared from pig intestinal mucosa.
There appears to have been no attempt to assess the 
heparin content of human prostate tissue.
Heparin has been widely studied as an enzyme 
inhibitor and has been shown to inhibit ^-glucuronidase, 
renin, hyaluronidase, alkaline phosphatase and 
collagenase (Ehrlich & Stivala, 1973). Whilst it 
has been suggested that it may be a non-specific 
inhibitor for some enzymes there is some evidence in 
certain systems that there is specificity in its 
action. For example, in rat adrenal , heparin and 
heparinoid substances reduce the production of 
aldosterone but do not diminish the synthesis of 
important glucocorticoids (G-laz & Sugar, 1964).
Recently there has been interest in heparin as 
an inhibitor of steroid 5#-reduction and it has been 
shown to be an effective inhibitor in rat liver 
(Hizanowski & Troop, 1968), adrenal (Lakatos et al., 
1970), testis (Steinberger & Fisher, 1971) and 
prostate (Blaquier & Calandra, 1973). In rat liver 
homogenates the A ring reductions of androstenedione, 
progesterone, deoxycortisol and testosterone are 
inhibited (Krzanowski & Troop, 1968). Cortisone
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reduction is also inhibited and may be reversed by 
the addition of the heparin antagonist protamine 
sulphate (Troop et al,, 1966). In vivo, heparin has 
been shown to have no effect on the hepatic 
5#-reductase enzyme levels when administered over a 
7"^  horir period, although plasma from these treated 
rats could inhibit the enzyme activity when added to 
the assay mixture (Troop & Ôiggs, 1965). This is 
presumably due to heparin in the plasma. However 
when the HADPH generating system was omitted from the 
assay a small effect could be seen (Carter et al., 
1968). Heparin has also been shown to have an anti­
inflammatory effect in intact but not in 
adrenalectomised rats, and to potentiate the anti­
inflammatory effect of cortisol in the adrenalectomised 
animals (Carter et al., 1 968). These workers also 
showed that the intravascular half-life of [^^c]- 
corticosterone was significantly prolonged after 
heparin administration, facts which’indicate heparin 
may influence adrenal steroid metabolism in vivo. 
Several polysulphated polysaccharides other than 
heparin have been shown to inhibit cortisone 
5oL-reduction by rat liver homogenates (Troop, 1 969). 
This study suggests that the sulphate content of 
polysaccharides appeared to be important in 
determining their inhibitory activity. The degree 
of sulphation of the heparin molecule itself has been
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shown to be important in determining its activity as 
a protein synthesis inhibitor (Waldman et al., 1974).
A well established role exists for heparin as 
an agent capable of affecting steroid A ring 
reduction. It was the intention of the work 
described in this chapter to assess the ability of 
heparin to inhibit rat and human prostatic 
testosterone 5oC-reductase in vitro and to extend the 
finding to investigate a possible role for heparin 
and related compounds in vivo. In the latter 
connection it was thought important to attempt an 
assessment of the heparin content of human 
hyperplastic glands.
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2. RESTÜXTS.
A. Initial Experiments.
The specific activity of prostatic testosterone 
5#-reductase varies considerably from species to 
species (Gloyna & Wilson, 1969). In particular 
its specific activity in human hyperplastic tissue 
is considerably greater than in rat tissue* Moreover, 
within a single species there is also marked 
fluctuation in the observed e n z y m e levels not only 
between glands, but also between different regions of 
the same gland. For these reasons it is often 
difficult to select the correct enzyme concentration 
to use in an individual incubation and the initial 
experiments described were designed to select 
homogenate dilutions for normal rat and hyperplastic 
human prostate tissue that would consistently yield 
testosterone conversions that could be measured 
accurately but were not excessive. Having arrived 
upon a suitable enzjnne concentration other parameters 
of the assay were examined to ensure that it was 
fully optimised.
Using the assay procedure described in Chapter 
II, homogenates of fresh human hyperplastic prostate 
tissue were prepared over the range 0.5-5% prior to 
measuring the 5#-reduction of 2ng of [i ,2-^h ]~ 
testosterone. The results from two separate 
experiments are recorded in Table III - 1. It is
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Table III - 1
The Effect of Enzyme Dilution on the Oonverslon of 
Testosterone to 5o(-Dihydrote8tosterone using Fresh 
Human Prostatic Homogenate.
Enzyme dilution 
(g- tissue/ 
ml buffer)
Specific Activity 
Cpmoles/hr/ 
mgprotein
% conversion of 
2ngTestosterone 
to DHT
Prostate A
1/20 5.4 95.4
1/60 9.2 47.6
1/1 00 47.4 26.8
1 /200 29.0 15.5
Prostate B
1/20 15.7 95.4
1/60 27.6 45.8
1/1 00 25.2 24.5
1/200 53.2 15.0
apparent that whilst the specific activities of the 
two preparations differed, the percentages of 
testosterone converted into DHT were similar and 
an homogenate of 1 g tissue per 1 00ml buffer was 
selected as the most suitable. Similar experiments 
with rat tissue revealed that an homogenate of 1 g 
tissue per 20ml of buffer was optimal. These 
concentrations were employed in all subsequent 
experiments although minor adjustments were often 
necessary when using frozen tissue to take into 
account the deterioration of testosterone 
5&-reduotase activity on storage.
Time course experiments were performed to check 
that only the initial rate of reaction was being 
measured. It was shown that the production of 
DHT was almost linear for the initial 20 ~ 30 rains, 
the reaction rate slowing down thereafter.
Since the enzyme requires NADPH for its function 
it is important to ensure an adequate supply of this 
cofactor. Hence, incubations including HADPH in the 
range of 0-0.5mM were performed. Enzyme activity 
increased rapidly from 0 to 0.imH NADPH, and at 
greater than 0,25mM NADPH no further increase in 
activity was obtained (Pig,Ill-Pa) therefore in all 
subsequent incubations 0.25#I NADPH was used.
It has been reported that rat prostatic 
testosterone 3%-reductase activity decreases with
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An homogenate preparation of human 
prostate was incubated for 20 min at 37^0 
with a substrate concentration of 4.3nM.
In (a) the NADPH concentration was varied 
from 0^ü .5eûM,*
Ih (b) KOI was added to the buffer to increase 
the ionic strength.
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(a) The Effect of NADPH Concentration on 
Testosterone 5o<--Reduc'base Activity,
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(b) The Effect of Ionic Strength on
Testosterone 5*-Rednctase Activity*
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increasing ionic strength (hoy, 1971), hence it was 
important to establish whether or not the same was 
true of the human enzyme. Addition of KCl to a 
Tris/HCl buffer of ionic strength 0,05 caused a 
linear decrease in activity until at an ionic strength 
of 1 the activity had dropped by 50fo CPig.IIl-2b),
It is clearly important therefore to keep the ionic 
strength of the buffer constant. Por the experiments 
presented in this chapter, 0,05M Tris/HCl buffer,with 
an ionic strength of 0.05, was used..
The precision of the assay must be known in order 
that valid comparisons can be made between control 
and experimental incubations. The coefficient of 
variation of each of eleven experiments with between 
four and ten control tubes was determined and ranged 
from 5*8^ to 11.0% with a mean of 7.5%',
B, The Effect of Heparin on the In Yitro 
5&-Reduction of Testosterone.
In order to examine the effect of exogenous 
heparin on the 5oc-reduction of testosterone by 
prostatic tissue, homogenates were incubated as 
described in Chapter II in the presence of increasing 
concentrations of added heparin. The results from 
two typical experiments, one for rat tissue and the 
other for hyperplastic human tissue are shown in 
Pig.III-3, The results are expressed in terms of
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Pig.Ill
The Inhibitory Effect of Heparin on Rat and Human 
Prostatic Testosterone 5oC“Reduetase.
1001
■g 80-
oo
>> SO'
*p
1000100 200 300 400  500
Heparin/Assay
©«Rat Prostate Homogenate (lg/20ml) 
o-Human Prostate Homogenate (1g/100ml)
Homogenates of rat or human prostate 
were incubated with t^H^-testosterone as 
described In Methods (p 62} in the presence 
of heparin over the concentration range 
0 — 1 OOO^g/assaye
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the percentage specific activity of the no heparin 
control tubes since this overcomes the variability 
between glands of the absolute specific activity of 
the testosterone 5&-reductase. Each point on the 
graph is the mean of at least two values and for the 
controls each point is the mean of at least four 
determinations.
The preliminary experiments just described were 
performed with an EAEPH generating system (0^065ml4 NAEP, 
0.65mH glucose—6-phosphate and 3 units glucose-6- 
phosphate dehydrogenase (SA 360 wilts/mg protein). 
Although Troop et al., (1966) claimed that heparin did 
not affect the rate of NAPPE production by glucose-6- 
phosphate dehydrogenase it was thought advisable to 
check this point. Accordingly, the enzymatic 
activity of glucose-6-phosphate dehydrogenase was 
determined by a standard spectrophotoiustric method 
(Lohr & Waller, 1963) over a range of NADP 
concentrations in the absence of heparin and in the 
presence of increasing concentrations of 
polysaccharide. The results presented i,n Pig.III-4a 
demonstrate that at high concentrations of heparin 
inhibition of glucose-6-phosphate dehydrogenase did 
take place, the Lineweaver & Burk plot (Lineweaver & 
Burk, 1934) shows that the inhibition follows 
competitive kinetics. Similar results were obtained 
for the inhibition of 6-phosphogluconate dehydrogenase,
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(a) Heparin concentrations 
#  -  0
o - 0*8 mg/ml
^ - 1.6 mg/ml
A - 4 mg/ml
(b) NADP concentrations.
• - 0.033 mM
Q m m 0.100 mM
▲ — 0*330 mM
A — 1 .000 mî4
Glucose-6-phosphate dehydrogenase 
activity was measured by the method of 
Lohr & Waller (1963). Enzyme activity was 
determined over a range of NADP 
concentrations (0.033-1.OmM) and in the 
presence of varying heparin concentrations 
(0-4.0mg/ml).
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Fig,III - 4
The Effect of Heparin on G-lucose-6-Phosphate; 
Dehydrogenase Activity.
(a) Ljjaeweayer & Burke plot.
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(b)  ^/v vs [l] plot.
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another enzyme commonly used in NADPH generating 
systems (Hohrst, 1965)*
1When the data is plotted as /V vs I the result 
is a hyperbolic curve (Pig.IIl-4b). W aen this shape 
of curve results it is an indication that an enzyme- 
inhibitor complex is not formed, but that the 
inhibitor changes the affinity of the enzyme for the 
substrate (Mahler & Cordes, 1966).
Whilst the heparin concentrations required to 
inhibit the production of NADPH were high, it was 
nevertheless considered undesirable to use a 
generating system for the studies of the action of 
heparin on testosterone 5^-reduction in prostatic 
tissue, and in all subsequent experiments NADPH 
itself was included in the incubation medium at a 
final concentration of 0*.25nl4, which has already 
been shown to be quite adequate under the assay 
conditions employed. The inclusion of exogenous 
NADPH in the incubation medium did not prevent the 
inhibitory effect of heparin on testosterone 
9%~reductase either from normal rat or from 
hyperplastic human prostate tissue. Pig,III-5 
shows the heparin dose response curves from three 
experiments with human tissue. The extent of 
heparin inhibition clearly varies from gland to 
gland and this emphasises the need for including 
a heparin inhibition curve in all experiments with
81a
Heparin Inhibition of Human Prostatic Testosterone 
5%-Rednota8e from Different Glands.
100
■s so-
so--p
4 0 '
20*
100 200 300 4 0 0 5 00
yjg Heparin/ml in assay
o lg tissue/80ral buffer
0 1 g tissue/SOial buffer
A 1g tissue/50ml buffer
The variability of heparin inhibition 
was examined using homogenate preparations 
from three different human glands» 
Testosterone 5o(--reducta8e activity was 
measured under standard conditions (p 62). 
In each case there was between 10 and 155^  
conversion of substrate in control 
incubations.
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potential inhibitors to permit standardisation.
Having established that heparin is an effective 
in vitro inhibitor of testosterone 5<^-reductase 
an investigation was planned to determine the nature 
of the inhibition. Accordingly testosterone 
5oi~reductase activity was determined using the 
standard assay system over a range of testosterone 
concentrations and in the presence and absence of 
added heparin. The results recorded in Pig.III-6 
are from a human hyperplastic prostate gland and 
they demonstrate that heparin apparently exhibits 
competitive kinetics with respect to substrate 
concentration. It is worthy of note that the 
apparent Michaelis constant, -Em., obtained for human 
prostatic testosterone ‘-reductase from Pig.III-6 
is 0.02x10 M, a figure that agrees well with that 
previously published (Wallace, 1975).
It was considered possible that heparin may 
also interfere with cofactor binding to the 
testosterone 5ot-*reductase. Accordingly, this was 
tested, and in the case of the enzyme from the rat 
prostate heparin can be shown to exhibit competitive 
type kinetics with respect to the NADPH cofactor.
The experiments just described have demonstrated 
that heparin, a polyanionic substance, is capable of 
inhibiting prostatic testosterone 5d-reductase,
The same enzyme has previously been shoim to be
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Lineweaver & Burk Plot showing Eepariii Inhibition 
of Human Hroatatio Testosterone 5d^Reduotase.
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}  Testosterone(njyl^) ^
© - Ho Heparin 
o - 500yOg Heparin/assay
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inhibited by a number of divalent cations, including 
zinc (Wallace & Grant, 1975). Since the prostate 
is a rich source of zinc (Mann, 1964) it was 
considered of interest to examine the activity of 
testosterone 5^ -^reductase in the presence of both 
heparin and zinc in order to determine whether or 
not the presence of zinc could reduce the 
effectiveness of heparin as an inhibitor.
Additionally, the activity of the enzyme was assessed 
in the presence of both heparin and protamine 
sulpha^te since the latter substance is well 
established as an antagonist of the blood anti­
coagulation properties of heparin (Ehrlich &. Stivala, 
1975).
The results of this combined study are shown in 
Pig.III-7a for the human enzyme and in Fig.III-Tb for 
the rat enzyme. In both cases the heparin induced 
inhibition of the enzyme was partially reversed by 
the addition of an equal mass of protamine sulphate, 
This may have been due to precipitation of a. 
heparin-protamine sulphate complex since assay tubes 
containing this mixture had a cloudy appearance.
By contrast the addition of increasing concentrations 
of zinc to the incubation media failed to reverse the 
heparin inhibition, and in the human system, at least, 
the presence of both heparin and 5 % 1 z i n c  induced 
a slightly greater inhibition than observed from
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Key
Human
0 = no additions
H = 1 00/ig Heparin
H + ? 1 OOyjg Heparin -i- 1 OOyJg Protamine Sulphate
H + 1 OOyjg Heparin + 5 X 10“Sî ZnCl
H + 100/jg Heparin + 5 X 10" ZnCl
H + Z, 1 00/jg Heparin -i- 5 X 10“ Si ZnCl
^2 5 % 10” 'M 2n.Cl
(b) Rat
0 = no additions
H = 2mg Heparin
H 4" P = 2mg Heparin + 2 mg Protamine Sulphate
H + Zi = 2mg Heparin + 5 X ZnCl
H + ^2 = 2mg Heparin + 5 X 10“ 'm ZnCl
H + Zj = 2mg Heparin + 5 X 10"^M ZnCl
^2 = 5 X 10“^M ZnCl
The conversion of testosterone to DHT 
was measured under standard conditions with 
homogenate preparations. Heparin,, zinc 
and protamine sulphate were included either 
singly or in the combinations indicated 
above.
Fig.Ill - 7
The Effect of Various Compounds on Prostatic 
Testosterone ^CK-Reduotase.
8313
(a) Human
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75-
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(b) Rat9 100 -
75-
50-
25-
—
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heparin alone. The concentrations of sine used in 
this study were chosen very carefully since it has 
previously heen observed that a concentration of 
5x10 M zinc is a mild stimi0.ator of the human 
prostatic testosterone 5#-reductase (Grant et al«, 
1971) whilst at 5x10 the same metal is a potent
inhibitor of the enzyme system (Wallace & Grant, 1975) 
In the present experiments it is worthy of note that 
5x10 M zinc alone had little effect on either the 
rat or human enzyme systems.
C.H The Effects of Selected Monosaccharides,
Polysaccharides and Polyanionic Substances 
on Prostatic Testosterone 5^-Reductase,
-The consistent inhibition of prostatic 
testosterone 5^-reductase by heparin prompted the 
question of the specificity of the effect.
Consequently it was decided to carry out a study of 
the effectiveness of other sulphated polysaccharides 
as inhibitors of testosterone 5oC'-reductase. Moreover 
a number of monosaccharides were screened for 
inhibitory activity as were a number of selected 
substances other than polysaccharides. It was hoped 
that the information gleaned from this investigation 
would provide evidence as to the structural 
requirements of an effective non-steroidal inhibitor 
of prostatic testosterone 5#-reductase,
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The compounds tested were obtained in the purest 
forms available and, because of the uncertainty of 
the molecular weights of many of them, were added 
to incubations by weight rather than by molarity.
A list of the main features of the polysaccharides 
studied is given in Table III -2.
It is apparent from Figs.III-8a & b that the 
monosaccharides glucose-6-SO^ and D-glucuronic acid 
caused no inhibition of the testosterone 50^ -reductase 
of human hyperplastic prostate nor did polyglutamate.
F-acetyl glucosamine, chondroitin sulphate and the 
synthetic compound Rol-8307 had only very small 
inhibitory effects. The other polysaccharides 
tested all showed considerable inhibition of the 
enzyme and on a strictly mass basis the relative 
potencies of the compounds were as follows
R02-7528 > R02-7059 > R02-3053 >
Hyaluronic acid > Heparin
The results displayed in Pigs.III-8a & b were obtained 
from a series of experiments and whilst heparin was 
included in ea.ch experiment as an internal standard 
it was considered important to confirm the ranking of 
inhibitory ability in a single incubation. Therefore, 
all the polysaccharides which had shown any ability 
to inhibit human hyperplastic prostatic testosterone 
5of-reductase were reassessed at a single 
concentration ( 500/4g/t.ube ) . The results shown in
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(a) e Heparin
o Hyaluronic Acid 
A H-Acetyl Glucosamine 
^ Glucuronic Acid 
■ Glucose-6-Sulphate 
o Polyglutamate
Cb) © Ro2 - 7528
o Ro1 - 8307
^ Ro2 ~ 7509
A Ro2 - 3053
B Chondroitin Sulphate
Homogenate enzyme preparations were 
incubated under standard conditions with 
the various test substances listed above 
in the concentration range 0 — 500^/assay.
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Fig.Ill - 8
The Effect of Selected Saccharides and Polyanions
on Human Prostatic Testosterone 5o^ ”Rcductase 
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Fi g*, III - 9 d e m o n s 1a. t e t ha. t t h e r an k in g pr e v 1 o u s 1 y 
obtained could be confirmed.
When similar experiments were performed with 
these compounds using rat prostatic 5%-reductase, 
the same trends were seen as with the human enzyme 
(Beastall, G-.Hi , unpublished data)..
Do Prostatic Testosterone 5^™Roductase Following
the In Vivo Administration of Heparin to Rats.
In order to assess whether heparin may have a 
physiological role in the control of prostatic 
testosterone 5#-reductase it is important to 
ascertain whether the molecule is capable of entering 
the gland from the circulation. Whilst it may seem 
unlikely that a molecule as large as heparin could 
be taken up by prostatic tissue,Glaz & Sugar (1964) 
demonstrated that the in vivo administration of 
heparin and heparinoid substances decreased the 
production of aldosterone by the adrenals,and 
Carter et al,, (1968) observed a reduction in adrenal 
5#-reductase activity following a similar 
administration regime. The experiment described 
below was adapted from that of the latter authors.
Male adult Sprague Dawley rats weighing 300 — 
400g were divided into three groups. The first 
group (S) were given intraperitoneal injections of 
8aline at three 12h int ervals and were sacrificed by
86a
Fie.Ill - 9
Polysaccharide Inhibition of Human Prostatic 
Testosterone 5&-Redaotase.
lOOi
60-
-p
ChS 'O' r^O^-' I'Qc,
6307 3CB3 7059 7528
Ke%: H - Heparin
ChS - Chondroitin Sulphate
HyA - Hyaluronic Acid
The standard testosterone reductase 
assay conditions were employed to test the 
inhibitory effect of selected,polysaccharides 
at a concentration of 50(^g/assay«
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cervical dislocation one hour after the last 
injection. The second group (L) and the third 
group (H) were given intraperitoneal injections of 
2500XJ and 12500Ü of heparin respectively, according 
to the same timetable. hot all the animals survived 
this injection schedule, one of the low dose group 
and four of the high dose group dying prior to 
completion of the experiment from internal 
haemorrhage, presumably resulting from the anti­
coagulant properties of the administered heparin.
The ventral prostates of all the surviving rats 
were removed immediately following sacrifice and kept 
on ice. They were dissected free of membranes, 
weighed, minced into ^mm cubes and washed with 
ice-cold saline. Each mince was transferred to a 
conical flask containing 5sal of Krebs Ringer 
Bicarbonate buffer pH 7.4 to which had been added 
50ng (lO^cpm) of [l ,2-"^ îî]-testosterone. The flasks 
were incubated at 37^0 for 30min. in a shaking water- 
bath. The reaction was terminated by the addition 
of ethanol (5ml), the lipids were extracted and the 
activity of the testosterone 5*-reductase determined 
in the usual manner and expressed as pmoles 
testosterone converted per hour per prostate.
The results are expressed in Table III .. 3,and 
it is apparent that the control group S exhibited a 
mean enzymic activity equivalent to a conversion
Table III - 3»
Rat Prostatic Testosterone ^^-Reduotase Activity 
Following the In Vivo Administration of Heparin.
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Animal
Group E
Mean Prostate 
weight(g) + SD
Testosterone 
5oc-Reductase 
(pmol/h) + SD
Control (S) 8 0.59 ±  0.11 1 44 16,3
Low Dose (L) 7 0.43 + 0.07 139 + 22
High Dose (H) 4 0.45 + 0.04 134 ±.14
Control - 
Low Dose
High Dose
0.3ml Saline per injection.
2500 U Heparin in 0.5ml saline 
per injection.
12500 U Heparin in 0,5ml saline 
per injection.
* p < 0.005
t p < 0.025
p refers to difference between control and 
appropriate test as determined by Students 
t test.
+ USP units
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of the added substrate. The testosterone 
5%-reductase levels observed in the two test groups 
L and H were not significantly different from those 
of the control group and it is apparent that under 
the conditions of this experiment it was not possible 
to demonstrate the uptake of heparin from the 
circulation by prostatic tissue.
It is of note that the mean prostatic weight 
of the control group S was significantly higher 
than for the two test groups, (p <0,005; p <0.025 
respectively) a fact that was obvious from a brief 
examination of the glands at the time of their 
removal, the prostates of heparinised animals having 
a dehydrated appearance. Nevertheless this 
reduction of prostate weight was not accompanied by 
a reduction in testosterone 5&-reductase activity,
E , Preliminary Investigation of the Endogenous
Heparin-like 0ontent of Benign Hyperplastic
Human Prostate.
The previous section suggested that heparin 
is unlikely to enter the rat prostate gland from 
the blood stream. It is reasonable, therefore, 
to assume that compounds related to heparin would 
also be unable to gain entry into the tissue and 
that the human prostate is likely to present the 
same barrier as the rat gland. Under these
89
circumstances it must be postulated that any 
in vivo role for heparin or related compounds 
in the control of prostatic testosterone 5K-reductase 
would arise as a result of synthesis of the 
inhibitor within the gland itself. Since there 
appears to be no reliable report of the heparin 
content of prostate tissue a preliminary investigation 
was initiated and a tissue extract obtained,which was 
tested both for heparin content and for its ability 
to inliibit testosterone 5K-reduotase,
Heparin was quantitated by the method of 
Bitter & Muir (1962) which measures the reaction 
of carbazole with uronic acid residues. However, 
this method could not be applied to whole tissue 
preparations since certain components present 
produced charring which interfered in the colouri- 
metric determination. Experimentation revealed 
that neither DNA, RNA or protein were responsible 
for the charring but both sucrose and glucose at 
concentrations of 100/Jg per assay tube produced 
gross discolouration.
Most of the procedures published on the 
extraction of heparin from animal tissues are 
based on the work of Charles & Scott (1935,a & b) 
which was developed for preparative rather than 
analytical purposes, using large quantities (Kg) 
of tissue, relatively rich in heparin. However,
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methods for the extraction of heparin from smaller 
quantities of tissue have been reported, and two of 
these were investigated in turn. In order to assess 
the efficiency of each extraction procedure a knoim 
amount of -heparin was added immediately
following homogenisation.
The first method was adapted from that of 
Freeman et al., (1957). A sample of tissue (5g) 
was homogenised with 5ml cold water, and immediately 
poured into 5 volumes of acetone to remove lipids. 
After standing for a few minutes the suspension was 
centrifuged and the supernatant discarded. The 
sediment was suspended in 10ml of 0.5M NH^Cl buffer, 
pHSe5 and heated in a boiling waterbath for 15min.
The suspension was transferred to dialysis tubing 
together with one millilitre of a 5Qh glycerol 
solution containing 100mg of purified trypsin. The 
mixture was dialysed against 0.5 litres of the 0.5H 
NH^Cl buffer for 48h at 37^. A second 1 ml aliquot 
of the trypsin solution was added, the buffer 
reservoir renewed and dialysis continued for a 
further 48hr. Finally the contents of the dialysis 
sac were dialysed against running tap water overnight. 
The contents of the sac were transferred to a 50ml 
centrifuge tube, NaCl was added to a concentration 
of Ifo and the solution boiled for 15min. in order to 
inactivate and coagulate the trypsin. The mixture
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was cooled to room temperature, centrifuged at 
1OOOg for 5min. and the supernatant decanted into 
5 volumes of acetone. After standing for 30min. 
the mixture was recentrifuged at 1OOOg for 5min. 
and the supernatant discarded. The sediment was 
dissolved in a small volume of NaCl and 5 vol. of 
methanol were added. After standing for a further 
30min. the solution was centrifuged at 1OOOg for 
5min., the supernatant discarded, the tubes inverted 
and drained for several minutes, and finally dried in 
a vacuum oven. The residue was dissolved in 2ml 
distilled water. Approximately 30^ 5 of the added
-heparin was recovered and 3mg of heparin-like 
material was extracted from 3g of tissue as estimated 
by the colourometric assay described in Chapter II. 
However the extract still contained a considerable 
amount of protein (Table III - 4).
Recoveries of -heparin from standard
protein solutions of bovine albumin (BSA) were found 
to be low ( < 1%), much of the heparin being lost with 
the protein removed in the earlier stages of the 
purification, and the acetone precipitation step 
also caused large losses.
An attempt was made to improve the method by 
the use of 10^ trichloroacetic acid (TCA) to 
precipitate the protein, leaving the heparin in 
solution. TCA could then be removed from, the
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Table III - 4
Composition of Final Heparin Extracts of Human 
Hyperplastic Prostate Tissue.
Method of 
Extraction
Amount of 
Tissue
Protein
Content
Estimated Heparin 
content
Extracted Carbazole Reductase
Freeman 
et al.. 
(1957)
5 g 9.6mg 2.5mg 0*32mg
Horner 
(1971 )
20g 0*6mg 2mg 2mg
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supernatant by extracting with diethyl ether. This 
process did not affect the potency of heparin in the 
reductase assay but it also did not improve the 
recovery of heparin from BSA or increase the yield 
from prostatic extracts.
The second approach to the problem used the 
method of Horner (1971) which is based on the 
precipitation of heparin from a protein digest with 
cetyl pyridinium chloride (CPO).
Human prostatic tissue (20g) was chopped into 
0..5cm cubes and exhaustively extracted firstly with 
two separate 250ml volumes of acetone then 1 litre 
of petroi.eum spirit (bpt 40-60^0) using a soxhlet 
apparatus. The product was first air dried, then 
vacuum dried, yielding an average of 2»5g of dried 
defatted tissue. This was suspended in 50ml of 
0.1MTris/HGl+0.01 MCaCl2jpH8.0 containing toluene 
0.1ml. Pronase (20mg) was added and the mixture 
incubated at 40^ for 48h with intermittent mixing.
After digestion NaCl was added to a concentration of 
1*0M, the gross solids were removed by vacuum 
filtration and washed with 1.OM NaCl at 40°G, prior 
to refiltration. The two filtrates were combined 
for treatment with cetyl pyridinium chloride (CPC).
The slightly cloudy filtrate was diluted with 
water to a NaCl concentration of 0.80M and solid 
NagSO^ was added to a concentration of 0.05M.
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The solution was warmed to 3 5 ^ and CPC added in a 
ratio of 1g/100ml, filtrate. One gram of Hyflo 
Supercel was stirred in before filtering through a 
Millipore filter (15ml with Whatman G*F«/C 25mm 
filter discs). The resulting precipitate was 
extracted with four 5ml portions of warm (40^C)
2.OM NaCl. Each extract was allowed to stand for 
1Omin. then recovered by centrifuging for 1Omin. at 
200g at room temperature. The combined extracts 
were mixed with 2 volumes of ethanol, 1 volume H^O 
then 2 volumes of ethanol. After standjjig overnight 
at the precipitate was centrifuged for 30min. at 
500g at room temperature, dissolved in 2e-OM NaCl emd 
precipitated again with ethanol as above. The 
precipitate was washed with ethanol and vacuum dried. 
Using Horner*s method, 75^ of added [^^s]-heparin was 
recovered from a standard protein solution although 
the recovery from prostatic homogenates was lower at 
35%• A yield of 2mg'of heparin-like material was 
obtained from 20g of human hyperplastic prostate as 
estimated by colourimetry, and in contrast to the 
previous method the extract was essentially free from 
contaminating protein (Table III - 4).
The extracts obtained by both methods were 
tested in the 5&-reductase assay and were shown to 
cause inhibition when added to the assay tubes 
(Table III - 4). The correlation between this
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estimate of heparin action and the colourimetrie 
estimate was especially good with the material 
extracted by Horner*s method.
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3* DISCUSSION.
The assay for prostatic testosterone 5&-rednctase 
was successfully validated and the within batch 
precision of the method established. No attempt 
was made to assess the between batch precision of the 
method since each preparation of enzyme came from a 
different source of tissue. Instead, each 
experiment was carefully designed so that sufficient 
controls were included to enable a conclusion to be 
reached without the need for inter assay comparison.
It is interesting that the ionic strength of the 
reaction mixture had such a profound effect on the 
activity of human prostatic testosterone 5^-reductase, 
Such an observation has been made previously for rat 
prostatic testosterone ^^^reductase (Roy, 1971), In 
this study ionised substances were being assessed as 
potential inhibitors and hence it was clearly of 
paramount importance to standardise upon an ionic 
strength for use throughout the study.
Using the standardised assay system it was 
apparent that heparin is an effective in vitro 
inhibitor of the testosterone 5%-reductase enzymes 
of both rat and human prostate tissue. These 
results extend the isolated observation of Blaquier 
& Calandra (1973) that a high concentration of 
heparin can inhibit rat prostatic testosterone 
5&-reductase,
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High concentrations of heparin were demonstrated 
to affect the reduction of NADP by glucose-6-phosphate 
dehydrogenase and 6-phosphogluconate dehydrogenase, 
but the effect of the polysaccharide on the reduction 
of testosterone was shown to be independant of the 
provision of an adequate supply of cofactor.
The mechanism of the heparin inhibition of 
testosterone 5#-reductase was investigated and 
competition was apparently demonstrated between 
heparin and both the substrate and the cofactor.
It is perhaps surprising that heparin should produce 
such kinetics when it is structurally unrelated to 
either testosterone or NADPH, but similar effects 
of heparin have been observed in the production of 
angiotensin by the kidney enzyme renin (Seale y 
et al., 1967). Furthermore the investigations 
described in this chapter have demonstrated that 
heparin also apparently exerts competitive kinetics 
with respect to the reduction of NADP by both 
glucose—6—phosphate dehydrogenase and 
6-phosphogluconate dehydrogenase,
A clue to this apparent anomaly may be obtained 
from the vs I plots for the two NADPH generating 
systems since the results suggest that no enzyme- 
inhibitor complex is formed but rather that the 
heparin changes the affinity of the enzymes for the 
NADP substrate (Mahler & Cordes, 1966). Since
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heparin contains many sulphated residues it is a 
highly charged molecule and it is not unreasonable 
to suppose that it would bind to positively charged 
groups within a protein molecule. It is possible, 
therefore, that the observed effects of heparin 
result from a non-specific binding of the poly­
saccharide to basic amino acids adjacent to the 
substrate and cofactor binding sites of the enzymes 
under study. In the case of the prostatic 
testosterone 5%-reduotase the enzyme has not yet 
been obtained in a semi-purified form so it is 
likely to be many years before the three-dimensional 
structure of the active site of the enzyme is 
elucidated.
The pronounced effect of Ionic strength on the 
prostatic testosterone 5&-reductase activity cannot 
be altogether ignored since the addition of heparin 
to incubations would undoubtedly Increase the ionic 
strength of the medium. However it is unlikely 
that such an effect would depend upon the 
concentrations of substrate and cofactor, and one 
would therefore have expected different kinetics 
if ionic strength was playing a major part in the 
inhibition process.
Heparin is not a specific inhibitor of prostatic 
testosterone 5x-reductase and in addition to the 
effects on the enzymes previously mentioned it has
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been demonstrated to inhibit (î)-glucuronidase, RITA 
polymerase, fumarase, alkaline phosphatase, 
collagenase, elastase and serum protease (Ehrlich 
& Stivala, 1973). Such a spectrum of action would 
support the mechanism of action outlined above and 
would certainly suggest that attention be given to 
these effects before employing heparin therapy. 
However, heparin is not a universal enzyme inhibitor 
having no effect on staphylococcal coagulase 
(Fumarola,1969) and actually stimulating other 
enzymes such as pepsinogen (Horowitz et al., 1970) 
and diamine oxidase (Hansson & Ihysell, 1970).
The acidic nature of heparin means that in 
addition to binding to basic proteins it should be 
capable of binding other cationic substances. In 
this context the physiological action of histamine 
is reduced by heparin (Tidball, 1967) and heparin 
inhibits calcification in vitro presumably by binding 
calcium ions (Harris et alj 969). Einallv. although the 
role of heparin in anticoagulant therapy is now 
thought to result primarily from its interaction with 
the protein factors associated with the conversion of 
prothrombin to thrombin, it is not yet possible to 
discount a role for heparin in preventing the 
provision of the calcium ions essential for the 
coagulation process (Ehrlich & Stivala, 1973).
The prostate is an organ which contains high
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levels of cations, and in particular zinc, which is 
found in higher levels here than elsewhere in the 
body (Mann, 1964)* Since zinc is known to have a 
strong inhibitory effect on the 9&-reductase 
(Wallace, 1975) it did not seem unreasonable to 
postulate that there could be an ionic interaction 
between the zinc and heparin, which could have 
bearing on the control, of the enzyme. However, it 
was not possible to demonstrate that added zinc 
affected the in vitro inhibition of the testosterone 
50'^—reductase of either human or rat prostate, although 
this simple approach to a complex topic does not 
necessarily exclude all possibility of an ionic 
interaction in vivo. It is worthy of note that 
protamine sulphate, which is used to reverse the 
anticoagulation properties of heparin (Ehrlich & 
Stivala, 1973), was also capable of reversing the 
effects of heparin.on prostatic testosterone 
5ct-reductase, again presumably as a result of an 
ionic interaction.
As heparin is a large complex molecule with 
many functional groups, it was thought relevant to 
establish whether the overall structure in general 
or any one of the groups in particular was 
responsible for the 5%-reductase inhibition. Thus 
a number of related monosaccharides and poly­
saccharides containing various functional gx*oups
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were tested in the assay system. Of the 
monosaccharides tested only H-acetyl glucosamine 
showed any inhibition over the wide range tested. 
Although all the monosaccharide units of heparin are 
not commercially available, those that make up 
hyaluronic acid were tested, and whilst the 
individual sugar units had only a small effect on the 
enzjone, when combined together as hyaluronic acid a 
potent inhibitor of testosterone 5&-reductase 
resulted. The finding that hyaluronic acid inhibits 
the prostatic 5&"reduotase differs from a similar 
study of cortisone reduction in rat liver conducted 
by Troop (1969) who found no inhibition with this 
carbohydrate, even at concentrations greater than 
those used in the present study. Other 
polysaccharides studied by Troop, Eo2-3053, Ro2-7309, 
R02-7528, heparin and chondroitin sulphate, showed 
similar trends to those reported here, but appeared 
to be less potent in the inhibition of cortisone 
reduction; and Ro1-8307 which was only marginally 
effective in the prostatic system showed as much 
potency as Ro2~3053 in rat liver. Rol-8307 was also 
shown to be as effective as heparin in decreasing 
aldosterone production in the rat adrenal (C-flaz &
Sugar, 1964).
The degree of sulphation alone does not seem to 
determine the extent of inhibition of testosterone
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^(X-reductase as hyaluronic acid with a low sulphur 
content (< 0.05^) was potent,whilst Chondroitin 
sulphate and Rol-8307, with 6»3^  ^and 15^ sulphur 
respectively, showed little effect. In a Krebs 
ascites cell-free system heparin was shown to be 
a potent inhibitor of rabbit giobin mRNA translation 
(Waldman et al., 1974). This group exaiained the 
effect of sulphate content by progressively de- 
sulphating the molecule with mild acid, and testing 
for anticoagulant activity and protein synthesis 
inhibition. Anticoagulant activity was reduced by 
50^ within one hour, but at least eight hours of 
treatment were req^uired before of the protein
synthesis inhibition was lost. These experiments 
indicate that sulphate content is important, but to 
varying degrees in different systems.
Before speculating about the physiological 
implications of the data presented it was necessary 
to establish the presence of heparin in prostatic 
tissue. In normal individuals the plasma heparin 
levels are almost undetectable (Ehrlich & Stivala, 
1973) and it seems unlikely therefore that any 
heparin in the prostate would be manufactured in 
another site and transported. Further evidence 
against the concentration of heparin within the 
prostate gland from the blood is shown in the 
in vivo experiments, where the intraperitoneal
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injections of high doses of heparin did not reduce 
prostatic 5^-reductase activities. Whilst it seems 
reasonable to assume that a molecule as large as 
heparin would have difficulty in crossing the cell 
membrane, there are reports of in vitro systems which 
claim this can occur (Costachel et al., 1964). If 
heparin is not transported into the gland one is 
left with the alternative that the tissue itself 
must synthesise it. This is quite a reasonable 
hypothesis as heparin is commonly associated with 
connective tissue (Schubert & Hamerman, 1968) in 
the form of glycoproteins in the mast cells. The 
simplest way to test for the presence of heparin in 
the prostate is to isolate an appropriate fraction 
from the tissue, and to test for both heparin content 
and testosterone 5^-reductase inhibitory properties.
The results presented suggest that human hyperplastic 
prostate does possess some uronic acid containing 
molecules which show mild ^d-reductase inhibition , 
and are present in quantities which correlate with 
reported levels of heparin in other tissues. Ho 
attempt was made to further identify the uronic acid 
residues within prostatic tissue since such a major 
project seemed outwith the scope of this thesis.
The fact that heparin-like compounds are found 
in whole tissue extracts does not mean that they will 
be located within the cell where they can influence
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the testosterone 5‘^-reductase. Evidence to support 
or contradict this hypothesis would be most difficult 
to produce since the amount of tissue which would be 
required to obtain measurable amounts of heparin 
after subcellular fractionation would be beyond the 
limits of practicable experimentation. At present, 
therefore, it is not possible to do more than 
speculate as to the role heparin and related compounds 
may play in the aetiology of human benign prostatic 
hyperplasia. The lack of specificity of the 
described effects argues against a central role for 
heparin in controlling the activity of prostatic 
testosterone 5#-reductase although a decline in 
tissue concentrations of the polysaccharide may 
contribute to the removal of a brake on the enzyme 
and so encourage greater 5&-dihydrotestosterone 
formation which in turn could promote hyperplasia.
For heparin to be of any value in the treatment 
of prostatic hyperplasia, in vivo administration 
should result in a lower testosterone 5^-reductase 
activity. Glaz & Sugar (1964) reported in vivo 
inhibition of aldosterone production both with 
heparin and heparinoid compounds, and Carter et al.* 
(1968) reported that in vivo administration of 
heparin inhibited cortisone A ring reduction by 
intact cells in liver slices from female rats. The 
in vivo administration of heparin reported here was
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based on the regime of Carter et al., (1968) but 
no similar inhibition in prostatic slices was 
observed. Moreover, the survival rate among the 
treated rats was low,indicating that lower doses of 
heparin would have been necessary in further 
experiments, and in this context perhaps a lower 
dose administered over a longer time period would 
have shown some effect.
Even if heparin were freely accessible to 
prostatic testosterone 5oC-reductase it is still 
unlikely that it would be used in the treatment of 
benign prostatic hyperplasia since its multiplicity 
of physiological action would produce undesirable 
side effects.
In conclusion, heparin and related compounds 
have been shown to be effective in vitro inhibitors 
of the testosterone 9#-reductase of both rat and 
human prostatic tissue, although the inhibition 
appears to be lacking in specificity. Whilst 
prostatic tissue seems unlikely to concentrate 
heparin from the circulation it may well be capable 
of synthesising significant quantities of related 
substances and it remains to be established whether 
these compounds can in any way influence the onset 
of benign prostatic hyperplasia.
CHAPTER XV.
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CHAPTER IV.
THE INTERACTION OP SPIRONOLACTONE METABOLITES 
WITH PR08TATIC TESTOSTERONE 5#-REDH0TA8E,
1. INTRODUCTION.
The spironolactones are a group of substances 
widely used in clinical practice as aldosterone 
antagonists. Their action is achieved by competition 
between the spironolactones and aldosterone for the 
mineralocorticoid binding sites in the renal tubules 
(Parnestil, 1968),and the reduction in aldosterone 
induced effects produces Na*^  loss and promotes K* 
retention. Spironolactone itself, the form in 
which the drug is most widely administered, is a 
steroid with a basic androstane skeleton (Eig.IY - 1). 
Following absorption spironolactone is rapidly 
metabolised, mainly to aldadiene (canrenone) and to 
eanrehoate (Fig.IV ~ 1)(Sadie et al,, 1973),which 
exist together in the plasma in equilibrium.
Relatively large doses of spironolactone (e.g. 200mg) 
are necessary to inhibit the physiological effects 
of 1 mg of aldosterone.
Recently, interest has been stimulated, in the 
possible antiandrogenic side effects of spironolactone
Pie.iv 1 .
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and its metabolites following the observation of 
gynaecoinastia,- menstrual irregularities and impotence, 
in patients receiving oral spironolactone (Dymling 
et al., 1972). Moreover, Basinger & G-ittes (1 974) 
noted the atrophic appearance of rat seminal vesicles 
and prostates, but not adrenals, in spironolactone 
treated animals . Histologically these glands were 
shown to have low columnar epithelium, a decrease in 
cytoplasmic to nuclear ratio and a loss of epithelial 
involutions. Similarly,spironolactone has been 
demonstrated to inhibit the survival of cultured 
human prostatic tissue (Castro & Sellwood, 1974).
The antiandrogenic effects of spironolactone 
may in part be due to an inhibition in androgen 
production and in part to a blocking of the action of 
androgens. Thus, in rat testis,the drug hsis been 
shown to decrease the formation of testosterone from 
progesterone as a result of inhibition of the 
cytochrome P450 dependent steroid 1 7oC-hydroxylase 
(Menard et al., 1974), and a significant rise in 
plasma concentrations of progesterone and 17ef-hydroxy 
progesterone have been reported following the 
administration of 400mg/day spironolactone to healthy 
men (Stripp et al., 1975), which is consistent with 
loss of P450 dependent 17ot*hydroxylase and desmolase 
activity. Several studies have been carried out to 
assess the Offeet of spironolactones on the binding
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of DHT to the prostatic androgen receptor and it is 
now well established that there is a marked inhibition 
of binding of DHT to both cytoplasmic and nuclear 
receptors in the presence of those compounds. Thus 
Bonne & Raynaud (1974) showed potent effects on DHT 
binding for spironolactone itself and for aldadiene 
but not for potassium canrenoate.
The effects of spironolactones on the activity 
of testosterone 5^-neductase are far less well 
defined, for whilst Corvol et al., (1975) have shown 
no effects of spironolactone or potassium canrenoate 
on enzyme activity the inhibitory role of aldadiene 
does not seem to have been assessed. This omission 
is perhaps surprising in view of both the 
quantitatively significant role of aldadiene and the 
structural features that make it potentially the most 
likely inhibitor of testosterone 5^-reductase. In 
this study the effects of the two principal 
spironolactone metabolites, aldadiene and potassium 
canrenoate, have been examined with the human 
prostatic testosterone 5^-reductase enzyme system.
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2. EXPERIMENTAL AND RESULTS,
A. Interaction of Aldadiene and Potassium 
Canrenoate with Testosterone 5#-reductase.
An oral dose of 10Omg spironolactone is a
standard regime which produces a peak plasma 
aldadiene concentration of 250ng/ml (Searle, personal 
communication). Accordingly, the concentration 
ranges in the following experiments were based on 
this plasma concentration. Fig.IY - 2 shows the 
effect of adding either aldadiene or potassium 
canrenoate to the standard testosterone 5c^™reductase 
assay described in Chapter II. Aldadiene had a 
significant inhibitory effect on the enzyme activity 
at 250 and 50Ong/ml. Potassium canrenoate on the 
other hand would appear to have had no effect over 
this concentration range,
B. The Purity of Aldadiene.
The purity of the added aldadiene was checked 
by thin layer chromatography. Aldadiene (1 OQjug) 
was spotted on to Silica TLC plates and developed in 
a solvent system of benzene/ethylacetate:6/4, The 
aldadiene had an Rf of 0.19 in this system and no 
other spots were visualised under CV light at either 
264nm or 550nm. Scanning a solution of the 
aldadiene preparation on a Dnicam SP800 
spectrophotometer from 200 - 450nm showed the compound
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The spironolactone metabolites^ aldadiene 
and canrenoate, were tested over the 
concentration range 0-500ng/ml for their 
ability to inhibit the standard testosterone 
5oC"-reductase assay described on page 62.
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to have a single absorption maximum, at 283nm - which 
is characteristic of the conjugated double bond 
system in the A and B rings of aldadiene. The single 
absorption maximuiia and single spot on the 
cliromatogram would indicate that there were no 
significant contaminating impurities and that the 
inhibition of the testosterone 5(X.-reduotase was due 
to aldadiene itself.
0. Kinetics of Aldadiene Inhibition of Testosterone 
5K-Reductase ITsing Homogenate Preparations.
In order to assess the type of inhibition 
exerted on the enayme by aldadiene, homogenate enzyme 
preparations were incubated at varying substrate 
concentrations in the presence or absence of 
aldadiene (250ng). At this concentration, however, 
aldadiene is nearing the limit of its solubility in 
water,and the presence of the steroid in the 
homogenate preparations led to consistently imprecise 
determinations and the need for a more homogeneous 
enzyme preparation was indicated,
A microsomal preparation was considered most 
suitable for the purpose. Nuclear preparations were 
ruled out both on the grounds of the difficulties in 
removing contaminating connective tissue fragments, 
and because of low yields (Wallace, 1975)^
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D« Preparation of Microsomes and Validation of
the Method.
The method used was based on that of Wallace 
(1 975) and is detailed in Chapter II*. Human 
hyperplastic prostatic tissue was thoroughly 
homogenised and centrifuged at 15»000g for 10min* 
to precipitate whole cells, mitochondria and nuclei.
The low spin supernatant was then recentrifuged at 
105,000g for 1h to precipitate the majority of the 
microsome fragments. The high spin precipitate was 
suspended in TICM + sucrose buffer prior to incubation. 
The previously described variability in specific 
activity of human prostatic testosterone 5d.-reductase 
was particularly evident in these microsomal 
preparations and great care was required to ensure 
that optimal enzyme activity was s,dded to incubation 
tubes. As a general approximation the microsomes 
from 1 gram of human prostatic tissue were su.spended 
in 5ml of buffer and '500^ of this solution was used 
in each assay tube.
Table IV - 1 shows the results of the distribution 
of testosterone b^l-reductase during the preparation of 
microsomes from two different preparations, together 
with the percentage conversion of testosterone 
substrate obtained in the assay system with each 
cellular component. It is apparent that the high 
speed pellet contained a higher spec'j.fic enzyme
11 Oa
Table IV-1.
Homogenates of human prostate were 
centrifuged at 15,000 g for 10 min (low spin) 
followed by 10$,000 g for 60 min (high spin). 
The corresponding pellets were resuspended 
as indicated and testosterone 5o(“reductase 
activity determined in all fractions using 
the method described in Chapter II,
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Table IV - 1
Distribution of Testosterone 9t?<"Reductase Activity 
in Different Preparative Fractions.
PROSTATE A PROSTATE B
Prep, and 
vol.
SA
pmoles/h / 
mg protein
io Gonv.
SA
pmoles/h/ 
mg protein
^ Gonv.
VJhole Homo g. 
250/41 17.5 26.5 10.2 26.1
Low spin pel. 
100/jl 56.4 55.5 21 .0 24.9
250/41 24.4 59.9 20.0 46.5
500/.1 16.1 77.0 8.15 55.4
High spin pel. 
100/0. 59.1 20.6 9.2 2.0
250/1 55.5 40.4 12.7 5.8
500/1 25.6 66.. 4 11.6 11 .4
High spin sup. 
500/1 0.72 2.7 0.57 2.2
PROSTATE A
1Og tissue homogenised in 100ml TK>! + Sucrose 
Low spin Pellet suspended in 25ml TEII -i- Sucrose 
High spin Pellet suspended in 1 5ml TKïd -F Sucrose
PROSTATE B
10g tissue homogenised in 100ml TKM -}•■ Sucrose 
Low spin Pellet suspended in 50ml TKM + Sucrose 
High spin Pellet suspended in 100ml TKI4 + Sucrose
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activity than the homogenate, although this specific 
activity was suhraaximal if the percentage conversion 
of substrate was permitted to exceed
A time course for the incubation of 2ng 
testosterone with an optimal amount of microsomal 
preparation showed that the reaction was approximately 
linear for the first 30 minutes, thereafter the 
activity decreased (Pig.IV - 5). This indicates 
that in the standard assay, with a 20min. incubation 
period, velocities similar to initial reaction 
velocities were being measured. For each time point 
over 95/^  of the total, radioactivity at the end of the 
incubation could be accounted for by [^h]-testosterone 
and Ph]-DKT. No [^H]-5X-androstane-5^h17p-diol 
was detected.
E • Kinetics of Aldadiene Inhibition of Testosterone 
5oC-Reductase using Microsome Preparations.
The use of microsome preparations allowed a 
marked improvement in the precision of the enzyme 
assay, with the mean coefficient of variation 
improving from 25*4^  ^for the homogenate assay to 
for the microsome assay, as calculated from 
three determinations at five different substrate 
concentrations. Double reciprocal plots were 
repeated using the microsome preparations. However, 
whilst the precision had improved considerably, it
111a
Time Course for Testosterone 5o^”ReduQtase using 
a Microsome Preparation.
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Microsomes from 1Og tissue were made up to 
50ml in TKÏ4 + Sucrose buffer and 500yl 
added per assay.
was still not possible to distinguish the type of 
kinetics exhibited by aldadiene (Pig,I¥ - 4). 
Extending the range of substrate concentrations and 
increasing the inhibitor concentrations would be 
possible ways of overcoming this problem, but would 
necessitate Suioreases of inhibitor concentrations 
beyond the levels of solubility of aldtidiene in the 
solutions used.
E. Metabolism of [l , 2“ h]-Aldadiene .
It vas considered possible that aldadiene could 
be metabolised by the testosterone 5^-neductase, thus 
accounting for its inhibitory properties on the 
enzyme. Accordingly, incubations were set up to 
test this hypothesis.
A standard homogenate enzyme preparation was 
incubated for 0, 15, 30 and 60min. with [l ,2-^H]- 
aldadiene (5ng, 500,OOOopm) and 4mM NAEPH, The 
reaction was terminated with ethanol (2ml) and the 
steroids extracted with chloroform, evaporated under 
nitrogen and spotted on paper chromatography strips. 
The strips were run in the Bush B system and after 
radioscanning only a single peak could be detected, 
with an Rf value of 0.6. This peak corresponded to 
aldadiene Itself and it was therefore concluded that 
no significant metabolism of this steroid had taken 
place.
1 1 2a
Fig.IV - 4
I "  "I i *nint
Double Reciprocal Plots of ^oC-Reductase Inhibition 
by Aldadiene.
(a) Homogenate preparation.
0-1 0-2 O G
/S (rH testosterone ^)
(b) Microsome preparation,
0 -1 -
0'1 0*2 0*3
j^ S (nM testosterone"*^ )
Key: o Ho Aldadiene
A 4- 250ng Aldadiene 
Bach point is the mean of triplicate incubations.
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3* DISCUSSION.
The spironolactone metabolites, aldadiene and 
canrenoate were tested in the standard human prostatic 
5oc»reduotase assay system for possible inhibition 
properties. At concentrations similar to those 
found in the plasma of spironolactone treated patients, 
aldadiene caused a small but significant inhibition 
of testosterone reduction. Canrenoate showed no 
inhibition at either this or higher concentrations.
The inhibitory properties of aldadiene could not be
attributed to impurities in the steroid preparation*
The lack of effect of canrenoate is consistent 
with the literature report of Corvol et al., (1975) 
for the rat prostate system. The effectiveness 
of aldadiene as an inhibitor of testosterone 
5oi~reductase probably results from the presence of 
the lactone ring which may be required for binding 
to the surface of the enzyme. A similar requirement 
for the lactone ring has been shown by Bonne &
Raynaud (1974) for binding to the prostatic DHT 
receptor and the varying effects of spironolactone 
metabolites as Inhibitors of adrenal steroid
hydroxylation have similarly been attributed to
structural differences (Cheng et al., 1976).
Considerable difficulty was experienced in 
determining the type of inhibition exerted on the 
testosterone Sot-reductase by aldadiene. This
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difficulty was in part due to the poor solubility 
of aldadiene and in part to relatively small degree 
of inhibition being studied. Although the use of a 
microsomal preparation of 5°^ -reductase significantly 
improved the precision of the enzyme assay it did not 
permit conclusive evidence a,s to the nature of the 
inhibition, although the failure of the enzyme system 
to metabolise aldadiene suggests that simple 
competitive kinetics are unlikely.
Spironolactones would thus seem to have three 
possible sites of action as antiandrogens - 
inhibition of androgen synthesis, inhibition of 
androgen metabolism and competition for the DHT 
receptor site. It is impossible to predict from 
a simple study of this nature the relative importance 
of these three sites of action in vivo although it is 
not unreasonable to suppose that the small 
inhibitory effects of aldadiene on testosterone 
5o(-reduction are unlikely to be of major importance 
in deciding the antiandrogenicIty of spironolactone 
preparations,
CHAPTER V.
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CHAPTER V.
THE INVESTIGATION OP AN ISOTOPE EFFECT IH
THE CHEMICAL AMD BIOLOGICAL METABOLISM OF 
1 7c^ “TRITIATED ANDROGENS.
1. INTRODUCTION.
The following study was Initiated as a result
of a casual observation made during the validation
of the experimental model used in the simultaneous
superfusion of human prostate slices with [l -
testosterone and [l , 2-.t^h]-DHT. Following the
chromatographic separation of the testosterone and
DHT fractions from the tissue it was noted that not
all the radioactivity in the DHT fraction was
converted into 5&-androstane-3,17-dione by chromic
acid oxidation. Further experimentation revealed
that this resistance to dehydrogenation resulted
%
from the presence of the 17<X- H atom and it was 
decided to investigate this isotope effect in 
greater detail.
Isotope effects arise because of the varying 
energy required to break isotopically different 
bonds, and in general, the greater the mass of the 
isotope the higher the activation energy of the bond.
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Primary isotope effects are usually most apparent 
since the isotopic bond is directly involved in 
the rate limiting step. Secondary isotope effects 
do not involve the isotopic bond but may result 
from the close proximity of the isotope (Evans, 1974).
Isotope effects are particularly common in 
reactions involving hydrogen isotopes since there 
is a greater proportional difference in the masses 
of protium, deuterium and tritium than for any 
other atomic species. Accordingly protium 
reactions have been reported to be five to eight 
times as fast as deuterium whilst tritium isotope 
effects may be twice as large as those of deuterium 
(Morrison and Boyd, 1966)*
Isotopic labelling results in a different 
vibration frequency in the bond holding the labelled 
atom to the molecule, and hence a difference in the 
susceptibility of that bond to breakage. Such a 
change may affect the'participation of the 
labelled species not only in chemical reactions, 
but also in enzymatic reactions where binding of 
the substrate to the enzyme, and hence the Michaelis 
constant, may be affected. Therefore, it does not 
necessarily follow that tritium labelled substrates 
behave in an identical manner to their non­
radioactive counterparts - an essential assumption 
in any radiotracer study.
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Great care must be taken before an isotope 
effect can be-established since there are several 
artifacts which can apparently bring about 
differential metabolism of isotopically different 
substrates. Uncertainty about the specific 
activity of a substance is often the cause of 
unexpected results, as is a lack of knowledge of 
the stereospecific nature of the labelled species.
Tritium atoms are particularly labile and this may 
result in low reaction rates, whilst intramolecular 
migration of tritium can produce very confusing data.
The existence of isotope effects in the 
oxidation of alcohols has been established for many 
years. As early as 1949 Westheimer and Nicolaides 
compared the rates of chromic acid oxidation of 
propan-2-ol and 2~deutero-propan~2-ol. Their 
demonstration of a slower oxidation of the deuterated 
species was consistent with the mechanism below, in 
which there is the initial formation of a chromic 
acid ester followed by the rate-determining 
abstraction of the carbinol proton by an elimination 
process :
1. 4 CrO^ ^  C r O ^ H
^  ^  © G.H D G)
2. C - O " CrO^H ^  H^O -b -bCrO^H
118
A similar mechanism has been confirmed for 
the chromic acid oxidation of the steroid alcohols 
5#rcholestane-^#-ol (Eliel et al., 1965) and 
5&-pregnane-11^-ol (Rocek et al., 1962) and in both 
cases the mechanism was confirmed by the use of 
deuterated species and the demonstration of an 
isotope effect.
Isotope effects have also been observed and 
used in enzyme reactions. Fisher and his 
colleagues (1953) used 1 ,1-dideuteroethanol to 
demonstrate a direct transfer of hydrogen from 
ethanol to NAD in the reaction catalysed by alcohol 
dehydrogenase, and Talalay and his colleagues (1955) 
used 17x-deutero-17p-hydroxy-4-androstene-3-one to 
show a direct transfer of hydrogen between 
testosterone and position 4 of NAD in the reaction 
catalysed by 17^-hydroxysteroid-dehydrogenase. Both 
these authors discussed the occurrence of isotope 
effects during their studies.
Thus, although an isotope effect has not been 
specifically reported for either the chemical or 
biological oxidation of 17X-tritiated androgens 
there seems little reason why such a phenomenon 
should not exist and accordingly it was decided to 
fuTther investigate the observation made during the 
validation of the superfusion system.
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2. RESULTS.
A. Initial Observations.
V/hen human prostatic tissue is superfused 
simultaneously with [^1 7o<-^h]-testosterone and 
[l,2-^hJ-DHT the resulting mixture of steroids 
extracted from the tissue and perfusate includes 
[l 7ot^H]-testosterone, |[l 7oC^l{j-DHT and [l ,2-^h]-DHT. 
Testosterone and DHT can be readily separated by 
chromatographic methods. However, the [i7oC^ h]-DHT 
and [_1 ,2-^ï^-DHT require further processing before 
the radioactivity due to the different isotopically 
labelled compounds can be distinguished. The 
separation is facilitated by oxidation of the 
steroids with GrOy in glacial acetic acid, a 
procedure which results in the production of 
5c<—androstane-3» 17~dione from DHT, (and 4-androstene- 
3r17“dione from testosterone). This oxidation 
involves the conversion of the 17^-hydroxyl group 
into a 17-keto group with the loss of the 17ol- 
hydrogen atom. Thus in a mixture of - and
[l,2-^n]-DHT the steroid formerly labelled at the 
17ûî^ position becomes non-radioactive following 
oxidation, leaving the only radioactivity in the 
5#-androstane-3,17-dione as that originating from 
,2-'^ hJ-DHT. Provided correction is made for 
procedural losses, it is thus possible to determine 
the fraction of 1^ 7o(-^hJ-DHT in the original mixture. 
(Pig. V - 1).
1 1 9a
Pig.V - 1
# | |  w  ,, I a r J w »  I I —
The Chromic Acid Oxidation of B ,2-^Hj-DHT and 
C17oC-^H] -DHT.
D H T Mixture
Total Radioactivity = A cpm/mol.
OH
[l ,2-^h ]-DHT
OH
+
[1 -DHT
CrO
5o^-“Androstan0-3 » 1 7-dione Mixture «
Total Radioactivity = B cpm/mol. 
(Corrected for procedural losses)
H-
[1 ,2-^H] -Sot-androstane-
3,17-dione
non-radioactive 
5#-androstane- 
3 f 17-dicne
Calculation: [l 7oI“'^h]-DHT ~ A - B cpm/mol.
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During the validation of the superfusion
system the chromic acid oxidation, step was examined.
The DHT fraction from the paper chromatograms
(see Chapter II), containing [l ,2-^hJ-DHT and
7o<-^h ]-DHT from the tissue and added [4~^^c]-DHT,
was oxidised as described in Chapter II, and the
products subjected to silica gel TIC. Bands
corresponding to DHT and 5o^-androstane—3y 17-dione
were eluted from the plates and radioassayed. As
1 Aexpected, greater than 95% of the C isotope was 
recovered in the 5o(-androstane—3,17-dione fraction
with negligible ^^C being found in the DHT fraction.
%
Conversely, approximately 30% of the applied
remained in the DHT band. It was apparent, therefore,
14- 3that during the oxidation step G and species 
of DHT were being oxidised at.different rates.
Since this step is of key importance in the 
validation of the superfusion work up further 
studies were undertaken.
B. Systematic Study of the Oxidation of Testosterone
A systematic study of the chromic acid oxidation 
step was carried out using different isotopically 
labelled species of testosterone. Testosterone was 
chosen rather than DHT since large quantities of pure 
7c<^h] “DHT were unavailable and could not be 
prepared readily without risking randomisation of
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the tritium atoms. The product of chromic acid 
oxidation of testosterone is 4~androstene~3» 17-dione 
which can be separated from the substrate In the 
same TLC system used for the resolution of DHT and 
5oC-androstane-3,17-dione (Chapter II - System 2).
Approximately equal masses (50yu^ ) of [4-^  '^ c] - 
testosterone, [l ,2-^e]-testosterone and [l -
testosterone were oxidised in the usual manner 
either alone or in combination. The oxidation 
products were subjected to TLC and the developed 
plates scanned using the Panax Radio-chromatogram 
Scanner. The results obtained are displayed in 
Figure V - 2 and whilst results from the Panax 
are only semi-quantitative it is nevertheless 
apparent that a considerable proportion of the 
-testosterone remained whereas both the 
other radioactive species were apparently
quantitatively converted in 4-androstene-3,17-dione.
3In order to demonstrate that the H atom 
could be removed by oxidation of [l 7oC-'^h3-testosterone, 
variable reaction conditions were employed. A 
fixed substrate mixture of [17oC-^hJ- testosterone 
(lO^cpm), [4-^  "^ c] “testosterone ( 1 .1 x1 O^cpm) and 
unlabelled testosterone (ROO^ u^ ) was oxidised at 
either 20*^ 0, 3 7 or 60^C for either 30min. or 60min. 
The products were extracted in the usual manner and 
divided into two fractions. One half of the extract
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Figure V-2. Panax Radiochromatogram Scans of the
Chromic Acid Oxidation Products of Testosterone.
5. [i7«-h]-T +
[4J4g]„y
25
22
0TA
0 ~ origin T = testosterone
A ™ 4“androstene~3,1 7”dione
Silica TLC plates in a solvent system. 2*
Figures in peaks refer to peak heights in cm.
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*5 14was counted directly and the H/ C ratio determined 
whilst the second half of the extract was 
chromatographed and the plates scanned as described 
previously.
The results shown in Table V-1 demonstrate 
that almost quantitative removal of the 17o(- H atom 
occurs in the oxidation performed at 37^C for 60min. 
By contrast, only 23% of the tritium is lost under 
the normal oxidation conditions of 20^0 for 30min^ 
This can be increased substantially for the same time 
period by increasing the reaction temperature.
The developed TLC plates were examined under 
ultraviolet light before radioscarming. In no 
plate was a band visible in the testosterone region 
whereas an intense 4-androstene-3,17-dione band was 
seen in all extracts. An additional band was 
observed at the origin of the plate containing the 
products of the 60*^ C, oxidation. The results of the 
radioscanning shown in Figure V-3 confirm the
data in that progressively less radioactivity 
remains in the testosterone region as the reaction 
temperature is increased. The scan from the 
oxidation carried out at 37^0 for 60min. confirms 
the almost total loss of the 0 7oC“^hJ “-testosterone, 
The small peaks of radioactivity observed at the 
origin of scans 4 and 5 presumably represent 
oxidation products arising from the opening of the
1 22a
Table 7 - 1
Ratios Following the Chromic Acid 
Oxidation of a Mixture of [iT^-^h] — 
Testosterone and [4-^  ^ c]-Testosterone.
Oxidation
Temperature
(^G)
Time of 
Oxidation 
(min)
V k
of Product
% Loss 
of  ^H
20 0 9.08 0
20 30 7.01 23
37 30 3.19 65
57 60 0.17 98
60
. __________ „ ___________
30 1 .74 81
—  — ..
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'F lp ^ ire V - 3
Panax Raâiochromatogram. Scans of the Products of
Chromic Acid Qxi.dation of a Mixture of [l 7o^ -^h] -
and [4-'^ ^ c]-testosterone .
Reaction time/
1
temperature
22 0 time
^Omin/20'
,0
5. -A
A T
pOmin/60^
Ü = origin T = testosterone
A = 4~androstene-3y 17-dione 
SlXica TLC plates in solvent s:/steni 2, 
Figures refer to peak heights in cm,.
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steroid nucleus - particularly since scintillation
counting revealed these products contained only the 
1 4 C -isotope.
C« The Purity of G -T estosterone .
The previous section has shown that [l -
testosterone is apparently oxidised more slowly than 
either [4— ^c]-testosterone or [l , 2-^h]—testosterone. 
Before concluding that an isotope effect is 
responsible, it is necessary to establish that the 
[17ûi-^H]-testosterone used in this study did not 
contain contaminants of an equal polarity that might 
co-chromatograph with testosterone in the TIC system 
used.
(i) Assessment of purity by paper chromatography,
An aliquot of [l 7o^ -^h ]-testosterone was 
chromatographed on paper strips using the Bush B 
solvent system (Chapter II). Radio scanning of 
these strips showed a single peak of radioactivity 
corresponding to testosterone.
(11) Assessment of purity by thin layer chromatography.
The [17û^-^H]-testosterone was chromatographed 
using Silica TLC plates and a solvent system of 
CHCl^/Acetone :7/l . Wcien radioassayed again only a 
single band of radioactivity was detected in a 
position corresponding to testosterone.
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(lit) Assessment of purity by recrystallisa.tion.
An aliquot of ^7^-^H]-testosterone was taken,
 ^ and unlabelled testosterone were added, and 
the solution crystallised from hexane/acetone as 
described dm Chapter XI . Samples of the original 
solution, the crystals and the mother liquor were 
taken, dried, and the tritium to carbon-14 ratio 
measured by scintillation counting. The resulting 
ratios were 9.62, 9.45 and 9.53 respectively, 
indicating that the [l 7oC-^ h^]-testosterone appeared 
to have a purity > 95^ .^
(iv) Assessment of purity by derivative formation, 
Derivative formation is a method coimaonly used 
in chemistry for the identification of compounds and 
the determination of their purity.
Acétylation of [l 7o^-^H]-testosterone , 
testosterone and a mixture of these two Isotopes was 
carried out as detailed in Chapter II , followed by 
chromatography on Alumina TLC plates in solvent 
system - 1. In all cases only a single band of 
radioactivity was detected on the plates in a 
position corresponding to testosterone acetate, lie 
radioactivity remained at the origin or was found in 
the band corresponding to testosterone. The
^C ratio of the testosterone acetate product 
(13-4) was almost identical to that of the substrate 
mixture (13*6),
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D• Assessment of the Stereochemical Purity of
[l -Testosterone.
The previous four paragraphs have established 
that the [l 7®c-^H]-testosterone used in this study 
was essentially free of non-testosterone contaminants. 
It remained to be established however, that the 
tritium atom within the substrate was located 
exclusively in the 17c<- position.
The results of section B. demonstrate that using 
prolonged oxidation conditions it was possible to 
remove SQfo of tritium from the [l 7£^"^h]-testosterone 
substrate. The only carbon atom of testosterone 
which could carry tritium and behave in this manner 
during a chromic acid oxidation yielding 4-androstene-
3,17-dione as product, is carbon atom 17. Tritium 
in the 17-hydroxyl position would exchange with the 
hydrogen of the solvents and would be lost on 
acétylation. As this does not occur here it seems 
reasonable to conclude that the tritium is in the 
17-carbon position. It is possible that the 
[l -testosterone (1 7^-hydroxy~4-androstene-3-one )
species could be contaminated by [i7P-^h]- 
epitestosterone (1 7c*C-hydroxy-4-androstene~3-one). 
Whilst testosterone and epitestosterone would not 
be expected to co-crystalise it was considered 
desirable to obtain chromatographic proof concerning 
epitestosterone contamination of the [i7oc h^ ]-
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testosterone substrate.
An aliquot of the substrate was acetylated and 
the products of acétylation applied to alumina TLC 
plates which were developed continuously for 18h 
with cyclohexane/ethylacetate (9/1)- Elution and 
radioassay of the bands corresponding to testosterone 
acetate (4*5cm from the origin) and epitestosterone 
acetate (6.5cm from the origin) revealed that only 
the former band contained any appreciable radio­
activity.
It must be concluded from these studies that the 
[l7#-^H]-testosterone used for chromic acid 
oxidation was greater than 95^ pure and that the 
presence of impurities could not therefore be 
responsible for the apparent resistance to oxidation 
of the labelled species.
E. Time Course of the Chromic Acid Oxidation of
Isotopically Labelled Species of Testosterone.
In Sections A and B semi-quantitative data was 
produced to suggest that [l 7c>i“^H]-testosterone is 
oxidised more slowly by chromic acid than is 
[l ,2-^H]-testosterone, Having established the 
purity of the [l 7c<-^h]-testosterone species in 
Sections G and D, it was considered important to 
obtain quantitative evidence as to the differing 
rates of oxidation of the two tritiated testosterone
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substrates.
Accordingly two substrates mixtures were 
prepared :
(a) [l y2“^H]-testosterone (lO^cpm)y [4-^^c]- 
testosterone (1O^cpm), unlabelled testosterone
(200/Jg).
(b) [1 iDt-^H^-testosterone (5x1 O^cpm) ^ [4-^  ^ c]- 
testosterone (lO'^cpm)y unlabelled testosterone 
(200yJg).
These substrate mixtures were simultaneously
oxidised at 20*^ 0 using a standard concentration of
chromic acid. The reaction was stopped at intervals
over the time period 0—50min, and at each time point
the reaction products were extracted and examined by 
5 14TLC. The "^ H/ C ratio of the testosterone band was
assessed at each time point and a time-course plotted
for the oxidation of both substrate mixtures.
Figure V-4 reveals that for mixture (a) containing
[1,2-^h]-testosterone the ^C ratio does not
change with time even though at 50min, less than 1$^
of the original testosterone remains. Hence the
rates of oxidation of [l,2-^h]-testosterone and
[4-"^ ^ c]-testosterone are identical. By contrast 
3 14the "^ H/ C ratio for mixture (b) increases markedly 
as a function of time and by consideration of the 
slope of the line and the percentage conversion of 
[4-^ "‘c]-testosterone it is apparent that
Pig.V - 4 .
Time Course of Chromic Acid Oxidation of 
Testosterone Isotopes.
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Testosterone substrate mixtures -(200/lg) 
were oxidised with chromic acid as described
on page 57? f 0 - 5 0 m i n ,  The ratio of
the remaining testosterone was determined at 
each time point.
[l -testosterone is oxidised only 15^  ^as
quickly as the carbon labelled species.
Acétylation of the eluted testosterone bands 
followed by TIC resulted in no change in any of the 
ratios.
P, The Enzymic Metabolism of B -Testosterone.
The demonstration of an isotope effect in the 
chemical oxidation of [l 7©<-“^h ]-testosterone raises 
the question whether a similar effect can be observed 
in a biological system. Hence the metabolism of 
[l 7ot-^H]-testosterone by two different enzyme systems 
was examined. In the first system [i7o^ -^h]- 
testosterone was oxidised in a manner analagous to 
the chromic acid technique by the 17p»-hydroxysteroid 
dehydrogenase of Pseudomonas testosteroni. In the 
second system [l 7o^ -^h]-testosterone was used as 
substrate for the 5c^-reductase enzyme of human 
hyperplastic prostate.
(i) Metabolism of [l 7o<-^h1-testosterone by the 
17^~bydroxysteroid dehydrogenase of 
Pseudomonas testosteroni.
Prior to examining the time course of 
testosterone metabolism by 1 Tp-hjrdroxysteroid 
dehydrogenase it was necessary to optimise the 
concentration of enzyme used. Accordingly enzyme 
dilutions over the range ^/100 - ^/10,000 (0.5ml)
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were incubated with [4-^  "^’c]-testosterone ( 50ng, 1 O^ opra)
for lOmin at 37^C in 1.5ml pyrophosphate buffer
containing NAD (0.5mM). The products of the
incubation were extracted and chromatographed on
silica gel TLC plates using solvent system 2. The
percentage conversion of testosterone into
4—androstene-5f17“dione was assessed for each
dilution of enzyme and it is apparent from Table V-2 
-1
that a /4?000 dilution of the extract of Pseudomonas
testosteroni yielded an optimal conversion of 5C9L
1
Using an enzyme dilution of /4jOOO, a time 
course was carried out,of testosterone oxidation by 
17^-bydroxysteroid dehydrogenase,
Two testosterone substrates were employed:
(a) [4-”^  ^ c]-testosterone (1 O'^ cpm) -f
[1 ,2-^H]-testosterone(6x1O^cpm) — 50ng/tube
(b) [4-^  ^ c]-testosterone ( 1 O^cpm) 4-
[1 7(?C-^H]-testosterone(9x1 O^cpm) - 50ng/tube
and the extent of metabolism assessed over the period
0 — 20min. The ^0 ratio of the testosterone
fraction was determined at each time pojjit. It can
14.
be seen from Pigure V-5 that the H/ 0 ratio of
substrate (a) was independent of time indicating
that [4-^  ^ c]-testosterone and [l , 2-\l]-testosterone
are metabolised at the same rate, whilst the increase 
3 1Ain. H/ 'C ratio of substrate (b) must be interpreted 
as a resistance to oxidation of [l -testosterone.
Table V - 2 -
Metabolism of .Testosterone by Different Enzyme 
Concentrations of the 1T^-Hydroxysteroid 
Dehydrogenase of Pseudomonas Testosteroni.
Enzyme
Dilution
Percentage Conversion of 
cl“testosterone into
4-andro s tene-5,17-dione
1 29a
1/1 00 
1 /I 000
99
90
1/4OOO 30
1/1 0 ,0 0 0
1 29b
Time Course of Oxidation of Testosterone Isotopes 
by the 1 7P-H.yclroxy-Steroid D ehydrogenase from 
P. Testosteroni.
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B - substrate (a) 
A - substrate (b)
[l , 2“^h]-testosterone 4- 
[4-^^c]-testosterone
[1 ^h] “testosterone +
[4-^  ^ 0] -testosterone
Testosterone substrate mixtures (50ng) 
were oxidised using the 1 Yf^-hydroxysteroid 
dehydrogenase from P.testosteroni as described 
on page 65- The * h / *4c~ ratio of the remaining 
substrate was determined following 0“20min 
incubations ®
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Consequently, the isotope effect has been confirmed 
in an enzymic-oxidation as well as in a chemical 
oxidation. The ['4*“^ -testosterone was metabolised 
approximately twice as rapidly as the [l -
testosterone.
(il) Metabolism of Q -testosterone by human
prostatic testosterone 5o^~reductase.
By analogy with the 17(^-hydroxysteroid 
dehydrogenase experjjment a time course of testosterone 
metabolism was performed with homogenates of human 
hyperplastic prostate tissue. The same two 
testosterone substrates (a) and (b) (25ng/tube) were 
incubated with.a 5^ homogenate of prostate (0.5ml)
5n the presence of 0.5mM NADPE over a time period 
of 0-30min. The reaction was terminated and the 
products extracted and separated according to the 
standard assay procedure described in Chapter II.
The ^C ratio was determined at each time point
both for the testosterone substrate and the DHT 
product. The results in Table V-3 demonstrate 
that the ^C ratios of both testosterone and
DHT are constant as a function of time both for 
substrate (a) and for substrate (b). Clearly 
[1 7>c~^hJ-testosterone can be reduced as rapidly as 
either [4-^  ^ c]-testosterone or [l,2-^h] “testosterone.
1 30a
Table V - 3
Time Course of Testosterone M t a bollsiTi by the 
5oL-£edi’ictase_of Human Hyne?rpl:'.stic P r o s t a te Tissue
Time of 
Incubation î 
(min) 1
Isotopes
in
Substrate
^H/1 4C Ratio
T 1 DHT
. ....
ii (a) i
0 !!
I
[l ,2-^h ] -I-
[4-'H]
I
13.4 1
I
5 ! 1 13.4 1 1 0.2
10 1 14.2 i 1 1 .2
20 ’ I t 14.4 1 10,5
30 1 13.3 10.4
(b)
0 [i7oC-^ h ] + 
I [4-^1]
12.0 “
12.1 1 1 ,8
I 10 12.7 12.0
20
1; ti 12.6 12.4
! 30
1
1 12.4 12.5
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3. DISCUSSION.
It is clear from the experiments described 
in this chapter that [l 7os™^h]-testosterone is less 
readily oxidised than [l ,2--'^h]—testosterone and that 
the resistance to oxidation can be observed in both 
chemical and biological systems. By contrast 
the 5*-reduction of [l 7c<-'^ H]“testosterone proceeds 
at the same rate as that of [l , 2-'^ h]-testosterone.
The cause of the impaired oxidation of 
[l 7o4-^h ]—testosterone would seem to be due to the 
tritium atom Itself, since the substrate was shown 
to be free of contaminants and the tritium atom, was 
clearly located only in the 17^-position. The 
larger tritium atom results in a higher activation 
energy of the carbon-tritiura bond than the carbon- 
hydrogen bond and thus renders it more resistant to 
breakage. In the biological system it is also 
possible that the tritium atom interferes with the 
normal binding of the substrate to the active site 
of the 17^-hydroxysteroid dehydrogenase. Such an 
interference in binding would exhibit itself as a 
reduction in reaction rate.
Whilst the experiments described were not
specifically designed to quantitate the relative
rates of oxidation of 17ci-protium and 17o<.-tritium
kHatoms an estimate of the " /kT could be obtained.
?or the chromic acid ox.idation the ' /kT was
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approximately 7 whilst for the 1T^-hydroxysteroid 
dehydrogenase■reaction the ^^/IcT was approximately 2* 
The magnitude of the ratio in the chromic acid 
reaction agrees well with those published for the 
oxidation of [5(^-^H]-5o(.-chole8tan-5^-ol (Ellel et al., 
1965) and of [l 1c<~^h]-*5o^ “Pregnane™11(S-ol (Rocek et al. 
1962) by the same reagents. The smaller effect in 
the enzyme catalysed oxidation may be explained by 
the fact that the enzyme lowers the activation energy
necessary for the reaction and stabilises the
transition state, thus making the differences in 
bond energy of less importance in determining the 
overall reaction rate.
The isotope effects described for 
testosterone are presumably equally applicable to the 
oxidation at carbon atom 17 of [_1 7«<"-^ h] -DET and it 
seems most likely therefore, that the initial 
observation of [^h ]~DHT remaining following chromic 
acid oxidation can be attributed to the presence of 
[l 7oC—^h ]“DHT which was more resistant to oxidation 
than either the [l ,2~^h ]“DHT or the [4“  ^^ c]-DHT.
The apparent absence of an Isotope effect in the
5oC“reduction of the tritiated testosterone species 
was to be expected, since the tritium atoms of both 
substrates tested were remote from the region of the 
molecule being reduced, and thus unlikely to play 
any part in the reaction itself. Under these
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circumstances any Isotope effect could only be of 
the secondary type and hence of minimal importance.
The implications of the observed isotope effect 
need carefuD. consideration. In the superfusion 
system being validated the isotope effect is 
unlikely to bring about any significant discrepancies. 
In the prostatic tissue itself the predominant route 
of testosterone metabolism is via the 5^^reduotase 
enzyme, Beastall,(l975)Euuï Malathi & Gurpide (I977,b) 
have estimated that in the superfusion system the 
reductive pathway is greater than 50 times as active 
as the 1 7p.“hydroxysteroId dehydrogenase pathway. 
Consequently, small differences in the minor 
transformation of testosterone into 4“androstene-5? 
17-dione are unlikely to affect the calculation of 
the parameters used in the study. Clearly an 
entirely different picture would be produced in a 
biological system having considerable 17|^ “hydroxy- 
steroid dehydrogenase activity, and it wouü.d be 
completely invalid to use [iyu-^H]“testosterone in 
any quantitative study of testosterone metabolism in 
such a tissue.
The isotope effect first presented itself during 
the work up procedure following superfusion.
However, the presence of the isotope effect in the 
chromic acid oxidation of [l 7<><.™^h ]“DHT does not 
alter the values of the derived parameters since the
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oxidation step was included specifically to remove 
all tritium atoms from the 1 position and it does 
not matter whether this removal is achieved by 
oxidation or by a lack of reaction since only the 
radioactivity associated with the 5o^-androstane-5? 
17-dione product is used in subsequent calculations.
The observation of an isotope effect in such a 
simple metabolic study stresses the need for 
validation of the system being used. It is 
commonplace to assume that tritiated precursors 
behave in an identical manner to their unlabelled 
counterparts, but it is very rare for investigators 
to take the trouble to show that this is the case.
In this particular study sufficient experimentation 
was performed to establish that an isotope effect 
existed, but further Investigation of the effect 
was considered beyond the scope of the project.
CHAPTER VI
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CHAPTER VI.
THE INTERACTION OF PROGESTERONE 
AND RELATED COMPOUNDS WITH 
PROSTATIG TESTOSTERONE 5a-REDUCTASE,
1, INTRODUCTION.
Aatiandrogens have figured prominently in the 
pharmacological approach to the treatment of benign 
prostatic hyperplasia and prostatic carcinoma.
Thus, the following steroids have all been claimed 
to relieve, at least partially, some of the symptoms 
of these common conditions; cyproterone acetate 
(Geller et al., 1 975; Scott _& Wade, 1 969), 
medrogestone (Rangno et al., 1971; Paulson & Kane,
1975), flutamide [sCH 1352l] (Caine et al., 1975), 
17*-hydroxyprogesterone caproate and cliloramidone 
acetate (Geller et al», 1969), spironolactone 
(Castro et al., 1971) and estrogens (V/endel et al., 
1972).
Whilst the mode of action of these substances 
has not always been established it is generally 
accepted that they act at one or more of three 
possible levels; the hypothalamic^pituitary axis 
to reduce gonadotrophic production, the testes to
156
prevent androgen production, and the prostate to 
prevent androgen metabolism and action. Thus both 
estrogens (Sherins & Janick, 1976) and medrogestone 
(6f17-dimethylpregna-4,6-diene-5f20-dione) (Paulson 
& Kane, 1975) have been shown to reduce circulating 
PSH and LH levels, medrogestone has been demonstrated 
to reduce testosterone production in the testes 
(Paulson & Kane, 1975) and many of the active agents 
are thought to act within the prostate either to 
reduce testosterone metabolism or to prevent DHT 
binding to the receptor (King & Mainwaring, 1974),
Significantly,many of the agents thought to be 
acting within the prostate itself also give rise to 
progestational side effects such as impotence and 
gynaecomastia,and it is not surprising to discover 
that many of these steroids are structurally closely 
related to progesterone. The use of such substances 
as pharmacological agents raises the question of a 
possible role for progesterone and related compounds 
in the aetiology of benign prostatic hyperplasia 
since such steroids are part of the normal, spectrum 
of hormones found in adult plasma and changes either 
in their production or metabolic clearance rates, as 
a function of age, could well alter the intracellular 
concentrations of key steroid metabolites within the 
prostate gland.
Progesterone, itself, has been shown to inhibit
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the conversion of testosterone to DHT in the human 
prostate gland (Jenkins & MoCaffery, 1974; Tan et al., 
1974; Morfin et al., 1975) and has been suggested 
for use as an antiandrogen (Mauvais-Jarvis, 1974). 
However, whilst progesterone has been shown to be an 
inhibitor of the 5&~reduotase, little information is 
available regarding the mechanism of the progesterone 
inh.ibition in the human gland, or the structural 
components of the progesterone molecule necessary 
for interaction with the enzyme. Hence it was 
proposed that a study of this type should be 
undertaken, using the previously described assay 
system to test the kinetics of inhibition and the 
relative potencies of several structurally related 
and naturally occuring steroids.
In vitro effects cannot be directly extrapolated 
with confidence into the in vivo situation, and it 
was decided therefore, that the progestin with the 
most potent 5^-reductase inhibiting properties 
should be investigated further, using an experimental 
design which produces conditions more closely 
resembling those encountered in vivo. Hence a
study of the entry, metabolism, retention and release 
of progesterone from prostatic tissue was undertaken 
using an in vitro.superfusion system in the hope that 
it would provide useful information about the 
interaction of potential inhibitors of the prostatic
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testosterone 5^”reductase.
Many of the details specific to the superfusion 
of the human prostate gland have already been 
described in full elsewhere (Gurpide & Welch, 1969; 
Giorgi et al., 1971, 1973). Superfusion offers a 
major advantage over static incubation methods for 
studying steroid metabolism, for with the former 
technique it is possible to work under steady state 
conditions, both for the substrate and for the various 
products. This may be explained by reference to 
Pig.VI - 1 , which considers the time courses of the 
simple metabolic reaction A B 0 when studied by 
a static incubation (a) and by tissue superfusion (b). 
In the static incubation the tissue takes up the 
substrate A and converts it to B which in turn is 
converted to 0. As there is only a finite amount 
of substrate A the tissue concentration of A reaches 
a peak before falling again, to zero in the case of 
complete metabolism. The time course 'for E is 
similar to that of A, the time of the peak being 
later, whilst that of C rises progressively until in 
the case of complete metabolism it accounts for the 
total product level. During superfusion on the 
other hand the substrate A in the tissue is being 
constantly replaced from the medium, and a situation 
will eventually be reached where a steady state 
exists between the entry of A into the tissue and
138a
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the metabolism and release of A. A similar 
argument can be applied to B and C and thus it is 
theoretically possible to achieve a time point when 
A> B and C are all at the steady state.
In vitro superfusion techniques may be used 
for the simultaneous measurement of the entry of 
steroids into the tissue, the metabolism of steroids 
within the tissue, the release of the steroids and 
their metabolites back into the medium, and the 
retention of the steroids and their metabolites 
within the tissue. This is illustrated in 
Pig.VI “ 2. Two different but metabolically related 
steroids may be superfused simultaneously, and it is 
apparent that the maximum information can only be 
obtained from the system if there is some way of 
distinguishing those steroids derived from X from 
those produced from Y. The simplest way for this 
to be achieved would be by using different radioactive 
labels for X and Y, such as [^ r J-X and- 
However, because of the difficulty in synthesising 
^c]-labelled steroids with high specific 
radioactivity this would necessitate the undesirable 
use of steroid concentrations in excess of those 
encountered physiologically. This problem has been 
overcome by the use of two different [^ ïï]-labelled 
steroids, one labelled conventionally on carbon 
positions 1 and 2, and the other with the tritium
139a
Pig.VI - 2.
Parameters Measured by Superfusion
X
Uptake Y
Uptake X
u  =
^ = 
cm =
/O  =
entry of steroids into tissue, 
release of steroids from tissue, 
irreversible metabolites of steroids, 
metabolism of X X or X X
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introduced at carbon atom 17. For studies with 
testosterone and related steroids the latter tritium 
atom can be removed by a simple chemical oxidation 
step, thus enabling the source of the steroid under 
study to be elucidated.
The existence of the steady state during 
superfusion offers the advantage that the mathematics 
of the system are much simplified and thus also the 
quantitation of the previously mentioned parameters.
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2. RESULTS.
A . The Inhibition of Testosterone !5ot.--Reductase by 
Progesterone and Other 021 Steroids,
Several groups of workers have shown that 
testosterone U&~reductase can be inhibited by steroids 
related to progesterone (Erederiksen & Wilson, 1971; 
Tan et al., 1974). However no systematic study has 
been performed for human prostatic testosterone 
9*—reductase and no attempt has been made to correlate 
the structural features of a potential Inhibitor with 
its actual effectiveness.
Accordingly the testosterone 5<X-reduotase 
activity of human hyperplastic prostate was determined 
by the standard method in the absence of added 
inhibitor and in the presence of up to 2pmoles/litre 
of the steroids listed in Pig.VI - 3- The results 
of a single typical experiment are recorded in 
Pig.VI - 4. It is apparent that progesterone itself 
was the most potent inhibitor of testosterone 
5oC-reductase and the inhibitory capacity of the 
added steroid decreased with the number of hydroxyl 
groups attached to the steroid nucleus. Moreover, 
the position of the additional hydroxyl group also 
exerts a profound effect upon the ability of the 
steroid to inhibit testosterone 5oc-reductase, with 
the 11^-hydroxyl having a greater effect than the 
17#-hydroxyl group which in turn had a greater effect
1 41 ^
gig. VI - 3.
Progestins Examined, as Possible Inhibitors of the 
Testosterone 5t><"Reductase Activity of Human Prostate.
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than the 21-hydroxy group. Neither cortisol 
(11(i>17oi., 21 “trihydroxy—progesterone) nor the 
reduced product of progesterone (5d-pregnane-
2,20-dione) had any significant Inhibitory effect 
on testosterone ^(X^-reductase activity.
B. The Inhibition of Testosterone 5^-Heductase 
by Naturally Occurring Androgens.
In view of the observed marked inhibition of 
testosterone 5^-reductase by progesterone, it was 
considered important to compare these results with 
the effects of adding androgens, at similar 
concentrations, to the system. Accordingly the 
androgens listed in Pig,IV - 5 were assessed for 
their ability to inhibit the prostatic testosterone 
5#rreductase preparation. For comparative purpose® 
testosterone itself was included, the concentration 
of additional testosterone being treated separately 
from that of the radioactive substrate,- It is 
apparent from Pig,VI - 6 that the effect of the 
added testosterone was similar to that of 
progesterone at equimolar concentrations although 
when compared in a single experiment the progesterone 
was a marginally more potent inhibitor.
The presence of a ketone group on carbon atom 17 
in 4“-androstene-;5, IT'-dione rather than the 
17 hydroxyl group in testosterone only marginally
1 42a
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Androgen8 Ezamlned as Possible Inhibitors of the 
Testosterone 5^-»Reduotase Activity of Human Prostate
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Fig.VI. - 6.
The Inhibition of the 5oC-Reduction of 0,2- Ep-Testosterone 
by Naturally Occurring Androgens.
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reduced the inhibitory properties of the steroid 
which is not unexpected as 4-androstene-3,iV-dione 
is also a substrate for the rat ventral prostatic 
enzyme (Frederiksen & Wilson, 1971). Compared to 
testosterone and 4-andro8tene-^,j7-&io%e, DHT does 
not have a great effect, indicating that product 
inhibition is probably of little importance in this 
enzyme system. The effect of DHT is similar to 
that of 5^—pregnane~3»20-dione (Fig.VI - 4) and the 
absence of the 4-5 double bond presumably reduces 
the possible interaction of the steroid with the 
enzyme system.
It has been suggested that steroids of adrenal 
origin may play a part in the control of prostatic 
function (Harper et al., 1974), and for this reason 
dehydroepiandrosterone sulphate (DHAS) was also 
considered for possible inhibitory actions. The 
lack of effect over the concentration range studied 
(Fig.VI - 6) may possibly be explained either by the 
presence of the bulky sulphate group at carbon atom 3 
or by the 5-6 double bond.
C. The Kinetics of Progesterone Inhibition of
Testosterone 5^-Reductase.
The preceding experiments have shown that of the 
compounds studied progesterone is the most effective 
inhibitor of the testosterone 3&-reductase of human
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hyperplastic prostate and for this reason it was 
chosen for further study. The first requirement 
was to confirm the type of kinetics exhibited by the 
enzyme when subjected to progesterone inhibition of 
testosterone metabolism.
A microsomal enzyme preparation (Chapter II) 
was incubated with increasing levels of testosterone 
in the presence and absence of 40nM progesterone and 
the results obtained were analysed by double 
reciprocal plots (Michaelis & Menten, 1913)- It 
is apparent from Fig.VI - 7 that Vmax is not altered 
by the addition of progesterone, whereas Km is 
increased, indicating that the inhibition is of the 
competitive type with respect to substrate. The 
following parameters were determined from the double 
reciprocal plots
Vmax - 1.25 nmoles/hr/mgprotein
Km - 1
Kmi - 1.67 X 10“ll
D. The Effect of Progesterone on Testosterone
Metabolism in Superfused Human Prostatic Tissue,
In vitro incubations of the testosterone 
5oc-reductase enzyme preparations with progesterone 
have shown this compound to be a potent competitive 
inhibitor of the enzyme under the conditions used. 
However, extrapolation to the in vivo situation must
1 44a
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The Inhibition^by Progesterone^of Testosterone 
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be treated with great caution, since in the in vitro 
enzyme preparation, one is far removed from the 
situation where the physiological parameters of 
molecular entry into the cell, cellular 
compartmentation and cofactor balance, play an 
important part in determining the potency of 
biological compounds, A closer approximation to 
the in vivo situation is possible by using tissue 
culture or tissue superfusion methods. For the 
enzyme system under examination in this study, 
in vitro superfusion of thin tissue slices was the 
method of choice. As previously stated this system 
allows the sirauitaneous calculation of entry, 
metabolism, retention and release of the steroids 
under study. The validation and calculation of 
parameters and observations obtained with this system 
are presented below.
(i) A Time Course for the Uptake of Testosterone,
The tissue was prepared as detailed in Chapter II 
and placed in an open superfusion chamber. For 
testosterone and DHT uptake studies the tissue was 
perfused with buffer containing 5 » OOOcpm [l -
testosterone/ml and 5,000cpm [l , 2-^HJ-'DHT/mJ..
Aliq.uots of tissue were removed at Intervals and 
analysed together with the perfusate and buffer. 
Radioactivity in the tissue increased untiJL about
U 6
60 min whereafter there was a leveling off until 
90 " 120min. Indicating that the steady state had 
been reached. After this time the tissue began to 
deteriorate and radioactivity in the tissue increased 
again (Fig.VI - 8). . Wlien the metabolic products
of testosterone were separated >it was
apparent that the majority of testosterone taken up 
by the tissue had been metabolised to DHT,
Progesterone uptake studies were carried out at 
5ng/ml and 50ng/ml of steroid. In each case 
lOjOOOcpm [l ,2,6,.7-^Hj-progesterone/ml were used 
together with unlabelled testosterone (0*8ng/ml) and 
DHT (0.12ng/ml). Repeated experiments indicated 
that the steady state was approached between 60 ~ 
120min. of superfusion. Typical examples of these 
superfusions are shown in Fig,VI ~ 9. It is perhaps 
worthy of note that human prostatic tissue has a 
large capacity for the uptake of progesterone since 
the amount of radioactive steroid in the
tissue did not decrease greatly with the Increasing 
concentrations of superfused non-radioactive 
progesterone.
Having established that the steady state is 
approached between 60 and 90min. of superfusion for 
all three steroids, this time period was used in 
further experiments for the calculation of the 
parameters of entry, uptake, release and metabolism.
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Time Course for the Uptake of Progesterone
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Slices of human prostate were superfused 
in an open chamber with buffer containing 
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[1,2,6J- Hj-progesterone(either 5ng or 50ng/ml)® 
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(ii) The Parameters Calculated from the SuperT?Lision 
of Testosterone and DHT and the Errors in 
their Measurement,
(a) Calculation of the parameters.
By measurement of [l 7°^ "^ h ]-“testosterone, 
[i7°<-^ h ]-DHT and [i ,2-^h]-DHT In the buffer, 
perfusate and tissue, all the information required 
for the calcuJ-ation of the parameters of entry, 
retention, release and metabolism of these two 
metabolically related steroids is available.
Inclusion of P^c]~testosterone and T^c]-DHT before 
extraction of the above steroids permits the 
correction for procedural losses to be made. 
Verification of the model was made by Giorgi et al., 
(1971, 1974) and is illustrated in Eig.VI - 10.
The basic assumption necessary for the use of 
a superfusion experiment to calculate the various 
parameters, is that at the steady state an equal 
fraction of steroid enters (<x) and leaves the tissue* 
Thus for DHT
“ dHB " """ ^DHT    ' ^ ^
where im^^^ is the fraction of steroid leaving as 
metabolites and is the fraction of steroid
released unchanged from the tissue. The difference 
in concentration (cpm/ml) between the superfusing 
buffer and the collected, perfusate, divided by the 
concentration In the superfusing buffer gives us
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EÊZ:
T and DHT indicate testosterone and 
5#-dihydrotestosterone respectively; brackets ( ) 
indicate the concentration of steroids in cpm/ml 
followed by the suffixes P and t, which refer 
to perfusing buffer, collected perfusate and tissue 
respectively. (It is assumed that 1 g tissue s 
1ml buffer).
The fraction of superfused steroid entering 
the tissue is denoted by is the fraction of
superfused steroid released back into the medium 
and ^ is an index of the fraction of 
testosterone entering the tissue which is converted 
to DHT, whilst im is the fraction of superfused 
steroid irreversibly metabolised. The 
concentration of steroid in the tissue Is expressed 
in ng/gtissue, and "uptake" is an expression of the 
ratio of the steroid within the tissue to that in 
the superfusing buffer.
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The Parameters Measured In. Hiunan Prostatic Tissue after 
Superfusion with Testosterone and DHT.
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(1 ,2-^H-DHT)r, - (1 ,2"^ff~DHT)   (2)
—   — ------------------------------------------------
(1
The testosterone entering the tissue is in part 
metabolised to DHT, and it is assumed that this will 
be in a common pool with the DHT entering the tissue 
from the buffer. Therefore any DHT leaving the 
tissue will be made up of both [l ?c(“^h ]“DHT and 
[l ,2-*^ h]-DHT in the same proportion as that of the 
tissue. Thus we can also calculate DHT
 _______3"^ \
DHT = i X l z ^ )  d h t ] X
h _____________________....(3)
( 1 ,2 -^H -D H T)2
This in turn means that ( x c a n  also be calculated 
from equation (1).
These calculations can also be applied to 
testosterone. It has been shown in experiments by 
Giorgi et al., (1972) that testosterone is not 
released in measurable amounts from the tissue and 
it is thus permissable to let =0.
The uptake, or ratio of the concentration of 
steroid in the tissue compared to that in the buffer, 
is another parameter of interest and is defined by 
equation (4). It is calculated from the cpm/ml of 
buffer and cpm/g of tissue, where it is assumed that 
1g tissue is equivalent to Irai buffer.
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nptake^„^= ... (4)
C 1 , 2 - ^ H ~ D H T ) 2
The same equation applies equally for [l7°t- h]~
testosterone.
Also of importance is the concentration of 
steroid derived both from the buffer and intra­
cellular formation which is retained in the tissue
retention^ = (9)
Sp.Act.[l7o<“^H]-T
retention^^^ = + ( 1 7o<-%-DHT)  ^ ..(6)
Sp.Act.[l ,2- h ]~DHT Sp.A0t.[l7«-'^H]~T
where Sp.Act. is the specific radioactivity of the 
superfused steroids (cpm/ng).
When two metabolically related compounds are 
being superfused, it is of interest to know the 
fraction of the entering steroid which is being 
converted to the other,
Thus the conversion factor for testosterone to 
DHT is
(1,2-^H-DHT) B
P  T.DHT
oC
...(7)
J 7a-/H7 J
Further parameters, such as the rate of 
formation of metabolites, and intracellular clearance 
rates can also be cal.culated, but in the experiments 
presented here these were not determined.
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(b) The errors .involved in measurement of the
superfusion parameters.
Macroscopic examination of hyperplastic human 
prostate reveals a nodular appearance. These 
nodules vary in size, and have a paler and tougher 
texture, and may have different biochemical potential 
than the surrounding tissue. For this reason it was 
of vital importance to ensure that the division of 
tissue between the separate superfusion chambers was 
as systematic as possible. This wa,s achieved most 
easily by using one petrie dish for each superfusion 
chamber, and placing the slices into each dish in 
rotation, before weighing and transferring the slices 
to the superfusion chamber. In order to make valid 
comparisons between control and experimental 
superfusions it is necessary to know the variations 
obtained between control superfusions themselves.
Since a maximum of three chambers only can be 
superfused at any one time duplicate lines cannot • 
be run during all experiments. It was therefore 
necessary to perform a specific experiment to test 
the precision.
Three identical chambers were set up, each 
containing 500mg of tissue slices, and these were 
perfused for 90min. with buffer containing 
[l 7c4“^h]-testosterone and [l ,2-^h ]-DHT. The 
60 90min. perfusate, the tissue and a sample of
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buffer from each line were collected and processed 
as detailed in Chapter II, and the parameters 
calculated for each chamber. The results of these 
superfusions are expressed in Table VI- 1a and b.
The coefficient of variation (CV) of each of 
the steroid fractions from the three separate lines 
was less than 10^ for all except the tissue [i7oc-^h]- 
testosterone and the perfusate [l 7oC-^h]-DHT. The 
large variation in these two cases can be accoimted 
for by the relatively small levels of radioactivity 
present in these fractions. This variation is also 
reflected in the calculated parameters in Table VI-1b 
and the values of io CV obtained may be used as a 
basis in deciding the possible significance of effect 
of additional compounds used. It can be seen in 
Table VI-1 a that there are relatively few counts 
in the tissue testosterone fraction compared to the 
amount of [l 7ot-^H]-DHT in the tissue, indicating 
that the majority of the testosterone has been 
metabolised to DHT. This is reflected in the high 
value of in Table VI-1b. The entry (c4 ) of
testosterone and of DHT is similar. The release 
(p ) of DHT is very small, and contributes in a 
large part to the error in other calculations which 
depend upon it, for example ot and P .iJri.L '
However, the value of all these parameters are vrithin 
the range reported by Giorgi et al,, (1971, 1973,1974).
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Table VI - 1.
The Errors Involved in the Measurement of the 
Superfusion Parameters.
(a) The Radioactivity in Separate Assayed Fractions.
Fraction
Assayed
Corrected cpm/g tissue or /ml buffer
[l7o4-t]-
Testosterone [l ,2-%]-DHT [l 7ci-^H]~DHT
Tissue 21 90 H- 384 
(17.6)
12308 + 662 
(574)
15274 + 1836 
(12.0)
Perfusate 631 5 + 288 
(4.6)
4851 + 412 
(8.5)
37 + 36 
(98)
Buffer 7635 +119 
(1 .6)
6117 + 366 
(67o)
0
(b) The Calculated Parameters.
Parameter
un
/?
d
/Co
(o)t
P t .DH'J}
Ci
Testosterone
0.172 + 0.038 (22) 
0.286 + 0.050 (18) 
0.156 + 0.027 (17) 
1.038 + 0.229 (22)
DHT
0,187 + 0,069 (37) 
0.005 + 0.006 (103) 
0.191 +0.075 (39) 
2,062 + 0.111 (5)
1 .200 + 0.129 (11 )
Figures in brackets refer to fo Coefficient 
of Variation.
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As mentioned previously tissue varies greatly 
from one prostate to another and this is reflected 
in a relatively large variation in many of the 
calculated parameters. The parameters obtained 
from a series of superfusions with six prostates is 
shown in Table 71 - 2.
(ill) The Effect of Added Progesterone on the
Parameters of Testosterone and DHT Metabolism.
Progesterone has been shotm to be a potent 
inhibitor of the testosterone 5oC-reductase, causing 
almost inhibition of the enzyme at equimolar 
concentrations to the testosterone substrate. Hence 
it was decided to examine the effects of superfused 
progesterone on the parameters of testosterone and 
DHT metabolism.
In initial experiments 5ngprogesterone/ml buffer 
was added along with the standard amount of radio­
active testosterone and DHT. This is approximately 
twenty times the concentration of progesterone 
normally found in male plasma (Yermeulen & Verdonck,
1976) and is almost five times greater than the 
concentration of testosterone in the superfusion 
buffer. No consistent significant effect on either 
testosterone or DHT entry, uptake, metabolism or 
release was observed during four superfusions at 
this progesterone concentration (Table VI - 3). 
Superfusions with further 10 fold increases of
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Table VI - 5.
The Effect of Progesterone at Different Concentrations 
on the Parameters Obtained by Simultaneous 
Siiperfusion with Testosterone and DHT.
Progesterone
Concentration
oL 2 ^^/GoT ^T.DHT
0 0.540 0.582 0.375 1 .497
5ng/ml 0.286
(-12)
^ 1 .257 
(+29)
’’0.567
(+28)
2.262
(+29)
0 0.498 0.582 0.232 0.782
5ng/ml 0.482
(+2)
0.669
(+10)
0.275
(+12)
0.745
(-3)
0 0.081 0 0 2.972
5ng/ffil *0.240
(+70)
0.049
(+)
0.01 9
( +)
2.622
(-9)
0 0.250 0.567 0.241 0.877
5ng/ml ^0.564
(+26)
0.700
(+15)
0.298
(+15)
0,824 
(—4 )
50ng/ml 0.221
(-9)
0.680
(+13)
0.289
(+13)
0.972
(+7)
0 0.100 0.266 0.102 1 .636
500ng/ml 0.086 
(—1 1 )
*0.675 
(+61 )
*0.259
(+61 )
*0,709
(-56)
Û 0.100 0.131 0.757 1 .241
5/jg/ml 0.078
(-16)
*0.746
(+99)
*4.30
(+38)
*0.539
(-80)
5>.gT/ml *0.029
(-78)
*0.890
(+105)
*5.131
(105)
'’0.754
(-34)
8.D, of test. (+22) (+ 18) (± 17) (+ 22)
* values outwith 2 8.D. 
t values outwith 1 8.D.
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P DHT °''DHT Ci/OoDHT (‘^d h t )^
0 .3 2 0 0.126 0.447 5.634 3 .2 2 3
0.186
(-57)
0 .047
(-6 5)
^0 .2 3 4
(-44)
*4 .313
(-19)
*5.628
(+38)
0.384 0.076 0.461 7.771 6 .924
0.361
(—4)
0.061
(-15)
0 .423
(-6)
^8.757
(+8)
*3.584
(—46)
0 .0 9 9 0.060 0.160 0.980 0 .647
0 .3 0 4
(+72)
0 .142
(+57)
^0.446
(+67)
*1.925
(+4 6)
*1.191
(+4 2)
0 .2 3 3 0 .068 0 .302 3 .254 1 .236
0.282
(+13)
0.1 21 
(+40)
0 .404
(+20)
*4 .227
(+18)
^ 1.633 
(+20)
0 .225
(-2)
0.106 
(+31 )
0 .332
(+7)
T 5 .034
(+3 0)
*1 .744 
(+24)
0.100 0.007 0.108 1 .841 1.198
0 .103
(+2)
0 (-) 0 .0 7 6
(-2 5)
*2.421
(+19)
’’0.901
(-20)
0.038 0 .023 0.061 1 .265 14.858
0 .052
(+64)
0.008
(-65)
0.061 
( = )
*0.663
(-50)
*1 .551 
(-115)
0 .0 3 0
(-16)
'’’0 .002
(-118)
0 .033
( -42 )
*0.693 
(—41 )
*2 .653
(-98)
(+ 37) (+ 103) (+ 39) (+ 5) (+11) 
.... ..
Figures in brackets refer to 
io Coefficient of Variation.
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progesterone (50ng/ml, 500ng/ml and 5 g/ml) were 
also performed. Very little effect was seen with 
the 50ng/ml progesterone, but when 500ng/ml and 
5>Jg/ml progesterone were included in the buffer 
results that might be expected from progesterone 
inhibition of testosterone ^^-reduotase in the 
tissue slices were seen (Table VI - 3). There was 
a very significant decrease in p  ^ when 5 /^ g /m l
of progesterone was added, suggestive of a 
significant inhibition of the enzyme ; a similar 
though less marked effect was seen with 500ng 
progesterone/ml. At lower progesterone 
concentrations no significant decrease in 
was observed.
In a single experiment ^pgtestosterone/ml 
was added to one superfusion chamber as a further 
control. In this experiment the 5^*-^gte3tosterone 
was treated purely as a potential inhibitor for 
comparison with progesterone and only the 
concentration of the superfused radioactive 
testosterone was used in the calculation of the 
parameters. It is clear from Table VI - 5 that 
this concentration of testosterone lowers the 
apparent /<=> ^ value significantly, a3.though the 
reduction in this parameter is not as great as is 
seen with the same concentration of progesterone.
With a reduced conversion of testosterone into
1 54
DHT in the tissue following progesterone 
administration, one could reasonably expect to see 
an increase in the concentration of testosterone in 
the tissue. This is in fact the case as ^^ T^  the 
concentration of testosterone in the tissue, shows a 
significant increase in each case where a decrease 
in occurs, i.e. at higher progesterone
concentrations the concentration of DHT in the tissue, 
(^DHt )^ , also appears to fall in correlation with the 
fall in ^ and rise in (^t )^. However the
variations of this parameter at lower concentrations 
of progesterone make interpretation difficult.
In conclusion, the results presented in 
Table VI - 3 suggest that progesterone is indeed 
exerting some effect on testosterone metabolism in 
prostatic tissue, but that the effect is much less 
marked than the homogenate enzyme studies had 
suggested.
H , Uptake and Retention of Progesterone,
Testosterone and Cortisol within the Prostate.
In Section D it was shown that progesterone 
inhibited testosterone 5c<“reductase in prostate 
tissue slices, but that the extent of this inhibition 
was considerably less than was predicted from the 
inhibition of the enzyme by progesterone in an 
homogenate. In the homogenate 50^ inhibition was
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caused by equiinolar concentrations of progesterone 
and testosterone substrate, whereas in the 
superfusion a 500 fold excess of progesterone was 
required before any effect could be seen. The 
reasons for this lack of inhibition are not obvious, 
but lack of entry of progesterone into the cells was 
considered, although it has been shown that in vivo 
progesterone is taken up by human prostatic cells in 
preference to testosterone (Orestano et al., 1975) 
and this might also be expected to occur in vitro.
Prostatic tissue contains within it a large 
quantity of plasma proteins, which are not totally 
washed out of the tissue even after as much as 2hours 
of superfusion (Cowan et al., 1976), It could 
therefore be argued that much of the uptake and 
retention of the superfused steroids previously 
discussed was due to binding to these plasma 
proteins rather than to specific intracellular 
receptors. One of the major plasma steroid binding 
proteins is cortisol-binding globulin (CBG) which 
binds not only cortisol but also other steroid 
hormones. Progesterone is bound to CBG- with high 
affinity, but the binding of testosterone is much 
less avid (Doe & Deal, 1963), a fact which could 
account in part for the previous observations of 
progesterone uptake without the expected effect on 
the testosterone 5^-reductase: that is, uptake of
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progesterone by the extracellular protein components 
of the tissue rather than entry into the prostatic 
cells themselves. In order to test this hypothesis 
superfusions were performed with [l , 2, 6,7-^h ]- 
progesterone or [l ,2,6,7-^h ]-cortisol and 
testosterone, This regime allowed simultaneous 
radioassaying of the steroids, without separation 
of all the possible metabolites involved, since only 
the entry and retention of testosterone derived, 
progesterone derived or cortisol derived radio­
activity was being considered.
The following experiments were performed with 
Krebs-Ringer Bicarbonate buffer containing 
approximately 6,000cpm each of P h]-progesterone 
or . [ h^]-cortisol and [*^c]-testosterone. Ron- 
radioactive progesterone or cortisol was added to 
compensate for the different specific radioactivities 
of the steroids, and thus enable them to be perfused 
at near equimolar concentrations.
After slicing and weighing, the tissue was 
rinsed in buffer and placed in open superfusion 
chambers. During uptake experiments the same 
buffer was perfused throughout, and samples of tissue 
were removed at 20min, intervals. Retention studies 
were performed by perfusing with buffer containing 
the radioactive steroids for 75min., after which the 
tissue was removed from the chamber, washed with
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buffer (5 X 5ml) and transferred to a fresh chamber 
which was then perfused with buffer containing no 
steroid. Tissue slices were then removed at 20min. 
intervals and tissue from uptake and retention 
studies were then treated in the same manner.
After the tissue had been removed from the superfusion 
chamber it was rinsed in ice cold buffer(3 ^ 3ml) 
blotted free of excess fluid, weighed, finely minced 
and placed in glass scintillation vials along with 
6ml non-aqueous scintillator. The vials were stored 
overnight at 4^0 to allow the steroids to be 
extracted from the tissue. The scintillator was 
transferred to fresh vials, leaving behind all the 
tissue, and the radioactivity measured in a liquid 
scintillation spectrophotometer. All values were 
corrected for spillover between channels and 
efficiency, and expressed as concentration steroid/g 
tissue.
Perfusates (1 ml) were counted In aqueous 
scintillator (10ml) and again all values were 
corrected for spillover between channels and 
efficiency, and were expressed as concentration of 
steroid/ml buffer.
(i) Uptake and Retention of Testosterone and Cortisol.
The tissue slices were superfused with buffer 
containing [4“"* ^ c]-testosterone (0.1 2nmoles/ml) and 
[l ,2,6,7-^h ]-cortisol (O.l6nmoles/ml) which gave a
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cortisol/testosterone ratio (^/T) of 1.35. There 
was a rapid uptake of testosterone, and by 80min. 
the concentration of testosterone in the tissue was 
tenfold greater than in that of buffer (^^/Co - 10.0). 
The concentration of cortisol in the tissue did not 
differ significantly from that of the buffer 
(Ci/Qo ~ 0.9). This difference in uptake resulted 
in a fall in ^/T from 0.22 at 20min. to 0.12 at 
160min, as illustrated in Fig.VI -11.
Wash out experiments indicate a preferential 
retention of radioactivity derived from testosterone 
by the tissue, the tissue cortisol concentration 
being extremely small by the end of the washout 
period.
The results presented would indicate that there 
is a different specificity and mechanism for the 
uptake and retention of cortisol and testosterone by 
the prostatic tissue, and supports the theory that 
cortisol is bound extracellularly to CBG and other 
plasma proteins, whereas testosterone is bound 
intracellularly to high affinity proteins or 
receptors, probably as the metabolite DHT.
(ii) Uptake and Retention of Testosterone and
Progesterone.
In this study the perfusing buffer had a steroid 
concentration of 0.19nmoles progesterone/ml and 
0.09nmoles testosterone/ml giving a progesterone/
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Tissue slices of human prostate were 
super fused with buffer containingOt-'^c] - 
testosterone (0.1 2nmoles/ml) and Q^ 2,6,7-^h] - 
cortisol (0.1énmoles/ml).
During uptake studies aliquots of tissue 
were removed at intervals and total ^  H and 
9^*0 radioactivity determined.
Tissue for retention studies was 
superfused as above for 75min then- 
transferred to a fresh chamber and superfused 
with buffer containing no steroids for the 
remaining period.
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Pi&.VI - 11.
Uptake and Retention of Testosterone and Cortisol 
by Human Hyperplastic Prostate.
(a) Uptake.
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Ptestosterone ratio ( /T) of 2.2. It can be clearly
seen in Fig.VI - 1 2  that there was a rapid uptake of
both progesterone and testosterone, and by SOrain.
Giwhen the steady state was reached /Oo^ was 11.0 
Ciand /COp was 12.0. Over the period of superfusion 
the concentration of "progesterone” in the tissue 
increased four fold from 0.07nmoles/g at 20min. to 
0*29nmoles/g at 160min., where as the "testosterone" 
concentration rose only two fold from 0«.05nmoles/g 
to 0.1nmole/g and resulted in a change in tissue ^/T 
from 1.4 to 2.8. This may be a reflection of 
preferential uptake of progesterone, but care must 
be taken in interpreting this since the tissue /T 
was essentially the same as that of the perfusing 
buffer from 60 to 120min. when the steady state is 
approached.
Although there appears to be specific retention 
of both steroids within the tissue, it would appear 
that progesterone is retained in preference to
p
testosterone since tissue /T increases markedly 
in the washout experiment.
The pattern of uptake and retention of 
progesterone resembles that of testosterone rather 
than cortisol and would indicate that the binding 
protein involved is not predominantly CBG, but more 
probably an intracellular component, binding
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Tissue slices of human prostate were 
superfused with buffer containing 
testosterone (0.09nmoles/nil) and --
progesterone (0.19nmples/ml).
During uptake studies aliquits of tissue 
were removed at intervals and total ^  H and 
radioactivity determined.
Tissue for retention studies was 
superfused as above for 75min then 
transferred to a fresh chamber and superfused 
with buffer containing no steroids for the 
remaining period.
Uptake and Retention of Testosterone and 
Progesterone by Human Hyperplastic Prostate,
(a) Uptake.
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progesterone or one of its metabolites.
If progesterone is taken up by the tissue into 
intracellular location, an explanation other than 
lack of entry into the cells must be sought to 
explain the lack of effect of progesterone on 
testosterone metabolism at the lower superfusion 
concentrations•
The Metabolism of Progesterone within Human
Hyperplastic Prostate Cells.
The previous section has shown that progesterone 
is taken up and retained by prostatic tissue slices 
in a manner which can best be explained by 
intracellular entry and binding. More conclusive 
evidence of the intracellular location of progesterone 
could be obtained if the progesterone was metabolised 
by the tissue slices, since this is unlikely to take 
place extracellularly.
Using human prostatic tissue minces, Morfin 
et al » » (1975) showed that progesterone is metabolised 
to 5o^ “Pregnane-5»20"dione and 3p-hydroxy-5^-pregnane- 
20"One. It was considered that an investigation of 
possible metabolism, of progesterone in the tissue 
slices would provide a simple way of detecting entry 
of progesterone into the cells and of access to the 
enzyme system under study.
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(i) Preliminary investigations.
Tissue slices were prepared as described in 
Chapter II and superfused for 90min, with Krebs- 
Ringer bicarbonate buffer containing [l ,2,6,7-"^ h ]- 
progesterone at a concentration of 0.5ng/ml. The 
tissue, buffer and 60 - 90min. perfusate were 
extracted in ethylacetate as described in Chapter II. 
Gold steroid, 100/Jg each of progesterone, 5#-pregnane-
3,20-dione, 3^-hydroxy-5^ -pregnane-20-one and 
3#-hydroxy-5#-pregnane-20-one were added before 
extraction. The extracts were dried and spotted on 
thin layer chromatography plates. Alumina TIC 
plates and solvent system-1(Cyclohexane/Ethylacetate: 
3/1) gave three distinct bands^ corresponding to 
progesterone, 5^ -pregnane-5,20-dione, and to 
30C-+ 3 (2> ”hydroxy-™5oC“pregnane-20“One, which were not 
resolved in this system. Silica TIC plates and a 
solvent system of chloroform/Hethanol: 99/1 gave good 
resolution of the 3c<”. and 3^-hydroxy-pregnanes, but 
separation of progesterone from 5^-pregnane-3,20-dione 
was poor in this system (System 3)» The cpm 
obtained in each fraction are shown in Table VI - 4.
It can be seen that in the tissue there has been 
considerable metabolism of the progesterone which has 
entered the tissue mainly to 5o(-pregnane-3*20-dione 
and 3^-hydroxy-5^-pregnane-20-one, This is in 
agreement with the findings of Morfin et al., (197 5).
1 61 a
Table TI
Radioactive Products obtained from Prostatio Tissue 
after Superfusion with fl ,2,6,7-^H ■'Progesterone,
Chromatographic
fraction
Tissne
(cpm/aOOmg)
60-90min
Perfusate
(cpm/9ml)
Buffer
(cpm/5ml)
Progesterone 1071 15297 14608
5o^.~pregnane- 
3,20-dione 5754 809 405
3o£^ hy dr 0 xy-5oC"* 
pregnane-20">one 1151 95 68
3^“hydroxy-5oC- 
pr e gnane-2 0-one 5996 122
--- ' "
95
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It is interesting to note that the 5p>“isomer 
predominates over the 5#-isomer in the progesterone 
metabolism, (P/o4:^/1) which is the opposite case to 
the metabolism of testosterone where the 3oC-hydroxy- 
androstanediol is the predominant metabolite of DHT, 
Only a small quantity of the pregnane-5>20-dione 
and of the 5-hydroxy-5#-pregnane-20-ones are present 
in the perfusate,indicating that the release of these 
steroids from the tissue is small.
(ii) Time course of progesterone uptake and 
metabolism.
Human prostatic tissue was sliced and 800mg 
placed in an open superfusion chamber to permit 
removal of tissue samples during the period of 
superfusion. The perfusion buffer contained 
10,000 cpm/ml of [l,2,6,7”^h]-progesterone and 
unlabelled progesterone to make the final 
progesterone concentration either 0.5ng/ml or 5ng/ml, 
Tissue samples were removed at 50min. intervals and 
perfusates collected over each of these periods.
The tissue, perfusates (5ml) and buffer (5ml) were 
extracted as previously described after the addition 
of 1 00/tg each of progesterone, 5oC-pregnane-5,20-dione 
and 5p“hydroxy-5oC“Pregnane-20“One to permit recoveries 
to be monitored. Solvent system-1 and alumina TLC 
plates were used, as the three major metabolites are 
well separated on this system. No attempt was made
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to separate the 5^ and 5j^  hydroxy-pregnarn*20“~ones « 
Following separation of the steroids and elution 
from the TLC plates, half of each steroid sample 
obtained was radioassayed by liquid scintillation 
spectrophotometry, the rest being retained for gas 
liquid chromatography to monitor recoveries. A 
6foot X 1 /4inch column filled with y/o SE50 on gas 
chrom Q at 210^0 gave acceptable separation of the 
three steroids without excessive retention time.
The retention times for progesterone, 5^-pregnane-
5,20-dione and 5^“”hydroxy-5^-"Pregnane-20-one were 
12*5min., 9*75min. and 9min. respectively. The 
amount of steroid injected was related to peak 
height, and the injection of standard steroid 
solutions showed this relationship to be linear from 
0 to 1,000ng for each of the three steroids measured. 
The average peak height of at least two injections 
was used for the calculation of recoveries.
Progesterone was.taken up by the tissue and was 
metabolised to 5d^pregnane-5,20-dione and to 
5P“hydroxy-5o(“pregnane-20-one (Fig,VI - 15). More
5#-pregnane-5,20-dione was present in the tissue 
throughout all time points than either of the other 
two steroids, and this compound was also released in 
small quantities from the tissue. The release of 
the 5 -hydroxy steroids was extremely small and 
almost indistinguishable from background radioactivity.
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Pig.VI-1 5,
Tissue slices of human prostate were 
superfused with buffer containing lO^OOOcpm/ml 
Cli2*6,7~ h] -progesterone (either 0.5ug/ml or 
5ng/ml)* Aliquots of the tissue were removed 
at 50 min intervals and progesterone 
metabolites measured as described on p,162.
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13.
The Metabolism of Progesterone by Superfused 
Human Prostatic Tissue.
(a) 0.5ng progesterone/ml.
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Pig.VX - 13 illustrates the radioactivity in the 
three steroid fractions found in the tissue during 
the superfusion at the two progesterone concentrations, 
0#3ug/ml and 3ng/ml. The steady state is reached at 
both progesterone concentrations. At 0.5ng 
progesterone/ml the steady state extends from 60 ™ 
120min. as judged by the levels of 3d-pregnane- 
3r20“dione, the progesterone and 3^-hydroxy™3^« 
pregnan -20—one plateauing at 90 - 120min* The 
total radioactivity is however constant at 90 - 120min* 
When the progesterone is superfused at 5ng/ml the 
steady state appears to be at 30 - 90min. for all the 
steroids. Although there is a tenfold difference in 
the concentration of progesterone in the two 
superfusion buffers (the cpm/ml is the same in both) 
the cpm/g in the tissue is depressed by less than 50^, 
which would indicate not only a large capacity for 
progesterone uptake, but also for progesterone 
metabolism by prostatic tissue.
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3. DISCUSSION.
Progesterone was shown to be a more effective 
inhibitor of testosterone 5^ C”reductase than 
testosterone itself. The fact that the A, B and 
C rings of testosterone and progesterone have the 
same active groups, means that the geometry of these 
rings will be essentially identical, and thus, 
stereospecifically, a good fit in the active site of 
the enzyme may be achieved. Constituents on the 
D ring of progesterone and testosterone differ 
significantly, but it can be argued that the ^ 
side chain is less important in determining the 
binding of progesterone in the active site and as 
progesterone is efficiently metabolised by the enzyme 
this is probably the case. Another effective 
inhibitor is 4~androstene-3»17-dione, which is only 
slightly less potent than testosterone. Here again 
the difference in structure is small, the 17^™ 
hydroxyl of testosterone being replaced by a ketone 
function in 4-androstene-3,17-dione.
The addition of hydroxyl groups to the 
progesterone nucleus had a varying effect on the 
potency of these compounds as inhibitors of the 
testosterone 5oC“reductase. When the graphs were 
plotted a pattern emerged which indicated that the 
number and proximity of the hydroxyl group to the 
A ring was important in determining the potency of
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the inhibitors. It wo'ol.d appear that a C^^hydroxyl 
group has least effect followed by a 1 -hydroxyl, 
and that the 1 1^-hydroxyl reduces the inhibitor 
potential to the greatest extent. Combinations of 
two hydroxyls show the same pattern and when three 
hydroxyl groups are present, 11 [5 , 1 7(>^ and 21, as in 
cortisol, there is no inhibition. One can envisage 
that the addition of these hydroxyls interferes with 
the binding of the steroid to the active site of the 
enzyme and that the closer one gets to the A ring 
where the reduction is taking place the greater the 
effect on the binding, as distortions in the fit 
within the active site may be less well tolerated.
Reduction of the A 4 double bond of progesterone 
and testosterone to 5^-pregnane—3,20-dione and DHT 
respectively produces ineffective inhibitors, and 
would also indicate that product inhibition by DHT 
is not a limiting factor in the enzyme reaction.
The kinetics of the Inhibition by progesterone would 
appear to be of the competitive type as could be 
expected from the closely related molecular structure 
of progesterone and the substrate, testosterone.
This finding confirms the previous observation of 
Jenkins & MoCaffery (1974).
V/hilst it would have been interesting to extend 
this survey from purely naturally occurring compounds 
to other hydroxylated progestins and known
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antiandrogens, it was felt unnecessary in the context 
of this present project especially since studies of 
this type have been carried out previously (Tan et al., 
1974), Therefore, for the purpose of selecting a 
natural steroid with, potent 5#^reductase inhibiting 
properties for use with superfused tissue slices, 
the present studies proved sufficient.
Progesterone was the steroid of choice since it 
was the most potent of the progestins investigated.
It has previously been shown by Orestano et al.,
(1975) that progesterone and gestonorone caproate 
were effective inhibitors of prostatic testosterone 
metabolism. Concentrations of progesterone of only 
twice that of testosterone caused a decrease in 
5o("-reduction products by approximately 50'yo, which is 
similar to the results presented in the present 
investigations.
The use of an in vitro superfusion method to 
simulate the constant flow of material to and from 
the tissue which is found in vivo, emphasised the 
danger of direct extrapolation from one model to 
another. Superfusion with progesterone in the 
buffer resulted in no detectable decrease in 
testosterone metabolism until its concentration was 
in excess of 600 times that of the natur'al substrate. 
This is in direct contrast to the situation observed 
in an homogenate or microsomal enzyme assay, where
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equimolar concentrations of the progesterone 
inhibitor and testosterone substrate resulted in 
almost 50^ decrease in DHT production.
The explanation for this difference of effect 
in the two systems is not immediately obvious.
Uptake experiments indicate that the progesterone 
has a predominantly intracellular location in the 
tissue slices after superfusion, since the pattern 
of progesterone uptake resembled more closely that of 
testosterone than cortisol. Tissue concentrations 
of cortisol did not differ significantly from that 
of the buffer and could probably be accounted for by 
extracellular binding to plasma proteins such as CBG 
and albumin. Superfusion with radioactive 
testosterone and progesterone resulted in at least 
tenfold increases in tissue radioactivity over that 
of the medium and would indicate specific transport 
into intracellular compartments. This uptake of 
radioactivity by the tissue is in part due to 
intracellular metabolism of both progesterone and 
testosterone.
Retention studies also point to an intracellular 
location for progesterone or its metabolites, since 
there appears to be specific retention of radioactivity 
originating from progesterone and testosterone, but 
not from cortisol. The uptake and retention results 
also indicate that progesterone is taken'up and
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retained by the tissue even more avidly than is 
testosterone. This has previously been implied by 
Morfin et al., (1975), but further work would be 
necessary before this could be stated with confidence.
There is rapid metabolism of progesterone by 
prostatio homogenates and tissue slices. The major 
products of this metabolism were shown to be 
5c^ —pregnane-3,20-dione, 3^-hydroxy-5p-pregnane-20-one 
and 3|^ “hydroxy-*5^“Pregnane-20™one ; the ratio of the 
3-hydroxy pregnanes being /^oc :^ /1 . These results
are similar to those presented by Morfin et al., 
(1975), who also reported significant metabolism of 
progesterone to 5d“pregnane*»3, 6,20-trlone. Polar 
metabolites of this type were not investigated in 
the present study.
A tenfold difference in the specific radio­
activity of the superfused P h] -progesterone did not 
result in a parallel difference in the radioactivity 
extracted from the tissue slices. This can be seen 
also for testosterone in the work by G-iorgi et al., 
(1972) and indicates a large capacity for uptake, 
metabolism and retention of both testosterone and 
progesterone by the prostatic tissue slices. This 
large metabolic capacity of the tissue is possibly 
the explanation for the unexpected lack of potency 
of progesterone in decreasing testosterone metabolism 
in tissue slices, compared to homogenate and
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microsomal incubations.
At 90min. of superfusion the total concentration 
of steroid in the tissue resulting from testosterone 
entry is in the region of 10pmoles/g tissue and 
assuming a value of 1OOmg protein/g wet tissue, this 
would give a value of 0.1pmoles steroid/mg tissue.
When one considers the value of Vmax obtained using 
an homogenate preparation - approximately lOOpmoles/ 
hr/mg protein- it is apparent that if the same value 
is true in vivo and that if cofactor concentrations 
are not limiting, then the capacity for metabolism 
is far greater than the supply of substrate at the 
steroid concentrations used in the perfusing buffer.
The addition of the lower concentrations of 
progesterone does not increase the potential substrate 
concentration significantly and thus it also will be 
metabolised at the maximum rate. This maximum rate 
of metabolism of the steroids is reflected in the 
values o f obtained, where it is apparent that 
the majority of the testosterone entering the tissue 
is converted to DHT. This fact is more easily 
recognised by examination of the relative 
concentrations of jj! -testosterone and [l -DHT
present in the tissue (see Table VI - l). Thus it 
seems reasonable to postulate that only when the 
combined concentrations of testosterone and 
progesterone are reaching a level where enzyme
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concentration becomes the limiting factor, will any 
depression in testosterone metabolism due to the 
presence of progesterone be observed. An analogous 
conclusion was reached by Baulieu et al., (1975) 
from their work with rat ventral prostate explants 
in constant flow cultures. These workers found that 
when they added the antiandrogen 17 -ethynyl-4- 
esbrene-3-one (R4144) to the medium there was a 
decrease in the amount of DHT released into the medium,, 
but that DHT did not decrease in the explants 
themselves. They therefore suggested that for an 
anti-5oi-reductase agent to be efficient at lowering 
the intracellular DHT content it should be almost 
100^ effective as an enzyme inhibitor.
The implications to be taken from the results 
presented in this chapter are significant with respect 
to the mode of action of antiandrogenic compounds. 
Whilst many antiandrogens appear to inhibit the 
prostatio testosterone 5#-reductase, it is probable 
that this is not their main mode of action, since 
very high intracellular concentrations would be 
necessary for any other than those which were bound 
irreversibly to the active site of the enzyme. Thus 
for the majority of antiandrogens their major mode of 
action within the prostate will probably be found to 
be by competition with DHT for cytoplasmic and nuclear 
receptors.
CHAPTER TIT.
1 7 2
CHAPTER VII
CONGLUSIOHS AND
SCOPE FOR FUTURE INVESTIGATION.
In the previous chapters several compounds, both 
steroidal and non-steroidal, have been investigated 
with respect to their interaction with the 
testosterone 5oC-reductase from human hyperplastic 
prostate.
Heparin and severa.l other polysaccharides have 
been shown to reproducibly inhibit the testosterone 
5oC—reductase. Heparin itself exerts this inhibition
with competitive kinetics with respect to both 
substrate and cofactor. The inhibition is achieved 
by interference with substrate binding rather than 
by direct competition for the active site. Ho 
conclusions could be made in the present study about 
the part of the molecule responsible for inhibition, 
since no pattern was seen with change in size, 
sulphate content or glycoside linkage. Many more 
synthetic compounds would require testing to 
elucidate a possible pattern.
Administration of heparin in vivo to male rats 
produced no change in the enzyme activity within the
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prostate. The regime used, was the short term 
administration of high doses of heparin and it may 
he possible to produce more positive results if a 
long term regime were employed. This would 
necessitate the use of much lower doses of the drug 
to prevent the high mortality observed with the 
regime described.
The method of Horner (1971) was found to be the 
more satisfactory of the two methods used for 
extraction of. heparin from prostatio tissue. A 
uronic acid containing residue was obtained which 
was able to inhibit the prostatio 5^-reductase.
Further studies using thin layer chromatography and 
a combination of the spectrophotometric methods of 
Dische (1947) and Bitter & Muir (1962) would permit 
confirmation of the nature of the uronic acid residue. 
Identification of this type was not undertaken in the 
present study, since the larger quantity of prostatio 
tissue which would be necessary for this, was not 
readily available.
Investigations on the intra and extra cellular 
locations of heparin may also prove of value, and 
could be performed by both tissue fractionation and 
autoradiographic methods.
The antialdosterone agent, spironolactone, had 
previously been shown to have significant anti­
androgenic effects on the rat ventral prostate
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(Basinger & GitteSf 1974) and more specifically 
that spironolactone and its metabolic products, 
aldadiene and canrenoate, bind to the prostatio 
androgen receptor (Bonne & Raynaud, 1974). The 
present study confirms that canrenoate has no 
significant inhibitory effect on the testosterone 
5o(-reductase, but shows that aldadiene is capable 
of inhibiting the enzyme to an extent of 40% at a 
concentration of 250 .times that of the substrate.
Whilst there is a high concentration of aldadiene in 
plasma during spironolactone treatment, it is 
unlikely in view of the findings in Chapter VI that 
significant, inhibition of testosterone metabolism 
will take place in vivo. Therefore, one must 
conclude that any antiandrogenic effect.observed is 
lilcely to result from competition for the androgen 
receptor between DHT and the spironolactones, or to 
lowered androgen production by the tes bis. This 
latter possibility deserves further'investigation, 
for whilst it has been shown that spironolactone 
inhibits the c y t o c h r o m e d e p e n d e n t  steroid 
17^-hydroxylase, and desmolase activity, it is 
possible that the drug may also act at the pituitary 
level altering pituitary hormone production, thus in 
part accounting for the gynecomastia, impotence and 
menstrual irregularities observed as side effects of 
this drug.
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A deviation was made from the main line of 
investigation when an isotope effect was suspected 
during the oxidation of [l 7ot-^H]“-DHT with chromic 
acid. Further investigations of this isotope effect 
were made, using [l 7<^ ”'^h ]-testosterone, since this had 
been the starting material for the [l 7c<-^h]-DHT and 
was more readily available. The isotopic purity of 
the compound was established and an isotope effect 
confirmed when the labelled steroid was oxidised with 
either chromic acid or by 17^ hydroxysteroid 
dehydrogenase from Pseudomonas Testosteroni. Since 
no isotope effect was seen when the [l 7o(-^ H] - 
testosterone was reduced by the prostatic testosterone 
5ûC-reductase and since the conversion of testosterone 
to 4-andro8tene-3,1?-dione is very small compared to 
the conversion of testosterone to DHT in the prostate, 
it was decided that the observed isotope effect would 
not invalidate the use of steroids in the
superfusion system.
The demonstration of this isotope effect 
emphasises the dangers of using isotopically labelled 
species in biochemistry for tracer work. Isotope 
effects themselves can be made use of in determining 
reaction mechanisms, and one could envisage the use 
of variously labelled substrates and cofactors in 
further investigations of the mechanism of the 
5oC-reductase reaction.
I 7  0
A group of naturally occurring steroids were 
tested for inhibitory properties. The main 
difference between the pregnane series of compounds 
considered was the number and position of the 
hydroxyl groups. A pattern emerged from the study 
which indicated that the number and proximity of the 
hydroxyl groups to the A ring influenced the degree 
of inhibition seen. The reduced compounds 
5ck-pregiane-3 ,20-dione and DHT caused little inhibition 
even at the highest concentrations tested, Indicating 
that direct product inhibition is not likely to occur 
with this enzyme. The most potent inhibitors were 
shown to be progesterone and 4-androstene-3,17-”dione 
which were as potent as testosterone Itself in 
decreasing the radioactivity in the DHT product.
Progesterone was chosen as a test inhibitor for 
use in the superfusion system.. This system uses 
thin tissue slices and is designed to approximate 
more closely the in vivo environment than does a 
test tube incubation with a tissue homogenate. The 
results obtained with this system were quite different 
to those of homogenate incubations. Progesterone
did not cause any decreased production of DHT until 
it was over 500 times in excess of the substrate 
testosterone. This lack of effect could not be 
accounted for by lack of entry of progesterone into 
the cells, since the steroifi. was taken up and retained
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by the tissue, as well as being rapidly metabolised 
to 5ot"Pregnane“3f20-dione, 3^^hydroxy-3^-pregnan- 
20-one and 3p-hydroxy-3ü-pregnan-20-one.
The most satisfactory explanation for the lack 
of inhibition by progesterone in this system, lies 
in the concentration and activity of the 5c<.-reductase 
enzyme itself. The maximum velocity of the enzyme 
in an homogenate incubation was shown to be 
13 nmoles/hr/g tissue, which indicates that a high 
substrate concentration is required before the 
enzyme itself becomes the limiting factor in 
determining the reaction rate. Since progesterone 
is a competitive inhibitor and substrate, it does 
not alter Vmax for testosterone, thus one will not 
see an alteration in DHT production until the combined 
concentration of testosterone and progesterone exceeds 
the metabolic capacity of the enzyme present. The 
implications from these results are that inhibitors 
of testosterone 5<^-redu.ctase will have to be present 
in very high concentrations to influence the 
intracellular production of DHT. It seems likely, 
therefore, that the plasma concentration of 
progesterone and the majority of other antiandrogenic 
compounds used to date are not sufficiently high to 
affect DHT production by the prostate, and that their 
method of action is most probably due to competition 
with DHT for the androgen receptor with the gland.
IY«
Progesterone was specifically taken up, 
metabolised and retained by prostatio tissue. Indeed 
the data of Chapter VI suggested that progesterone 
may be taken up and retained in preference to 
testosterone. In support of the retention of 
progesterone being specific, Asselin et al., (1976) 
and Cowan et al., (1977) have shown the presence of 
a progesterone receptor-like protein in cytosol from 
human benign prostatio hyperplastic tissue. One may 
speculate a,bout the physiological sitgnificance of its 
presence, whether it is a progesterone receptor per se 
or an atypical androgen receptor.
In view of the significant metabolism of 
progesterone by the prostatic tissue it may also be 
important to determine the binding of ^d-pregnane- 
3,20-dione to these receptor proteins.
It is unclear as yet whether progesterone has 
a role in the normal functioning of the prostate. 
However, since progesterone enters the tissue, is 
metabolised by the tissue, and appears to be 
specifically bound within the hyperplastic prostate, 
it is not unreasonable to postulate some function 
for this steroid, and it remains to be determined 
whether this function is part of the normal gland 
per se, or merely a reflection of altered 
capabilities in the hyperplastic gland.
In vivo and in vitro work by G-eller et al., (1 97 6.)
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has shown that megestrol acetate administered in vivo 
caused a substantial fall in testosterone ^o^-reductase 
when measured in vitro. Similar results were 
obtained by Tan et al.,(1974) using medrogestone.
A fall in endogenous tissue DHT concentration and lack 
of P h]“DHT binding to a cytosol receptor protein after 
megestrol acetate administration was also reported by 
G-eller et al., (1976). It is unclear from these 
studies, however, whether the fall in testosterone 
bK-reductase activity is due to inhibition of the 
enzyme by endogenous antiandrogen, or whether it is 
a result of a lower enzyme concentration as a direct 
consequence of antiandrogenic displacement of DHT 
from the receptor, the latter being the more probable 
in view of the resul.ts presented here. It would be 
of interest to test this hypothesis using the method 
of tissue superfusion in parallel to homogenate 
incubations, as was done in the present study for 
progesterone.
In conclusion, it is clear that because 
prostatio testosterone 5^—reductase has a large 
metabolic capacity it is unlikely that attempts to 
control this enzyme alone wi]_l significantly alter 
the course of benign prostatio hyperplasia.
Therefore, for the future, we must look toward 
antiandrogens without the many side effects of those 
i j n  present use, and yet which will specifically 
interfere with DHT-receptor interaction.
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